EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 73

Results Generated From:
Embase <1980 to 2025 Week 05>
Embase Weekly Updates (updates since 2025-01-24)

<1>
[Use Link to view the full text]
Accession Number
2036438656
Title
Preventing, identifying and managing myocardial injury after non cardiac
surgery - A narrative review.
Source
Current Opinion in Anaesthesiology. 38(1) (pp 17-24), 2025. Date of
Publication: 01 Feb 2025.
Author
Wittmann M.; Dinc T.; Kunsorg A.; Marcucci M.; Ruetzler K.
Institution
(Wittmann, Dinc, Kunsorg) Department of Anesthesiology and Intensive Care
Medicine, University Hospital Bonn, Bonn, Germany
(Marcucci) Population Health Research Institute, Hamilton, Canada
(Marcucci) Clinical Epidemiology and Research Centre, Humanitas
University, IRCCS Humanitas Research Hospital, Milan, Italy
(Marcucci) Department of Health Research Methods, Evidence, and Impact,
McMaster University, Hamilton, Canada
(Ruetzler) Center for OUTCOMES RESEARCH, Department of Anesthesiology,
UTHealth, Houston, TX, United States
(Ruetzler) Division of Multispecialty Anesthesiology, Department of
General Anesthesiology, Cleveland Clinic, Cleveland, OH, United States
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose of reviewThere is mounting and convincing evidence that patients
with postoperative troponin elevation, with or without any clinical
symptoms, are at higher risk for both, short- and long-term morbidity and
mortality. Myocardial injury after noncardiac surgery (MINS) is a
relatively newly described syndrome, and the pathogenesis is not fully
understood yet. MINS is now an established syndrome and multiple
guidelines address potential etiologies, triggers, as well as preventive
and management strategies.Recent findingsSurveillance in high-risk
patients is required, as most MINS would otherwise be missed. There is no
reliable and established preventive strategy, but several potentially
avoidable triggers like hypotension, pain and anemia have been identified.
Managing patients with MINS postoperatively includes minimizing triggers
(such as hemodynamic abnormalities and anemia) that can continue the
damage. Long-term pharmacologic strategies include beta-blockers, statins,
antiplatelet agents, and anticoagulation.SummaryMINS affects up to 20% of
surgical patients, remains clinically mostly silent, but is associated
with elevated morbidity and mortality. A multidisciplinary approach, that
includes involvement of anesthesiologists, for the prevention, diagnosis,
and treatment of MINS is recommended.<br/>Copyright &#xa9; 2024 Wolters
Kluwer Health, Inc. All rights reserved.

<2>
[Use Link to view the full text]
Accession Number
645658794
Title
Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic
Stenosis.
Source
The New England journal of medicine. 392(3) (pp 217-227), 2025. Date of
Publication: 16 Jan 2025.
Author
Genereux P.; Schwartz A.; Oldemeyer J.B.; Pibarot P.; Cohen D.J.; Blanke
P.; Lindman B.R.; Babaliaros V.; Fearon W.F.; Daniels D.V.; Chhatriwalla
A.K.; Kavinsky C.; Gada H.; Shah P.; Szerlip M.; Dahle T.; Goel K.;
O'Neill W.; Sheth T.; Davidson C.J.; Makkar R.R.; Prince H.; Zhao Y.; Hahn
R.T.; Leipsic J.; Redfors B.; Pocock S.J.; Mack M.; Leon M.B.
Institution
(Genereux, Schwartz, Oldemeyer, Pibarot, Cohen, Blanke, Lindman,
Babaliaros, Fearon, Daniels, Chhatriwalla, Kavinsky, Gada, Shah, Szerlip,
Dahle, Goel, O'Neill, Sheth, Davidson, Makkar, Prince, Zhao, Hahn,
Leipsic, Redfors, Pocock, Mack, Leon) From Gagnon Cardiovascular
Institute, Morristown Medical Center, Morristown, NJ (P.G.); Columbia
University Medical Center/New York Presbyterian Hospital (A.S., R.T.H.,
M.B.L.), the Cardiovascular Research Foundation (D.J.C., R.T.H., B.R.,
M.B.L.), and Weill Cornell Medicine (B.R.), New York, and St. Francis
Hospital and Heart Center, Roslyn (D.J.C.) - all in New York; University
of Colorado Health, Medical Center of the Rockies, Loveland (J.B.O.);
Laval University, Quebec, QC (P.P.), St. Paul's Hospital, University of
British Columbia, Vancouver (P.B., J.L.), and McMaster University,
Hamilton, ON (T.S.) - all in Canada; Vanderbilt University Medical Center,
Nashville (B.R.L., K.G.); Emory University, Atlanta (V.B.); the Division
of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford
University, Stanford (W.F.F.), VA Palo Alto Health Care System, Palo Alto
(W.F.F.), California Pacific Medical Center, San Francisco (D.V.D.),
Cedars-Sinai Medical Center, Los Angeles (R.R.M.), and Edwards
Lifesciences, Irvine (H.P., Y.Z.) - all in California; Saint Luke's Mid
America Heart Institute, Kansas City, MO (A.K.C.); Beth Israel Deaconess
Medical Center/Harvard Medical School (C.K.) and Brigham and Women's
Hospital (P.S.) - both in Boston; Pinnacle Health Harrisburg, Harrisburg,
PA (H.G.); Baylor Scott and White The Heart Hospital Plano, Plano, TX
(M.S., M.M.); CentraCare Heart and Vascular Center, St. Cloud, MN (T.D.);
Henry Ford Hospital, Detroit (W.O.); Northwestern University, Chicago
(C.J.D.); Gothenburg University/Sahlgrenska University Hospital,
Gothenburg, Sweden (B.R.); and London School of Hygiene and Tropical
Medicine, London (S.J.P.)
Abstract
BACKGROUND: For patients with asymptomatic severe aortic stenosis and
preserved left ventricular ejection fraction, current guidelines recommend
routine clinical surveillance every 6 to 12 months. Data from randomized
trials examining whether early intervention with transcatheter
aortic-valve replacement (TAVR) will improve outcomes in these patients
are lacking. <br/>METHOD(S): At 75 centers in the United States and
Canada, we randomly assigned, in a 1:1 ratio, patients with asymptomatic
severe aortic stenosis to undergo early TAVR with transfemoral placement
of a balloon-expandable valve or clinical surveillance. The primary end
point was a composite of death, stroke, or unplanned hospitalization for
cardiovascular causes. Superiority testing was performed in the
intention-to-treat population. <br/>RESULT(S): A total of 901 patients
underwent randomization; 455 patients were assigned to TAVR and 446 to
clinical surveillance. The mean age of the patients was 75.8 years, the
mean Society of Thoracic Surgeons Predicted Risk of Mortality score was
1.8% (on a scale from 0 to 100%, with higher scores indicating a greater
risk of death within 30 days after surgery), and 83.6% of patients were at
low surgical risk. A primary end-point event occurred in 122 patients
(26.8%) in the TAVR group and in 202 patients (45.3%) in the clinical
surveillance group (hazard ratio, 0.50; 95% confidence interval, 0.40 to
0.63; P<0.001). Death occurred in 8.4% of the patients assigned to TAVR
and in 9.2% of the patients assigned to clinical surveillance, stroke
occurred in 4.2% and 6.7%, respectively, and unplanned hospitalization for
cardiovascular causes occurred in 20.9% and 41.7%. During a median
follow-up of 3.8 years, 87.0% of patients in the clinical surveillance
group underwent aortic-valve replacement. There were no apparent
differences in procedure-related adverse events between patients in the
TAVR group and those in the clinical surveillance group who underwent
aortic-valve replacement. <br/>CONCLUSION(S): Among patients with
asymptomatic severe aortic stenosis, a strategy of early TAVR was superior
to clinical surveillance in reducing the incidence of death, stroke, or
unplanned hospitalization for cardiovascular causes. (Funded by Edwards
Lifesciences; EARLY TAVR ClinicalTrials.gov number,
NCT03042104.).<br/>Copyright &#xa9; 2024 Massachusetts Medical Society.

<3>
Accession Number
2032974216
Title
Spinal Cord Stimulation for Refractory Angina Pectoris: Current Status and
Future Perspectives, a Narrative Review.
Source
Journal of Cardiovascular Development and Disease. 12(1) (no pagination),
2025. Article Number: 33. Date of Publication: 01 Jan 2025.
Author
Gazzeri R.; Mosca J.; Occhigrossi F.; Mercieri M.; Galarza M.; Leoni
M.L.G.
Institution
(Gazzeri, Occhigrossi) Interventional and Surgical Pain Management Unit,
San Giovanni-Addolorata Hospital, Rome, Italy
(Mosca) Department of Anesthesiology, Critical Care and Pain Medicine, La
Sapienza University of Rome, Rome, Italy
(Mercieri, Leoni) Department of Medical and Surgical Sciences and
Translational Medicine, Sapienza University of Rome, Rome, Italy
(Galarza) Regional Service of Neurosurgery, Virgen de la Arrixaca"
University Hospital, Murcia, Spain
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Refractory angina pectoris (RAP) is a clinical syndrome characterized by
persistent chest pain caused by myocardial ischemia that is unresponsive
to optimal pharmacological therapy and revascularization procedures.
Spinal cord stimulation (SCS) has emerged as a promising therapeutic
option for managing RAP, offering significant symptom relief and improved
quality of life. A systematic literature review was conducted to evaluate
the clinical effectiveness, mechanisms of action, and safety profile of
SCS in treating RAP. Comprehensive searches were performed in PubMed,
Scopus, and Web of Science for studies published between 1990 and 2023. Of
328 articles identified, 6 met the inclusion and exclusion criteria for
final analysis. The included studies consistently demonstrated that SCS
significantly reduces the frequency of anginal episodes and nitroglycerin
use while improving exercise capacity and quality of life. Proposed
mechanisms include modulation of pain signals via the gate control theory,
enhancement of autonomic balance, and redistribution of myocardial
perfusion. Novel stimulation modalities, including high-frequency, Burst,
and Differential Target Multiplexed (DTM), show potential advantages in
enhancing patient comfort and clinical outcomes. Nevertheless, long-term
studies are necessary to validate these findings and establish the
comparative efficacy of these advanced technologies. SCS is a safe and
effective therapy for patients with RAP who are unsuitable for surgical
interventions. Innovations in neurostimulation, including closed-loop
systems and personalized treatment strategies have the potential to
further optimize outcomes. Rigorous clinical trials are needed to
consolidate the role of SCS as a cornerstone therapy for the management of
RAP.<br/>Copyright &#xa9; 2025 by the authors.

<4>
Accession Number
2034429712
Title
Timing of multivessel revascularization in stable patients with STEMI: a
systematic review and network meta-analysis.
Source
Revista Espanola de Cardiologia. 78(2) (pp 127-137), 2025. Date of
Publication: 01 Feb 2025.
Author
Voll F.; Kuna C.; Scalamogna M.; Kessler T.; Kufner S.; Rheude T.; Sager
H.B.; Xhepa E.; Wiebe J.; Joner M.; Byrne R.A.; Schunkert H.; Ndrepepa G.;
Stahli B.E.; Kastrati A.; Cassese S.
Institution
(Voll, Kuna, Scalamogna, Kessler, Kufner, Rheude, Sager, Xhepa, Wiebe,
Joner, Schunkert, Ndrepepa, Kastrati, Cassese) Klinik fur Herz- und
Kreislauferkrankungen, Deutsches Herzzentrum Munchen, Technische
Universitat Munchen, Munich, Germany
(Scalamogna) Department of Advanced Biomedical Sciences, University of
Naples Federico II, Napoles, Italy
(Kessler, Sager, Joner, Schunkert, Kastrati) Deutsches Zentrum fur
Herz-Kreislauf-Forschung (DZHK), Munich, Germany
(Byrne) Cardiovascular Research Institute Dublin and Department of
Cardiology, Mater Private Network, Dublin, United Kingdom
(Byrne) School of Pharmacy and Biomolecular Sciences, Royal College of
Surgeons of Ireland University of Medicine and Health Sciences, Dublin,
Ireland
(Stahli) Department of Cardiology, University Heart Center, University
Hospital Zurich, Zurich, Germany
Publisher
Ediciones Doyma, S.L.
Abstract
Introduction and objectives: Multivessel percutaneous coronary
intervention (MV-PCI) is recommended in patients with ST-segment elevation
myocardial infarction (STEMI) and multivessel coronary artery disease
(CAD) without cardiogenic shock. The present network meta-analysis
investigated the optimal timing of MV-PCI in this context. <br/>Method(s):
We pooled the aggregated data from randomized trials investigating stable
STEMI patients with multivessel CAD treated with a strategy of either
MV-PCI or culprit vessel-only PCI. The primary outcome was all-cause
death. The main secondary outcomes were cardiovascular death, myocardial
infarction, and unplanned ischemia-driven revascularization.
<br/>Result(s): Among 11 trials, a total of 10 507 patients were randomly
assigned to MV-PCI (same sitting, n = 1683; staged during the index
hospitalization, n = 3460; staged during a subsequent hospitalization
within 45 days, n = 3275) or to culprit vessel-only PCI (n = 2089). The
median follow-up was 18.6 months. In comparison with culprit vessel-only
PCI, MV-PCI staged during the index hospitalization significantly reduced
all-cause death (risk ratio, 0.73; 95%CI, 0.56-0.92; P = .008) and ranked
as possibly the best treatment option for this outcome compared with all
other strategies. In comparison with culprit vessel-only PCI, a MV-PCI
reduced cardiovascular mortality without differences dependent on the
timing of revascularization. MV-PCI within the index hospitalization,
either in a single procedure or staged, significantly reduced myocardial
infarction and unplanned ischemia-driven revascularization, with no
significant difference between each other. <br/>Conclusion(s): In patients
with STEMI and multivessel CAD without cardiogenic shock, multivessel PCI
within the index hospitalization, either in a single procedure or staged,
represents the safest and most efficacious approach. The different timings
of multivessel PCI did not result in any significant differences in
all-cause death. This study is registered at PROSPERO
(CRD42023457794).<br/>Copyright &#xa9; 2024 Sociedad Espanola de
Cardiologia

<5>
Accession Number
2032837746
Title
A monthly roundup of key articles in other journals.
Source
Transfusion. 65(1) (pp 1-3), 2025. Date of Publication: 01 Jan 2025.
Author
McOmish C.
Institution
(McOmish) AABB, Bethesda, MD, United States
Publisher
John Wiley and Sons Inc

<6>
Accession Number
2032920306
Title
Human leukocyte antigen alloimmunization in a randomized trial of
amustaline/glutathione pathogen-reduced red cells in complex cardiac
surgery patients.
Source
Transfusion. (no pagination), 2025. Date of Publication: 2025.
Author
Norris P.J.; Stone M.; Di Germanio C.; Balasko B.; Kaidarova Z.; Friend
H.; Varrone J.; Corash L.; Mufti N.; Benjamin R.J.
Institution
(Norris, Stone, Di Germanio, Balasko, Kaidarova) Vitalant Research
Institute, San Francisco, CA, United States
(Norris, Stone, Di Germanio) Department of Laboratory Medicine, University
of California, San Francisco, San Francisco, CA, United States
(Norris) Department of Medicine, University of California, San Francisco,
San Francisco, CA, United States
(Friend, Varrone, Corash, Mufti, Benjamin) Cerus Corporation, Concord, CA,
United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Although alloimmunization risk of pathogen-reduced (PR)
platelets has been studied, the risk has not been reported with PR red
blood cells (RBCs). Study Design and Methods: In a Phase III, randomized,
controlled trial (Red Cell Pathogen Inactivation), cardiac or
thoracic-aorta surgery patients were randomized to transfusion with
amustaline/glutathione PR versus conventional RBCs. Pre-transfusion and
Day 28 samples were evaluated for Human leukocyte antigen (HLA) Class I
and Class II antibodies at low, medium, and high cutoff values.
<br/>Result(s): The HLA alloimmunization analysis included 114
participants (53% female) in the PR and 113 (51% female) in the
conventional RBC arms. In a modified intention-to-treat analysis, 13.7% (N
= 29) and 7.2% (N = 15) developed new high-level HLA Class I or Class II
antibodies, respectively; however, there was no signal that PR-RBCs
affected the rate of HLA Class I (odds ratio (OR) 1.3 [95% confidence
interval (CI) 0.62-2.9]) or Class II antibody formation (OR 0.99 [95% CI
0.35-2.8]). Female transfusion recipients had higher risk of developing
new high-level HLA Class I antibodies (OR 12.0 [95% CI 3.5-40.9]) and
Class II antibodies (OR 5.0 [95% CI 1.4-17]). The mean number of RBC (5.5
vs. 3.6 units, p = 0.018) and platelet (1.8 vs. 1.1 units, p = 0.043)
transfusions was higher in subjects with new high-level HLA Class II
antibodies. <br/>Discussion(s): Receipt of amustaline/glutathione PR-RBC
units did not affect HLA alloimmunization risk. Female sex and number of
RBC and platelet transfusions were risk factors for the development of new
high-level HLA Class I and Class II antibodies.<br/>Copyright &#xa9; 2025
AABB.

<7>
Accession Number
2036988750
Title
Use of continuous glucose monitoring and point-of-care glucose testing in
hospitalized patients with diabetes mellitus in non-intensive care unit
settings: A systematic review and meta-analysis of randomized controlled
trials.
Source
Diabetes Research and Clinical Practice. 220 (no pagination), 2025.
Article Number: 111986. Date of Publication: 01 Feb 2025.
Author
Cavalcante Lima Chagas G.; Teixeira L.; R.C. Clemente M.; Cavalcante Lima
Chagas R.; Santinelli Pestana D.V.; Rodrigues Silva Sombra L.; B. Lima B.;
J. Galindo R.; Abreu M.
Institution
(Cavalcante Lima Chagas, Cavalcante Lima Chagas) Federal University of
Ceara, CE, Fortaleza, Brazil
(Teixeira) Federal University of Campina Grande, PB, Campina Grande,
Brazil
(R.C. Clemente) Petropolis School of Medicine, RJ, Petropolis, Brazil
(Santinelli Pestana) Department of Internal Medicine, University of Texas
Southwestern, Dallas, TX, United States
(Rodrigues Silva Sombra) Department of Medicine, Division of Hospital
Medicine, University of Florida, Gainesville, FL, United States
(B. Lima) Division of Cardiology, Vanderbilt University Medical Center,
Nashville, TN, United States
(J. Galindo) Division of Endocrinology, Diabetes and Metabolism,
University of Miami, Miami, FL, United States
(Abreu) Division of Endocrinology, University of Texas Southwestern,
Dallas, TX, United States
Publisher
Elsevier Ireland Ltd
Abstract
The benefits of using continuous glucose monitoring (CGM) in hospitalized
patients with diabetes remain uncertain. Point-of-care (POC) glucose
testing is the standard of care in this setting. We compared the effect of
adding CGM to POC testing versus POC testing alone on glycemic outcomes in
this population. We have searched the Cochrane Library, Embase, and
MEDLINE databases and relevant conferences up to May 2024. We have
included six randomized controlled trials (n = 979 patients) comparing CGM
plus POC testing to POC testing alone in non-pregnant, non-critically ill
hospitalized adults with diabetes. The addition of CGM improved time in
range (mean difference [MD] + 7.24 %; 95 % confidence interval [CI]:
+5.06, +9.42; P < 0.00001; I² = 35 %), reduced time below range
< 70 mg/dL (MD: -1.23 %; 95 %CI: -2.27, -0.18; P = 0.02; I² =
64 %) and < 54 mg/dL (MD: -0.95 %; 95 %CI: -1.19, -0.70; P < 0.00001;
I² = 0 %), and time above range > 250 mg/dL (MD: -3.70 %; 95
%CI: -6.10, -1.29; P = 0.003; I² = 39 %) compared to POC
testing alone. We observed no statistically significant differences in
glycemic variability or insulin doses. In non-critically ill, hospitalized
adults with diabetes, the addition of CGM to POC testing for insulin
dosing resulted in superior glycemic control and reduction of hypoglycemia
compared to POC testing alone.<br/>Copyright &#xa9; 2025 Elsevier B.V.

<8>
Accession Number
2036984973
Title
The Efficacy and Safety of Angiotensin II for Treatment of Vasoplegia in
Critically Ill Patients: A Systematic Review.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Kotani Y.; Lezzi M.; Murru C.P.; Khanna A.K.; Zarbock A.; Bellomo R.;
Landoni G.
Institution
(Kotani) Department of Intensive Care Medicine, Kameda Medical Center,
Kamogawa, Japan
(Lezzi, Murru, Landoni) Department of Anesthesia and Intensive Care, IRCCS
San Raffaele Scientific Institute, Milan, Italy
(Khanna) Section on Critical Care Medicine, Department of Anesthesiology,
Wake Forest University School of Medicine, Winston-Salem, NC, United
States
(Khanna) Perioperative Outcomes and Informatics Collaborative, Wake Forest
University School of Medicine, Medical Center Boulevard, Winston-Salem,
NC, United States
(Khanna) Outcomes Research Consortium, Houston, TX, United States
(Zarbock) Department of Anesthesiology, Intensive Care Medicine and Pain
Therapy, University Hospital Muenster, Muenster, Germany
(Bellomo) Department of Intensive Care, Austin Hospital, Melbourne,
Australia
(Bellomo) Australian and New Zealand Intensive Care Research Centre,
Monash University, Melbourne, Australia
(Bellomo) Department of Critical Care, Melbourne Medical School, The
University of Melbourne, Melbourne, Australia
(Landoni) School of Medicine, Vita-Salute San Raffaele University, Milan,
Italy
Publisher
W.B. Saunders
Abstract
Objectives: To summarize evidence regarding intravenous angiotensin II
administration in critical illness and provide an updated understanding of
its effects on various organ dysfunction and renin-angiotensin system
(RAS) biomarkers. <br/>Design(s): A systematic review. <br/>Setting(s): A
search of PubMed, Embase, and the Cochrane Library from inception to May
3, 2024. Randomized controlled trials (RCTs), nonrandomized trials,
quasi-randomized trials, observational studies, case reports, and case
series were included. Comparative studies (RCTs and observational studies
with comparator) were used for the main analysis. <br/>Participant(s):
Critically ill adults and children. <br/>Intervention(s): Intravenous
angiotensin II administration. <br/>Measurements and Main Results:
Fifty-nine studies with a total of 2,918 participants (5 RCTs, 15
observational studies, and 39 case reports or case series) were analyzed.
Septic shock and cardiac surgery were the most common clinical conditions
(14 studies for each). In 14 comparative studies (5 RCTs and 9
observational studies), mortality was not different from that in controls,
except in 1 observational study. Several studies reported decreased renal
replacement therapy use, improved oxygenation and blood pressure response,
and decreased rate of myocardial injury with angiotensin II therapy. There
was no increase in thrombotic events or adverse events. Angiotensin II
therapy reduced renin and angiotensin I levels without affecting other RAS
biomarkers. <br/>Conclusion(s): Intravenous angiotensin II has been
reported in almost 3000 critically ill patients with diverse types of
shock. Despite unclear mortality impacts, angiotensin II seems to confer
beneficial effects on several organ systems and RAS derangements, without
increasing adverse events.<br/>Copyright &#xa9; 2024 Elsevier Inc.

<9>
Accession Number
2037067260
Title
Efficacy and safety of Shexiang Baoxin Pill (MUSKARDIA) in patients with
stable coronary artery disease across different weight subgroups.
Source
Journal of Ethnopharmacology. 341 (no pagination), 2025. Article Number:
119341. Date of Publication: 11 Feb 2025.
Author
Zhou J.; Shi H.; Zhao Y.; Jin Y.; Liu Y.; Wang S.; He S.; Lu F.; Li R.;
Xiong S.; Yan J.; Liu Q.; Wang Z.; Cong H.; Han Q.; Ge J.
Institution
(Zhou) Department of Cardiology, Zhongshan Hospital, Fudan University,
Shanghai, China
(Shi) Department of Cardiology, Huashan Hospital, Fudan University,
Shanghai, China
(Zhao) Department of Cardiology, The Second Affiliated Hospital of
Zhengzhou University, Zhengzhou, China
(Jin) Department of Cardiology, The Fourth Affiliated Hospital of China
Medical University, China
(Liu) Department of Cardiology, Tianjin Third Central Hospital, Tianjin,
China
(Wang) Department of Cardiovascular Medicine, Ningbo First Hospital,
Ningbo, China
(He) Department of Cardiology, Northern Jiangsu People's Hospital,
Yangzhou, China
(Lu) Department of Cardiology, The Affiliated Hospital of Shandong
University of Traditional Chinese Medicine, Ji'nan, China
(Li) Department of Cardiovascular Medicine, The First Affiliated Hospital
of Guangdong University of Traditional Chinese Medicine, Guangzhou, China
(Xiong) Department of Cardiovascular Medicine, Fujian Province People's
Hospital, Fuzhou, China
(Yan) Department of Cardiovascular, The First Affiliated Hospital of China
University of Science and Technology, Hefei, China
(Liu) Department of Cardiology, The Second Xiangya Hospital of Central
South University, Changsha, China
(Wang) Department of Cardiology, The Affiliated Hospital of Xuzhou Medical
University, Xuzhou, China
(Cong) Department of Cardiology, Tianjin Chest Hospital, Tianjin, China
(Han) Department of Cardiology, The First Hospital of Shanxi Medical
University, Taiyuan, China
(Ge) Department of Cardiovascular Internal Medicine, Zhongshan Hospital,
Fudan University, Shanghai, China
Publisher
Elsevier Ireland Ltd
Abstract
Ethnopharmacological relevance: Shexiang Baoxin Pill (MUSKARDIA), a
traditional Chinese patent medicine, plays a crucial role in both
preventing and treating diverse cardiovascular diseases, including
coronary heart disease, myocardial infarction (MI), and heart failure.
Preclinical research has demonstrated that the cardioprotective effects of
MUSKARDIA are achieved through multiple pathways, such as enhancing
coronary artery dilation, fostering new blood vessel growth, reducing
inflammation and oxidative stress, improving lipid metabolism, and
protecting vascular endothelium. Aim of the study: This subgroup analysis
aimed to evaluate the efficacy and safety of Shexiang Baoxin Pill
(MUSKARDIA) plus optimal medical therapy (OMT) across different weight
categories in treating stable coronary artery disease (CAD).
<br/>Method(s): This investigation was a subgroup analysis of a
multicenter, randomized, double-blind, placebo-controlled phase IV
clinical study. Patients receiving OMT were randomly assigned to either
MUSKARDIA or placebo group for a 24-month period. This analysis focused on
body weight as a distinguishing factor, using 65 kg as the cutoff. The
primary efficacy endpoint was the composite of major adverse
cardiovascular events (MACEs), including cardiovascular death, non-fatal
myocardial infarction (MI), and non-fatal stroke. Secondary efficacy
endpoint comprised a composite of all-cause mortality, non-fatal MI,
non-fatal stroke, hospitalizations for unstable angina or heart failure,
and coronary revascularization procedures. <br/>Result(s): A total of 2646
patients were included in the analysis, with 916 patients weighing less
than 65 kg and 1730 patients weighing 65 kg or more. The median ages were
68 (range: 35-90) years and 62 (range: 29-90) in these two subgroups,
respectively. For patients weighing less than 65 kg, the MUSKARDIA group
exhibited a significantly lower incidence of the primary efficacy endpoint
(0.65%) compared to the placebo group (2.64%) (P = 0.018), with a reduced
risk of MACEs (HR = 0.241, 95%CI: 0.068-0.856; P = 0.0168). Conversely, in
patients weighing 65 kg or more, no significant differences were observed
in the incidence rates or risks of primary or secondary efficacy endpoints
between the MUSKARDIA and placebo groups (All P > 0.05). Adverse events
were similar between two groups across both weight subgroups.
<br/>Conclusion(s): MUSKARDIA plus OMT demonstrated promising efficacy and
acceptable safety in CAD patients weighing less than 65 kg, potentially
reducing the risk of MACEs. For patients weighing 65 kg or more, further
investigation is needed to optimize dosing strategies.<br/>Copyright
&#xa9; 2025 The Authors

<10>
Accession Number
646194979
Title
Meta-analysis of MitraClip and PASCAL for transcatheter mitral
edge-to-edge repair.
Source
Journal of cardiothoracic surgery. 20(1) (pp 3), 2025. Date of
Publication: 03 Jan 2025.
Author
Balata M.; Gbreel M.I.; Elkasaby M.H.; Hassan M.; Becher M.U.
Institution
(Balata) Nurnberg, Friedrich-Alexander-Universitat Erlangen-Nurnberg,
Germany
(Gbreel) Faculty of Medicine, October 6 University, Giza, Egypt
(Elkasaby) Faculty of Medicine, Al-Azhar University, Cairo, Egypt
(Hassan) Department of Immunology, Theodor Bilharz Research institute,
Giza, Egypt
(Becher) Department of Internal Medicine II, Stadtisches Klinikum
Solingen, Solingen, Germany
Abstract
BACKGROUND: Despite the promising results of both MitraClip and PASCAL
systems for the treatment of mitral regurgitation (MR), there is limited
data on the comparison of both systems regarding their safety and
efficacy. We aim to compare both systems for MR. MATERIALS AND METHODS:
Five databases were searched until October 2024. Original studies were
only included and critically appraised using an adapted version of the
Newcastle-Ottawa scale for observational cohort studies and the Cochrane
risk of bias tool for randomized controlled trials. The risk ratio (RR)
and mean difference (MD) with their corresponding 95% confidence interval
(95% CI). <br/>RESULT(S): From the database search, we identified 197
studies, of which eight studies comprising 1,612 patients who underwent
transcatheter edge-to-edge repair with either MitraClip or PASCAL were
included in this meta-analysis. The statistical analysis revealed no
significant difference between the two devices in achieving a two-grade
reduction in MR severity (RR = 0.95; 95% CI: [0.86, 1.04]; p = 0.28),
one-grade reduction (RR = 1.17; 95% CI: [0.92, 1.49]; p = 0.19), or in
cases with no improvement (RR = 1.23; 95% CI: [0.79, 1.90]; p = 0.36).
Additionally, there were no significant differences between PASCAL and
MitraClip regarding procedure time, procedural success, reinterventions,
or all-cause mortality. However, PASCAL trended towards better residual MR
reduction, although this was accompanied by moderate heterogeneity. Both
devices demonstrated comparable safety profiles and were effective in
reducing MR and improving cardiac function. <br/>CONCLUSION(S): MitraClip
and PASCAL devices showed comparable safety profiles and procedural
success rates. However, the analysis did not reveal a statistically
significant difference between the two devices in reducing the severity of
MR.<br/>Copyright &#xa9; 2025. The Author(s).

<11>
Accession Number
2035487983
Title
The impact of threshold-loaded inspiratory muscle training and respiratory
biofeedback on preserving inspiratory muscle strength and vital capacity
after CABG: a randomized clinical trial.
Source
American Journal of Cardiovascular Disease. 14(6) (pp 375-383), 2024. Date
of Publication: 2024.
Author
Mehregan-Far B.; Naimi S.S.; Abedi M.; Salemi P.; Raeis-Sadat S.A.;
Beheshti-Monfared M.
Institution
(Mehregan-Far, Salemi) Student Research Committee, Department of
Physiotherapy, Faculty of Rehabilitation, Shahid Beheshti University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Naimi) Department of Physiotherapy, School of Rehabilitation, Shahid
Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Abedi) Department of Physiotherapy, Chronic Respiratory Diseases Research
Center, Dr. Masih Daneshvari Hospital, Shahid Beheshti University of
Medical Sciences, Tehran, Iran, Islamic Republic of
(Raeis-Sadat) Department of Physical Medicine and Rehabilitation Research
Center, School of Medicine, Shahid Modarres Hospital, Shahid Beheshti
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Beheshti-Monfared) Department of Cardiovascular Surgery, School of
Medicine, Shahid Modarres Hospital, Shahid Beheshti University of Medical
Sciences, Tehran, Iran, Islamic Republic of
Publisher
E-Century Publishing Corporation
Abstract
Objectives: Postoperative pulmonary complications (POPC) are common after
cardiac surgeries such as coronary artery bypass grafting (CABG) and are
influenced by factors including anesthesia and surgical trauma.
Inspiratory muscle training (IMT) with visual biofeedback may mitigate
these complications. This study investigates the impact of threshold
loading inspiratory muscle training (TL-IMT) combined with respiratory
biofeedback on the dynamic strength of inspiratory muscles (S-index) in
patients undergoing CABG surgery during their hospitalization phase.
<br/>Method(s): A single-blind study was conducted with 38 CABG candidates
at Shahid Modares Hospital, Tehran. Participants were randomized into two
groups: the TL-IMT with biofeedback group and the placebo IMT group. TLIMT
exercises were performed at 30% of maximum dynamic inspiratory strength
using the Power Breath K5 device, with visual biofeedback displayed on the
screen. The placebo group performed the same exercises at minimal load
without biofeedback. Both groups received standard respiratory
physiotherapy. Measurements of S-index, peak inspiratory flow (PIF), and
vital capacity (VC) were taken before surgery (T1), one day after surgery
(T2), and at discharge (T3). <br/>Result(s): Both groups showed
significant changes, with a decrease from T1 to T2 and an increase from T2
to T3. In the study group, T3 values remained the same as at T1, while the
placebo IMT group experienced a significant decrease. After surgery, both
groups had a drop in the S-index. However, the study group saw more
pronounced changes between T3-T2 and T3-T1 compared to the control group,
although no significant difference was found between T2-T1. By the time of
discharge, the TL-IMT group had higher S-index values than the placebo
group, returning to preoperative levels. Additionally, the TL-IMT group
showed improvements in PIF and VC. <br/>Conclusion(s): TL-IMT with visual
biofeedback effectively maintains dynamic inspiratory muscle strength and
improves key pulmonary parameters in cardiac surgery patients. These
findings suggest that integrating TL-IMT with biofeedback can enhance
postoperative recovery and reduce the incidence of POPC.<br/>Copyright
&#xa9; 2024, E-Century Publishing Corporation. All rights reserved.

<12>
Accession Number
2035401317
Title
Effects of Blood Flow Restriction Combined with Aerobic Stepping Exercise
in Sarcopenia: A Study Protocol for a Randomized Clinical Trial.
Source
International Journal of General Medicine. 17 (pp 6393-6405), 2024. Date
of Publication: 2024.
Author
Zhang H.; Li M.; Mao Z.; Yin T.; Qi J.; Wang F.; Wang L.
Institution
(Zhang) School of Nursing, Suzhou Vocational Health College, Jiangsu,
Suzhou, China
(Zhang, Mao, Yin, Qi, Wang, Wang) School of Nursing, Suzhou Medical
College of Soochow University, Jiangsu, Suzhou, China
(Li) School of Nursing, The Hong Kong Polytechnic University, Hong Kong,
China
Publisher
Dove Medical Press Ltd
Abstract
Background: Blood flow restriction training (BFRT) can produce effects
similar to high-intensity exercise at lower intensities, making it a
potentially more suitable method for older adults with sarcopenia. This
study aims to determine the efficacy of the intervention on improving
physical fitness in older adults with sarcopenia when blood flow
restriction (BFR) and aerobic exercise (AE) are combined (BFR-AE) and to
explore the related metabolic and signaling mechanisms. <br/>Method(s):
This is a three-arm, parallel, randomized controlled trial. A total of 171
participants, aged 60 to 90 years, with sarcopenia will be randomly
assigned (1:1:1) into one of three groups: a control group, an AE group,
and a BFR-AE group. The participants in the control group will maintain
their usual diet and activity habits. Those in the AE and BFR-AE groups
will undergo a 12-week program of AE and BFR-AE respectively. The primary
outcomes will include two long-term indicators: the 6-minutes walking test
and 30-s chair stand test. Secondary outcomes will include additional
long-term measures (eg, appendicular skeletal muscle mass index, handgrip
strength, five-time chair stand test, lower extremity knee extensor and
flexor muscle strength, sleep quality, emotion status, serum metabonomic
and signal proteins), as well as instantaneous indicators (eg, blood
pressure, heart rate, saturation of pulse oxygen, rating of perceived
exertion, pain score and blood lactate concentration), adherence to
exercise, and adverse events. Outcomes will be assessed at one of or all
the time points of baseline, 12 and 24 weeks. <br/>Discussion(s): It is
expected that, after 12 weeks of intervention, both exercise groups will
show improvements in cardiorespiratory and muscular fitness, with the
BFR-AE group demonstrating greater benefits than the AE group
alone.<br/>Copyright &#xa9; 2024 Zhang et al.

<13>
Accession Number
645759017
Title
Complete versus culprit-only coronary revascularization in patients with
myocardial infarction and multivessel disease undergoing percutaneous
coronary intervention: an updated meta-analysis.
Source
Panminerva medica. 66(4) (pp 408-416), 2024. Date of Publication: 01 Dec
2024.
Author
Rodriguez-Granillo A.M.; Masson W.; Lobo M.; Mieres J.; Perez-Valega L.;
Barbagelata L.; Waisten K.; Fernandez-Pereira C.; Rodriguez A.E.
Institution
(Rodriguez-Granillo) Centro de Estudios en Cardiologia Intervencionista
(CECI), Buenos Aires, Argentina
(Rodriguez-Granillo) Department of Interventional Cardiology, Sanatorio
Otamendi, Buenos Aires, Argentina
(Masson, Barbagelata) Department of Cardiology, Italian Hospital of Buenos
Aires, Buenos Aires, Argentina
(Lobo) Department of Cardiology, Campo de Mayo Military Hospital, Buenos
Aires, Argentina
(Mieres, Fernandez-Pereira, Rodriguez) Department of Interventional
Cardiology, Sanatorio Otamendi, Buenos Aires, Argentina
(Perez-Valega) Department of Cardiology, Canning, Argentina
(Waisten) Department of Cardiology, Buenos Aires, Argentina
(Fernandez-Pereira, Rodriguez) Centro de Estudios en Cardiologia
Intervencionista (CECI), Buenos Aires, Argentina
Abstract
INTRODUCTION: Recently, the FFR-Guidance for Complete Nonculprit
Revascularization (FULL REVASC) trial in ST elevation myocardial
infarction (STEMI) patients with multiple vessel disease (MVD) did not
show differences in the composite endpoint of death from any cause,
myocardial infarction, or unplanned revascularization than
culprit-lesion-only percutaneous coronary intervention (PCI) at 4.8 years,
although complete revascularization is a recommendation IA in current
guidelines. We want to determine through an updated meta-analysis whether
complete revascularization is associated with decreased mortality and hard
clinical endpoints compared to culprit lesion only PCI. EVIDENCE
ACQUISITION: We searched MEDLINE, Embase, ISI Web of Science, and Cochrane
Central Register of Controlled Trials) from January 1990 to April 2024
using the terms "percutaneous coronary intervention" combined with "non
culprit lesions" or "culprit lesion" or "complete revascularization" or
"incomplete revascularization." Additionally, a "snowball search" was
conducted. Only randomized clinical trials (RCT) reporting mortality,
re-infarction or new revascularization after at least 12 months and using
predominantly drug eluting stents were included. The summary effect of
different revascularization strategies on cardiovascular endpoints was
estimated and measures of effect size were expressed as odds ratios (ORs).
EVIDENCE SYNTHESIS: Eight RCT involving 9515 patients were included, with
a follow-up range between 12 months and 4.8 years. Main findings show that
culprit lesion revascularization was associated with an increased risk of
MI (OR: 1.38; 95% CI: 1.05 to 1.81, I2 42%) and ischemia-guided
revascularization (OR: 2.81; 95% CI: 1.86 to 4.26, I2 80%) compared to
complete revascularization, without differences in overall mortality (OR:
1.15; 95% CI: 0.98 to 1.36, I2 2%). <br/>CONCLUSION(S): In patients with
STEMI and MVD without cardiogenic shock, our metanalysis showed that
complete revascularization with PCI significantly reduced the risk of
non-fatal myocardial reinfarction and ischemic-driven revascularization
compared to culprit vessel-only revascularization, without differences in
overall mortality.

<14>
Accession Number
2023961323
Title
Platelet-rich plasma influence on the sternal wounds healing: A
meta-analysis.
Source
International Wound Journal. 20(9) (pp 3794-3801), 2023. Date of
Publication: 01 Nov 2023.
Author
Zhu S.; Gao J.; Yu W.; Xiong J.
Institution
(Zhu) Department of Thoracic Surgery, The First Affiliated Hospital of
Gannan Medical University, Ganzhou, China
(Zhu) Ganzhou Key Lab of Brain Injury & Brain Protection, Ganzhou, China
(Gao, Yu) The First Clinical Medical College, Gannan Medical University,
Ganzhou, China
(Xiong) Department of Cardiovascular Surgery, The First Affiliated
Hospital of Gannan Medical University, Ganzhou, China
Publisher
John Wiley and Sons Inc
Abstract
A meta-analysis research was executed to appraise the effect of
platelet-rich plasma (PRP) on sternal wound healing (SWH). Inclusive
literature research till April 2023 was done and 1098 interconnected
researches were revised. The 11 picked researches, enclosed 8961 cardiac
surgery (CS) persons were in the utilised researchers' starting point,
3663 of them were utilising PRP, and 5298 were control. Odds ratio (OR)
and 95% confidence intervals (CIs) were utilised to appraise the effect of
PRP on the SWH by the dichotomous approach and a fixed or random model.
PRP had significantly lower sternal wound infection (SWI) (OR, 0.11; 95%
CI, 0.03-0.34, p < 0.001), deep SWI (OR, 0.29; 95% CI, 0.16-0.51, p <
0.001), and superficial SWI (OR, 0.20; 95% CI, 0.13-0.33, p < 0.001),
compared to control in CS persons. PRP had significantly lower SWI, deep
SWI, and superficial SWI, compared to control in CS persons. However,
caution must be taken when interacting with its values since there was a
low sample size of some of the nominated research found for the
comparisons in the meta-analysis.<br/>Copyright &#xa9; 2023 The Authors.
International Wound Journal published by Medicalhelplines.com Inc and John
Wiley & Sons Ltd.

<15>
Accession Number
2032974204
Title
Current Trends and Perspectives of Pressure Wire-Based Coronary Artery
Bypass Grafting.
Source
Journal of Cardiovascular Development and Disease. 12(1) (no pagination),
2025. Article Number: 16. Date of Publication: 01 Jan 2025.
Author
Takami Y.; Maekawa A.; Yamana K.; Akita K.; Amano K.; Niwa W.; Matsuhashi
K.; Takagi Y.
Institution
(Takami, Maekawa, Yamana, Akita, Amano, Niwa, Matsuhashi, Takagi)
Department of Cardiovascular Surgery, Fujita Health University School of
Medicine, 1-98 Dengakugakubo, KutsukakeAichi, Toyoake, Japan
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Fractional flow reserve (FFR) has been well validated as a modality for
evaluating myocardial ischemia, demonstrating the superiority of
FFR-guided percutaneous coronary intervention (PCI) over conventional
angiography-guided PCI. As a result, the strategy for coronary artery
bypass grafting (CABG) is shifting toward FFR guidance. However, the
advantage of FFR-guided CABG over angiography-guided CABG remains unclear.
While FFR-guided CABG can help avoid unnecessary grafting in cases of
moderate stenosis, it may also carry the risk of incomplete
revascularization. The limited use of FFR due to the need for hyperemia
has led to the development of non-hyperemic pressure ratios (NHPRs). NHPR
pullback provides trans-stenotic pressure gradients, which may offer
valuable insights for CABG strategies. Recently, computed tomographic
coronary angiography (CTCA) has emerged as a non-invasive modality that
provides accurate data on lesion length, diameter, minimum lumen area,
percentage stenosis, and the volume and distribution of high-risk plaques.
With the introduction of FFR-CT, CTCA is now highly anticipated to provide
both functional evaluation (of myocardial ischemia) via FFR-CT and
anatomical information through serial quantitative assessment. Beyond the
diagnostic phase, CTCA, augmented by automatic artificial intelligence,
holds great potential for guiding therapeutic interventions in the
future.<br/>Copyright &#xa9; 2025 by the authors.

<16>
Accession Number
646322941
Title
Improving Atrial Fibrillation or Flutter Detection and Management by
Smartphone-Based Photoplethysmography Rhythm Monitoring Following Cardiac
Surgery: A Pragmatic Randomized Trial.
Source
Europace : European pacing, arrhythmias, and cardiac electrophysiology :
journal of the working groups on cardiac pacing, arrhythmias, and cardiac
cellular electrophysiology of the European Society of Cardiology. (no
pagination), 2025. Date of Publication: 17 Jan 2025.
Author
Gruwez H.; De Melio N.; Vermunicht P.; Van Langenhoven L.; Desteghe L.;
Lamberigts M.; Nuyens D.; Van Herendael H.; Rodrigus I.; Van Kerrebroeck
C.; Vandervoort P.; Heidbuchel H.; Pison L.; Rega F.; Haemers P.
Institution
(Gruwez, Lamberigts, Rega, Haemers) Department of Cardiovascular Sciences,
UZ Leuven, Leuven, Belgium
(Gruwez, Nuyens, Van Herendael, Van Kerrebroeck, Vandervoort, Pison)
Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium
(Gruwez, De Melio) Limburg Clinical Research Center, Faculty of Medicine
and Life Sciences, Hasselt University, Hasselt, Belgium
(Vermunicht, Desteghe, Rodrigus, Heidbuchel) Department of Cardiology,
Antwerp University Hospital, Antwerp, Belgium
(Van Langenhoven) KU Leuven - University of Leuven & Universiteit Hasselt,
L-BioStat, Leuven, Belgium
Abstract
BACKGROUND AND AIMS: Atrial fibrillation (AF) or atrial flutter (AFL)
after cardiac surgery are common and associated with adverse outcomes. The
increased risk related to AF or AFL may extend beyond discharge. This
study aims to determine whether photoplethysmography (PPG)-based
smartphone monitoring to detect AF or AFL after hospital discharge
following cardiac surgery improves AF management. <br/>METHOD(S): The
intervention group performed one-minute rhythm checks three times daily
using a smartphone-based PPG application during six weeks after
hospitalization for cardiac surgery. The primary outcome involved AF
management interventions by independent physicians, including initiation
of oral anticoagulation (OAC), direct cardioversion and up-titration or
initiation of antiarrhythmic drugs. <br/>RESULT(S): The study included 450
patients (mean [SD] age, 64.1 [9.2] years; 96 women [21.3%]; 130 patients
with AF history [28.9%]; median [IQR] CHA2DS2-VASc score, 2 [1-3]), of
whom 238 were randomized to PPG-based monitoring and 212 to usual care.
AF/AFL was detected with PPG or electrocardiography in 44 patients (18.5%)
in the monitoring group and 4 patients (1.9%) in the usual care group (OR
11.8; 95%CI, 4.2-33.3; P<.001), these were new detections in respectively
22 patients (9.2%) and 1 patient (0.5%) (OR 21.3; 95%CI, 2.9-166.7;
P=.003). AF management interventions occurred in 24 patients (10.1%) in
the monitoring group compared to 5 patients (2.4%) in the usual care group
(odds ratio [OR]), 5.1; 95%CI, 1.8-14.4; P=.002). <br/>CONCLUSION(S): In
unselected patients discharged home following cardiac surgery, PPG-based
smartphone monitoring revealed significantly more AF/AFL which led to
significantly more optimization of AF management.<br/>Copyright &#xa9; The
Author(s) 2025. Published by Oxford University Press on behalf of the
European Society of Cardiology.

<17>
Accession Number
2032986892
Title
Hydrophilic Polymer Embolization-A Scoping Review of the Available
Literature with Focus on Organ Involvement and Outcomes.
Source
Journal of Clinical Medicine. 14(2) (no pagination), 2025. Article Number:
433. Date of Publication: 01 Jan 2025.
Author
Abdulrasak M.; Kadim H.; Someili A.; Mohrag M.
Institution
(Abdulrasak, Kadim) Department of Clinical Sciences, Lund University,
Malmo, Sweden
(Abdulrasak, Kadim) Department of Gastroenterology and Nutrition, Skane
University Hospital, Malmo, Sweden
(Someili, Mohrag) Department of Medicine, Faculty of Medicine, Jazan
University, Jazan, Saudi Arabia
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Hydrophilic polymer embolization (HPE) is a scarcely reported
complication associated with endovascular procedures where the hydrophilic
coating dislodges and disseminates to more distal vascular beds, leading
to ischemic complications. The aim of this study is to assess the clinical
outcomes associated with HPE in the literature and try to quantify it in a
scoping manner. <br/>Method(s): All reports with regard to HPE in the
PubMed database where clinical data were available were included. Reports
were excluded if no clinical data were available and only
histopathological descriptions are available, if the language of the
report was not in English, and if access could not be obtained to that
specific report. <br/>Result(s): A total of 60 publications containing 111
patients were identified. The majority (N = 45, 75%) of the publications
were "single-patient" case reports. An overwhelming minority of the
reports reported underlying hypertension (N = 27, 45.0%) and ischemic
heart disease (N = 28, 46.7%). The most common implicated procedures for
HPE occurence were cardiac procedures (N = 28, 46.7%), intracranial
procedures (N = 13, 21.7%) and aortic procedures (N = 10, 16.7%). Steroids
were trialled in nine (15%) of the reports, mainly for HPE to the CNS
(7/9), with no mortality in that specific group. However, HPE-related
mortality, identified in 48/111 patients, was largely due to HPE with
pulmonary and cardiac involvement (combined 36/48 of all deaths).
<br/>Conclusion(s): HPE seems to be a rare occurrence, although
low-quality evidence (mainly case reports) comprises most of the research
on the subject. Fatal outcomes seem relatively common, and steroid therapy
may be trialled in select cases. Further research, potentially through
prospective registry studies may aid in providing more knowledge on
HPE.<br/>Copyright &#xa9; 2025 by the authors.

<18>
Accession Number
646324400
Title
Biomarkers of RV Dysfunction in HFrEF Identified by Direct Tissue
Proteomics: Extracellular Proteins Fibromodulin and Fibulin-5.
Source
Circulation. Heart failure. (pp e011984), 2025. Date of Publication: 17
Jan 2025.
Author
Behounek M.; Lipcseyova D.; Vit O.; Zacek P.; Talacko P.; Huskova Z.;
Kikerlova S.; Tykvartova T.; Wohlfahrt P.; Melenovsky V.; Benes J.; Petrak
J.
Institution
(Behounek, Lipcseyova, Vit, Petrak) First Faculty of Medicine,
Biotechnology and Biomedicine Center of the Academy of Sciences and
Charles University (BIOCEV), Charles University, Czech Republic. (M.B.,
D.L., Prague, United States
(Zacek, Talacko) Proteomic Core Facility, Faculty of Science,
Biotechnology and Biomedicine Center of the Academy of Sciences and
Charles University (BIOCEV), Charles University, Czech Republic. (P.Z.,
Prague, United States
(Huskova, Kikerlova) Center of Experimental Medicine, Institute for
Clinical and Experimental Medicine (IKEM), Czech Republic. (Z.H., Prague,
United States
(Tykvartova, Wohlfahrt, Melenovsky, Benes) Department of Cardiology,
Institute for Clinical and Experimental Medicine (IKEM), Czech Republic.
(T.T., Prague, United States
(Benes) Division of Cardiovascular Medicine, University of Utah School of
Medicine
Abstract
BACKGROUND: Right ventricular dysfunction (RVD) is common in patients with
heart failure with reduced ejection fraction, and it is associated with
poor prognosis. However, no biomarker reflecting RVD is available for
routine clinical use. <br/>METHOD(S): Proteomic analysis of myocardium
from the left ventricle and right ventricle (RV) of patients with heart
failure with reduced ejection fraction with (n=10) and without RVD (n=10)
who underwent heart transplantation was performed. Concentrations of 2 ECM
(extracellular matrix) proteins with the highest myocardial upregulation
in RVD, FMOD (fibromodulin) and FBLN5 (fibulin-5), were assayed in the
blood and tested in a separate cohort of patients with heart failure with
reduced ejection fraction (n=232) to test for the association of the 2
proteins with RV function and long-term outcomes. <br/>RESULT(S):
Multivariable linear regression revealed that plasma concentrations of
both FMOD and FBLN5 were significantly associated with RV function
regardless of the RV function assessment method. No association of FMOD or
FBLN5 with left ventricular dysfunction, cardiac index, body mass index,
diabetes status, or kidney function was found. Plasma levels of FMOD and
FBLN5 were significantly associated with patient outcomes (P=0.005;
P=0.004). Area under the curve analysis showed that the addition of FBLN5
or FMOD to RV function assessment had a significantly higher area under
the curve after 4 years of follow-up (0.653 and 0.631, respectively)
compared with RV function alone (0.570; P<0.05 for both). Similarly, the
combination of MAGGIC (Meta-Analysis Global Group in Chronic Heart
Failure) score, FBLN5, and FMOD had a significantly larger area under the
curve (0.669) than the combination of MAGGIC score+RVD grade (0.572;
P=0.02). The Kaplan-Meier analysis demonstrated that patients with the
elevation of both FMOD and FBLN5 (ie, FMOD >64 ng/mL and FMOD >27 ng/mL)
had a worse prognosis than those with the elevation of either FBLN5 or
FMOD (P=0.03) demonstrating the additive prognostic value of both
proteins. <br/>CONCLUSION(S): Our study proposes that circulating levels
of FMOD and FBLN5 may serve as new biomarkers of RVD in patients with
heart failure with reduced ejection fraction.

<19>
Accession Number
646330132
Title
A systematic review to explore the impact of cardiac sarcoidosis on
health-related quality of life.
Source
European Respiratory Journal. Conference: European Respiratory Society
International Congress, ERS 2024. Vienna Austria. 64(Supplement 68) (pp
PA2290), 2024. Date of Publication: 01 Sep 2024.
Author
Quijano-Campos J.C.; Sekhri N.; Thillai M.; Blower E.; Othen-Price L.;
Murphy E.; Clarke H.; Whight J.; Sanders J.
Institution
(Quijano-Campos) William Harvey Research Institute, Queen Mary University
of London; St Bartholomew's Hospital, Barts Health NHS Trust; Research and
Development, London, United Kingdom
(Sekhri) Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS
Trust; Queen Mary University of London, London, United Kingdom
(Thillai) Interstitial Lung Disease Unit, Royal Papworth Hospital NHS
Foundation Trust, University of East Anglia, Cambridge, United Kingdom
(Blower, Othen-Price, Murphy, Clarke, Whight) CARD-SARC Public and Patient
Involvement Group, London, United Kingdom
(Sanders) St Bartholomew's Hospital, Barts Health NHS Trust; William
Harvey Research Institute, Queen Mary University of London, London, United
Kingdom
Publisher
European Respiratory Society
Abstract
Background: People living with cardiac sarcoidosis (CS) are likely to have
worse clinical outcomes and greater impairment on health-related quality
of life (HRQoL) than other sarcoidosis manifestations. CS can result in a
constellation of intrusive symptoms (such as palpitations, dizziness,
syncope or dyspnoea) and/or life-threatening episodes, requiring
consideration of invasive cardiac procedures for diagnosis and for the
management of acute events. Additionally, the presence of multisystemic
involvement and persistent nonspecific sarcoidosis symptoms negatively
affect HRQoL. <br/>Aim(s): A systematic review was undertaken to explore
the impact of CS on HRQoL in adults with CS. <br/>Method(s): Multiple
bibliographic databases were searched for studies with HRQoL as primary or
secondary outcomes in CS(PROSPERO:CRD42019119752). Data extraction and
quality assessments were undertaken independently by two authors.
<br/>Result(s): From 1609 identified records, only 11 studies included
CS-patients but none specifically reported HRQoL-scores for CS-patients.
The average representation of CS-patients was 14.5% within these cohorts
[range 2-22%]. The majority (73%) were conducted in single-centre tertiary
care settings and only one study (9%) included longitudinal HRQoL data.
CS-patients were among those sarcoidosis patients with impaired HRQoL and
worse outcomes, requiring higher doses of sarcoidosis-specific therapy
which contribute to further deterioration of HRQoL. <br/>Conclusion(s):
Sarcoidosis studies do not incorporate stratified HRQoL-scores for
CS-patients. While there is a need for longitudinal and multicentre
studies assessing HRQoL outcomes in CS-cohorts, the development of
CS-specific tool is also needed.

<20>
Accession Number
2029634829
Title
Evaluating the Efficacy of the Erector Spinae Plane Block as a
Supplementary Approach to Cardiac Anesthesia during Off-Pump Coronary
Bypass Graft Surgery via Median Sternotomy: A Randomized Clinical Trial.
Source
Journal of Clinical Medicine. 13(8) (no pagination), 2024. Article Number:
2208. Date of Publication: 01 Apr 2024.
Author
Kim S.; Song S.W.; Jeon Y.-G.; Song S.A.; Hong S.; Park J.-H.
Institution
(Kim, Song, Jeon, Song, Park) Department of Anesthesiology and Pain
Medicine, Wonju College of Medicine, Yonsei University, Wonju, South Korea
(Hong) Department of Cardiovascular Surgery, Wonju College of Medicine,
Yonsei University, Wonju, South Korea
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: Pain control after off-pump coronary artery bypass graft
(OPCAB) facilitates mobilization and improves outcomes. The efficacy of
the erector spinae plane block (ESPB) after cardiac surgery remains
controversial. <br/>Method(s): We aimed to investigate the analgesic
effects of ESPB after OPCAB. Precisely 56 patients receiving OPCAB were
randomly divided into ESPB and control groups. The primary outcome was
visual analog scale (VAS) pain scores at 6, 12, 24, and 48 h
postoperatively. Secondary outcomes were the dose of rescue analgesics in
terms of oral morphine milligram equivalents, the dose of antiemetics, the
length of intubation time, and the length of stay in the intensive care
unit (ICU). <br/>Result(s): The VAS scores were similar at all time points
in both groups. The incidence of severe pain (VAS score > 7) was
significantly lower in the ESPB group (50% vs. 15.4%; p = 0.008). The dose
of rescue analgesics was also lower in the ESPB group (19.04 +/- 18.76,
9.83 +/- 12.84, p = 0.044) compared with the control group. The other
secondary outcomes did not differ significantly between the two groups.
<br/>Conclusion(s): ESPB provides analgesic efficacy by reducing the
incidence of severe pain and opioid use after OPCAB.<br/>Copyright &#xa9;
2024 by the authors.

<21>
Accession Number
646332472
Title
Respiratory Muscle Training using the Novel Multifunctional Respiratory
Device during the Mid-postoperative Period following Cardiac Surgery: A
Real-Life Pilot Study.
Source
European Respiratory Journal. Conference: European Respiratory Society
International Congress, ERS 2024. Vienna Austria. 64(Supplement 68) (pp
PA4124), 2024. Date of Publication: 01 Sep 2024.
Author
Novoa N.P.; Castillo E.R.; Phd S.S.B.; Espitia A.; Ramfrez-Sarmiento A.;
Orozco-Levi M.
Institution
(Novoa, Castillo, Phd) Fundacion Cardiovascular de Colombia, Direction of
Innovation and Technological Development, Floridablanca, Santander,
Colombia
(Espitia, Ramfrez-Sarmiento, Orozco-Levi) Fundacion Cardiovascular de
Colombia, Respiratory Department, Floridablanca, Santander, Colombia
Publisher
European Respiratory Society
Abstract
Respiratory muscle(RM) weakness increases the risk of complications,
hospitality length of stay, and mortality of patients in the postoperative
period for cardiac surgery. Nevertheless, RM dysfunction can be
potentially reversed using RM training. We developed and patented an
innovative device(TriBURTER) incorporating 5 effects, allowing
simultaneously to train inspiratory and expiratory muscles, provide
vibratile waves to mobilize secretions and to stimulate cough, and
incentivize respiratory movements. To compare with a flow-incentive
spirometer(IS) the efficacy of(TriBURTER) to increase the respiratory
muscle strength as an additional strategy to cardiac rehabilitation phase
II. A randomized(1:1) study was performed. Thirty adult patients(63+/-9
yrs, 13.3% women) were submitted to daily RM training sessions additional
to cardiac rehabilitation program. Training for 4 weeks with (TriBURTER)
or IS. The main outcomes were the maximum pressures measured in the mouth
(PImax, PEmax) at 1, 14, and 28 days. The groups were comparable in
demographic, anthropometric, and functional baseline variables. Both
groups disclosed improvements in PImax and PEmax(p<0,05). Nevertheless,
weak patients showed greater improvements in PImax(p=0.001) and
PEmax(p=0.0313) in the intervention group. The added value when compared
with IS group was +40% for PImax and +28% for PEmax. (TriBURTER)
represents a Colombian innovative device allowing to effectively and
safely to increase fastly and greater proportion the inspiratory and
expiratory muscle strength. TriBURTER provides additional valuable effects
that are not offered using the conventional IS.

<22>
Accession Number
646329022
Title
Late Breaking Abstract - BIOMARKER ALBUMIN MODIFIED BY ISCHEMIA AS A
PREDICTOR OF FUTURE CARDIOVASCULAR RISK IN PATIENTS WITH SLEEP APNEA
SYNDROME AND TREATMENT WITH CPAP VS USUAL CARE TREATMENT.
Source
European Respiratory Journal. Conference: European Respiratory Society
International Congress, ERS 2024. Vienna Austria. 64(Supplement 68) (pp
PA2710), 2024. Date of Publication: 01 Sep 2024.
Author
Barrio P.R.; Peralta S.R.; Castillo M.; Mediano O.; Barbe F.; Perez E.S.;
Zapata C.C.; Garcia Rio F.; De La Torre M.S.
Institution
(Barrio) ERS,Sleep Unit, Pneumology Department, Hospital Universitario de
Guadalajara, Guadalajara, Spain
(Peralta, Castillo) Pneumology Department, Hospital Universitario de
Guadalajara, Guadalajara, Spain
(Mediano) ERS,Sleep Unit, Pneumology Department, Hospital Universitario de
Guadalajara, Guadalajara, Spain
(Barbe) ERS,Centro de Investigacion Biomedica en Red de Enfermedades
Respiratorias (CIBERES), Madrid, Spain
(Perez) ERS,Sleep Unit, Pneumology Department, Hospital Universitario de
Guadalajara, 19002 Guadalajara, Spain
(Zapata) ERS,Centro de Investigacion Biomedica en Red de Enfermedades
Respiratorias (CIBERES), Madrid, Spain
(Garcia Rio) ERS,Centro de Investigacion Biomedica en Red de Enfermedades
Respiratorias (CIBERES), Madrid, Spain
(De La Torre) ERS,Centro de Investigacion Biomedica en Red de Enfermedades
Respiratorias (CIBERES), Madrid, Spain
Publisher
European Respiratory Society
Abstract
Introduction: The biomarker Ischemia Modified Albumin (IMA), accepted for
the diagnosis of cardiac ischemia in adults, is considered a biomarker for
direct measurement of oxidative stress, a common pathophysiological
mechanism with OSA. Objetive: To assess the evolution of IMA, in terms of
new cardiovascular events (CV mortality, admission for heart failure,
coronary revascularization procedures, unstable angina) throughout the
follow-up, depending on the baseline IMA values, severity of OSA and the
treatment applied (CPAP vs conservative treatment). <br/>Method(s): Nested
study in the ISAAC project, a multicenter, open-label, parallel,
prospective, randomized, controlled study (registration number: NCT
01335087) of patients with ACS and OSA. We included 925 patients who
underwent cardiorespiratory polygraphy in the first 24-72 as well as a
venous blood draw to determine IMA values. The patients were recruited
consecutively and the group distribution (based on the apnea/hypopnea
index [AHI]). Subsequently, patients with AHI > 15 events/h were
randomized to receive treatment with continuous positive airway pressure
(CPAP) or conservative treatment. <br/>Conclusion(s): Patients with
moderate-severe OSA, after being randomized to treatment with CPAP or
conservative treatment, do not present a higher rate of new cardiovascular
events (CV mortality, admission for CHF, coronary revascularization
procedures, unstable angina) throughout follow-up, depending on high or
low IMA values.

<23>
Accession Number
646329317
Title
Pregnancy Outcomes and Management in Lung and Heart Transplant Recipients:
A Systematic Review.
Source
European Respiratory Journal. Conference: European Respiratory Society
International Congress, ERS 2024. Vienna Austria. 64(Supplement 68) (pp
PA4987), 2024. Date of Publication: 01 Sep 2024.
Author
Tanaka A.; Filippidis F.T.; El Asmar M.L.; Reed A.; Gerovasili V.
Institution
(Tanaka, Filippidis, El Asmar) School of Public Health, Imperial College
London, London, United Kingdom
(Reed, Gerovasili) Department of Cardiothoracic Transplant Harefield
Hospital, Guy's and St Thomas' NHS Foundation Trust, 3. National Heart and
Lung Institute, Imperial College London, London, United Kingdom
Publisher
European Respiratory Society
Abstract
Introduction: Immunosuppression advances have enabled organ transplant
recipients to consider parenthood, but pregnancy poses risks to maternal
and fetal health. <br/>Aim(s): This is a systematic review on pregnancy
outcomes and immunosuppression management in cardiothoracic transplant
recipients. <br/>Method(s): We conducted a comprehensive literature search
of Medline, Embase, and Maternity & Infant Care Database in December 2022.
After screening, 54 relevant studies were identified. We also used data
from the Transplant Pregnancy Registry International (TPRI). A total of
406 pregnancies from 271 heart recipients (HTR) and 143 pregnancies from
120 lung recipients (LTR) were included in the review. <br/>Result(s):
78.7% and 69% of pregnancies resulted in live births among HTR and LTR
respectively (22% preterm). In HTR, graft dysfunction developed in 10.9%
and 12.4% during and after pregnancy respectively. In LTR, 17.2% and 18%
developed graft dysfunction during and after pregnancy. Other maternal
complications included hypertensive disorders (HTR: 22.4%, LTR: 45.5%),
preeclampsia (HTR: 9.1%, LTR: 14.5%) and diabetes (LTR: 15.9%, LTR:
31.4%). Maternal mortality was 17.1% for HTR and 29.3% for LTR. At the
time of pregnancy approximately half of HTR and two thirds of LTR were on
Tacrolimus. The most common immunosuppression changes were discontinuation
of MMF, with and dose adjustment of Azathioprine, Sirolimus and
corticosteroids. <br/>Conclusion(s): We found that, although the
proportion of successful pregnancies among heart and lung transplant
recipients reported in the literature was high, the risks of developing
new graft dysfunction and of maternal death post pregnancy were
substantial.

<24>
Accession Number
2032308320
Title
The prevalence of abnormal spirometry in children with CHD.
Source
Cardiology in the Young. 33(12) (pp 2548-2552), 2023. Date of Publication:
31 Dec 2023.
Author
Zhou G.Y.; Cerrone D.; Lewinter K.; Masood I.; Detterich J.; Singh S.;
Shah P.; Keens T.; Sabati A.; Kato R.
Institution
(Zhou) Department of Pediatrics, Children's Hospital Los Angeles, Los
Angeles, CA, United States
(Cerrone, Lewinter, Singh, Keens, Kato) Division of Pediatric Pulmonology
and Sleep Medicine, Children's Hospital Los Angeles, Los Angeles, CA,
United States
(Masood, Detterich, Shah) Division of Cardiology, Children's Hospital Los
Angeles, Los Angeles, CA, United States
(Sabati) Division of Cardiology, Phoenix Children's Hospital, Phoenix, AZ,
United States
Publisher
Cambridge University Press
Abstract
Background: The burden of pulmonary disease in children with CHD remains
under-recognised. Studies have examined children with single ventricle and
two ventricle heart disease and documented a decreased forced vital
capacity. Our study sought to further explore the pulmonary function of
children with CHD. <br/>Method(s): A retrospective review was performed of
spirometry in CHD patients over a 3-year period. Spirometry data were
corrected for size, age, and gender and analysed using z-scores.
<br/>Result(s): The spirometry of 260 patients was analysed. About 31% had
single ventricle (n = 80, 13.6 years (interquartile range 11.5-16.8)) and
69% had two ventricle circulation (n = 180, 14.4 years (interquartile
range 12.0-17.3)). Single ventricle patients were found to have a lower
median forced vital capacity z-score compared to two ventricle patients (p
= 0.0133). The prevalence of an abnormal forced vital capacity was 41% in
single ventricle patients and 29% in two ventricle patients. Two ventricle
patients with tetralogy of Fallot and truncus arteriosus had similar low
forced vital capacity comparable to single ventricle patients. The number
of cardiac surgeries predicted an abnormal forced vital capacity in two
ventricle patients except tetralogy of Fallot patients.
<br/>Conclusion(s): Pulmonary morbidity in patients with CHD is common
with a decreased forced vital capacity noted in single ventricle and two
ventricle patients. Forced vital capacity is lower in patients with single
ventricle circulation; however, two ventricle patients with tetralogy of
Fallot or truncus arteriosus have similar lung function in comparison to
the single ventricle group. The number of surgical interventions was
predictive of forced vital capacity z-score in some but not all two
ventricle patients and not predictive in single ventricle patients
suggesting a multifactorial to pulmonary disease in children with
CHD.<br/>Copyright &#xa9; The Author(s), 2023. Published by Cambridge
University Press.

<25>
Accession Number
2037076253
Title
Does methylene blue improve outcomes in patients with post-cardiac surgery
vasoplegic syndrome?.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 40(1) (no
pagination), 2025. Article Number: ivae221. Date of Publication: 01 Jan
2025.
Author
Zhu M.Z.L.; Scullion J.; Stroebel A.; He C.
Institution
(Zhu, Scullion, Stroebel, He) Department Cardiothoracic Surgery, Gold
Coast University Hospital, Southport, QLD, Australia
(Scullion, Stroebel, He) School of Medicine and Dentistry, Griffith
University, Southport, QLD, Australia
Publisher
Oxford University Press
Abstract
OBJECTIVES: A best evidence topic was written according to a structured
protocol described in ICVTS. The question addressed was 'In patients with
vasoplegic syndrome following cardiac surgery with cardiopulmonary bypass,
does adjunctive methylene blue improve outcomes including reduced
mortality, morbidity and vasopressor requirements?' METHODS: Ovid Medline
was searched using a reported search algorithm. Articles that represented
the best evidence to answer the clinical question were selected, tabulated
and discussed. <br/>RESULT(S): Seven articles were selected: 4 randomized
controlled trials and 3 observational studies. Studies were single centre
with sample sizes ranging from 30 to 120 patients. Two studies reported a
significant reduction in mortality among patients who received adjunctive
methylene blue for post-cardiopulmonary bypass (CPB) vasoplegic syndrome
compared with placebo or standard therapy. Four studies reported improved
haemodynamic stability and reduced vasopressor requirements following
methylene blue. No studies reported methylene blue-related adverse events
or worse outcomes compared to controls or standard therapy. There was
significant heterogeneity among the included studies in terms of the
timing and dosage of methylene blue therapy as well as the definition of
vasoplegic syndrome. <br/>CONCLUSION(S): The summation of the best
available evidence, which was limited to small clinical trials and
observational studies, suggests that the adjunctive administration of
methylene blue for refractory post-CPB vasoplegic syndrome is safe and may
provide benefits in terms of improved haemodynamic stability, reduction in
vasopressor requirements and reduced mortality. Questions surrounding the
optimal timing of methylene blue administration, as prophylactic,
adjunctive, or rescue therapy for vasoplegic syndrome, require further
investigation.<br/>Copyright &#xa9; 2024 The Author(s).

<26>
Accession Number
2037186026
Title
Continuous serratus anterior block for sternotomy analgesia after cardiac
surgery: a single-centre feasibility study.
Source
British Journal of Anaesthesia. (no pagination), 2025. Date of
Publication: 2025.
Author
Bailey J.G.; Hendy A.; Neira V.; Chedrawy E.; Uppal V.
Institution
(Bailey, Hendy, Neira, Uppal) Department of Anesthesia, Pain Management &
Perioperative Medicine, Dalhousie University, Halifax, NS, Canada
(Chedrawy) Division of Cardiac Surgery, Dalhousie University, Halifax, NS,
Canada
Publisher
Elsevier Ltd
Abstract
Background: Moderate-to-severe pain is common after cardiac surgery,
peaking during the first and second postoperative days. Several nerve
blocks for sternotomy have been described; however, the optimal location
for continuous catheters has not been established. This study assessed the
feasibility of a larger trial evaluating the efficacy of serratus anterior
plane (SAP) catheter analgesia for sternotomy pain. <br/>Method(s): This
double-blinded trial included patients undergoing cardiac surgery via
sternotomy. Bilateral SAP catheters were placed in all participants, and
randomised to ropivacaine or placebo. We assessed feasibility based on
predetermined endpoints: (1) average recruitment rate >4 per month; (2)
protocol adherence rate >90%; (3) primary outcome measurement rate >90%;
and (4) significant catheter-related adverse event rate <=2%. The quality
of recovery index (QoR-15) was compared using an independent t-test.
<br/>Result(s): Of 52 participants randomised, feasibility data were
available for 50. A definitive study was deemed 'not feasible' in our
standalone centre owing to a low recruitment rate (2.4 per month) and a
high adverse event rate (pneumothorax rate 12%). There were no major
protocol deviations but minor deviations in 12% of participants. Pain,
opioid consumption, complications, and quality of recovery were not
different between groups. Long-term pain at 3 months was low in both
groups. <br/>Conclusion(s): A single-centre trial was deemed not feasible
for our setting. With limited data, the quality of recovery was not
different with ropivacaine dosing of bilateral SAP catheters for
sternotomy pain. Clinical trial registration: NCT04648774.<br/>Copyright
&#xa9; 2025 The Author(s)

<27>
Accession Number
2037109444
Title
Long-term outcomes of second-generation drug-eluting stents versus
coronary artery bypass graft: A systematic review and meta-analysis of
randomized trials and multivariable adjusted data.
Source
Coronary Artery Disease. (no pagination), 2025. Article Number:
10.1097/MCA.0000000000001503. Date of Publication: 2025.
Author
Carvalho Ferreira A.L.; Benitez Gonzalez M.E.; Coelho Pessoa Lima A.E.;
Alamino Lacalle A.; Saad G.; Guida C.M.
Institution
(Carvalho Ferreira) Department of Medicine, Pontifical Catholic University
of Parana, Curitiba, Brazil
(Benitez Gonzalez) Department of Medicine, Advocate Illinois Masonic
Medical Center, Chicago, IL, United States
(Coelho Pessoa Lima) Department of Medicine, Bahiana School of Medicine
and Public Health, Salvador, Brazil
(Alamino Lacalle) Division of Cardiology, University of Sao Paulo,
Ribeirao Preto, Brazil
(Saad, Guida) Division of Cardiology, Dante Pazzanese Institute of
Cardiology, Sao Paulo, Brazil
Publisher
Lippincott Williams and Wilkins
Abstract
Long-term data are limited comparing percutaneous coronary intervention
(PCI) with second-generation drug-eluting stents (S-DES) vs coronary
artery bypass grafting (CABG) in patients with complex coronary artery
disease (CAD). We aimed to conduct a systematic review and meta-analysis
comparing these interventions in patients with left main or multivessel
CAD. We systematically reviewed PubMed, Embase, and Cochrane for studies
that compared PCI with S-DES and CABG in patients with left main or
multivessel CAD with a minimum mean follow-up period of 3 years. Outcomes
of interest were all-cause mortality, myocardial infarction (MI), stroke,
and major adverse cardiovascular events (MACE). We extracted data from
observational studies as multivariable-adjusted or propensity
score-matched hazard ratio to minimize confounding and pooled hazard
ratios with 95% confidence intervals (CIs) using a random effects model in
Review Manager 5.4.1. We included 10 studies, 3 of which were randomized
controlled trials, comprising a total of 26964 patients, of whom 14928
underwent PCI. As compared with CABG, S-DES had a significantly higher
risk of all-cause mortality (hazard ratio 1.35; 95% CI 1.22-1.49; P <
0.001; I2 = 0%), MACE (hazard ratio 1.27; 95% CI 1.08-1.50; P = 0.005; I2
= 67%), and MI (hazard ratio 2.43; 95% CI 1.80-3.28; P < 0.01; I2 = 0%).
There was no significant difference between groups in incidence of stroke.
In this meta-analysis of patients with complex CAD, PCI with S-DES was
associated with an increased risk of mortality, MI, and MACE compared with
CABG.<br/>Copyright &#xa9; 2025 Wolters Kluwer Health, Inc. All rights
reserved.

<28>
[Use Link to view the full text]
Accession Number
2037159717
Title
Nonintubated video-assisted thoracic surgery: Myth or reality?.
Source
Current Opinion in Anaesthesiology. 38(1) (pp 51-57), 2025. Date of
Publication: 01 Feb 2025.
Author
Piccioni F.; Rosboch G.L.
Institution
(Piccioni) Department of Anesthesia and Intensive Care, IRCCS Humanitas
Research Hospital, Rozzano, Italy
(Rosboch) Department of Anesthesia, Intensive Care and Emergency, A.O.U.
Citta della Salute e della Scienza di Torino, Torino, Italy
Publisher
Lippincott Williams and Wilkins
Abstract
Purpose of reviewThis review discusses nonintubated video-assisted
thoracic surgery (NIVATS) by presenting its physiological, technical
aspects and recent clinical data from the literature.Recent findingsIn the
last two decades, NIVATS has gained traction as an alternative to
traditional intubated thoracic surgery, offering potential benefits in
terms of reduced complications, faster recovery times, and improved
patient satisfaction. Several approaches to this technique have been
described in the literature, mainly divided into the awake patient
technique (awake-NIVATS) and the asleep patient technique (asleep-NIVATS).
The availability of various sedatives, numerous devices to ensure good
oxygenation, and the countless loco-regional techniques available today
for pain control in the thoracic region offer the possibility to develop
many anesthesia protocols in this context. Numerous studies have already
shown that NIVATS is feasible and safe with proper patient selection and
adequate collaboration of the surgical team. Some studies have also shown
that NIVATS may improve patient outcomes, but the evidence is still
limited.SummaryLiterature has demonstrated the feasibility of NIVATS and
suggest that it can improve patient outcomes. High-quality international
randomized multicenter studies comparing NIVATS and intubated
video-assisted thoracic surgery are necessary for a strong comprehension
to clarify whether it can be a technique that can guarantee safety and
improve the perioperative course of patients.<br/>Copyright &#xa9; 2024
Wolters Kluwer Health, Inc. All rights reserved.

<29>
Accession Number
2035527052
Title
A Systematic Review of the Potential of Cold Compresses Therapy: Strategy
for Preventing Hematoma and Alleviating Pain in Post Cardiac
Catheterization Patients.
Source
Journal of Pain Research. 18 (pp 161-175), 2025. Date of Publication:
2025.
Author
Sugiharto F.; Yusanti I.; Sari W.P.; Yuliandani E.; Kosasih C.E.; Trisyani
Y.; Priambodo A.P.; Nuraeni A.; Anna A.; Emaliyawati E.; Mirwanti R.
Institution
(Sugiharto, Yusanti, Sari, Yuliandani) Master Study Program, Faculty of
Nursing, Universitas Padjadjaran, West Java, Sumedang, Indonesia
(Kosasih, Trisyani, Priambodo, Nuraeni, Anna, Emaliyawati, Mirwanti)
Department of Critical Care and Emergency Nursing, Faculty of Nursing,
Universitas Padjadjaran, West Java, Bandung, Indonesia
Publisher
Dove Medical Press Ltd
Abstract
Background: Patients still frequently report complications after cardiac
catheterization procedures, such as hematoma and pain. These complications
increase the length of stay and hospital costs. Several studies have
determined cold compress therapy's effectiveness in preventing hematomas
and reducing pain in patients after cardiac catheterization. However, to
date, no review study has synthesized this comprehensively.
<br/>Purpose(s): This review aimed to explores the potential of cold
compress therapy as a strategy for preventing hematoma and alleviating
pain in post-cardiac catheterization patients. <br/>Method(s): Systematic
review was reported based on the PRISMA Extension. A literature search
used relevant keywords from six primary databases, such as CINAH Medline
Plus, PubMed, ScienceDirect, Scopus, Taylor and Francis, and one search
engine, Google Scholar. The quality of evidence was assessed using the
Joanna Briggs Institute critical appraisal checklist and Risk of Bias.
Data synthesis was used thematically with an explorative, descriptive
approach. <br/>Result(s): This review found and analyzed twelve articles.
Based on the results of the analysis, cold compress therapy for 15 to 20
minutes can potentially prevent hematomas and reduce pain in patients
after cardiac catheterization. <br/>Conclusion(s): This review concludes
that cold compress therapy can potentially prevent hematomas and reduce
pain in this population. Health workers, especially nurses, can consider
cold compress therapy as a strategy in the nursing care program for
patients after cardiac catheterization.<br/>Copyright &#xa9; 2025
Sugiharto et al.

<30>
Accession Number
646307888
Title
Myocardial Revascularization in Heart Failure With Reduced Ejection
Fraction.
Source
Deutsches Arzteblatt international. (Forthcoming) (no pagination), 2025.
Date of Publication: 07 Feb 2025.
Author
Haring B.; Bauersachs J.; Frey N.; Hoppe U.C.; Doenst T.; Bohm M.
Abstract
BACKGROUND: Heart failure (HF) patients with reduced ejection fraction
(HFrEF) now more commonly die of non-cardiovascular causes than they did
in the past. In patients with both HFrEF and ischemic cardiomyopathy (as
the cause of HFrEF or as an accompanying condition), the effect of
myocardial revascularization-i.e. percutaneous coronary intervention (PCI)
or coronary artery bypass grafting (CABG)-on long-term outcome is unclear.
<br/>METHOD(S): This review is based on publications that were retrieved
by a selective search of the literature for pertinent clinical studies and
current guidelines. <br/>RESULT(S): Drug treatment for HFrEF has markedly
prolonged these patients' survival. In a comparative study, HF
pharmacotherapy was found to add an average of 8.3 years to the lifespan
of a 55-year-old patient with HFrEF. Three of the four randomized
controlled trials on revascularization procedures were conducted prior to
the major pharmacotherapy improvements leading to better outcomes in HF
patients over the past decade. These trial data indicate a long-term
benefit from CABG compared to medical treatment alone in patients with
HFrEF and severe coronary heart disease. For example, in the STICH trial,
the hazard ratio for death from any cause after a follow-up time of nearly
10 years was 0.84 (95% confidence interval, [0.73; 0.97]). The role of
pre-procedural myocardial viability and ischemia testing remains to be
fully determined. The choice of method for myocardial revascularization
should be discussed within an interdisciplinary cardiac team in
consideration of the patient's symptoms and ischemic burden, the
complexity of the coronary findings, as well as the patient's
perioperative risk and current medical HF therapy. No RCTs comparing CABG
to PCI are yet available. <br/>CONCLUSION(S): Optimal guideline-directed
medical therapy is a key determinant of long-term survival in patients
with HFrEF.

<31>
Accession Number
2037126061
Title
Machine-learning versus traditional methods for prediction of all-cause
mortality after transcatheter aortic valve implantation: a systematic
review and meta-analysis.
Source
Open Heart. 12(1) (no pagination), 2025. Article Number: e002779. Date of
Publication: 21 Jan 2025.
Author
Zaka A.; Mustafiz C.; Mutahar D.; Sinhal S.; Gorcilov J.; Muston B.; Evans
S.; Gupta A.; Stretton B.; Kovoor J.; Mridha N.; Sivagangabalan G.;
Thiagalingam A.; Ramponi F.; Chan J.; Bennetts J.; Murdoch D.J.; Zaman S.;
Chow C.K.; Jayasinghe R.; Kovoor P.; Bacchi S.
Institution
(Zaka, Jayasinghe) Gold Coast Hospital and Health Service, Southport, QLD,
Australia
(Mustafiz) Griffith University, Brisbane, QLD, Australia
(Mutahar) Bond University Faculty of Health Sciences and Medicine, Gold
Coast, QLD, Australia
(Sinhal) The University of Adelaide, Faculty of Health and Medical
Sciences, Adelaide, SA, Australia
(Gorcilov, Evans, Stretton) Royal Adelaide Hospital, Adelaide, SA,
Australia
(Muston) Royal Prince Alfred Hospital, Camperdown, NSW, Australia
(Gupta) Royal North Shore Hospital, St Leonards, NSW, Australia
(Kovoor) The University of Sydney Westmead Applied Research Centre,
Westmead, NSW, Australia
(Mridha, Murdoch) The Prince Charles Hospital, Chermside, QLD, Australia
(Sivagangabalan) Cardiology Department, Westmead Hospital, Westmead, NSW,
Australia
(Thiagalingam, Zaman) Westmead Hospital, Westmead, NSW, Australia
(Ramponi) Yale School of Medicine, New Haven, CT, United States
(Chan) New York University Grossman School of Medicine, New York, NY,
United States
(Bennetts) Monash University, Melbourne, VIC, Australia
(Murdoch) The University of Queensland, Caribbean, Saint Lucia, Australia
(Zaman) The University of Sydney, Sydney, NSW, Australia
(Chow) The University of Sydney, Sydney Medical School, Sydney, NSW,
Australia
(Chow) The George Institute for Global Health, Sydney, NSW, Australia
(Kovoor) University of Sydney, Westmead Hospital, Sydney, NSW, Australia
(Bacchi) Massachusetts General Hospital, Boston, MA, United States
Publisher
BMJ Publishing Group
Abstract
Background Accurate mortality prediction following transcatheter aortic
valve implantation (TAVI) is essential for mitigating risk, shared
decision-making and periprocedural planning. Surgical risk models have
demonstrated modest discriminative value for patients undergoing TAVI and
are typically poorly calibrated, with incremental improvements seen in
TAVI-specific models. Machine learning (ML) models offer an alternative
risk stratification that may offer improved predictive accuracy. Methods
PubMed, EMBASE, Web of Science and Cochrane databases were searched until
16 December 2023 for studies comparing ML models with traditional
statistical methods for event prediction after TAVI. The primary outcome
was comparative discrimination measured by C-statistics with 95% CIs
between ML models and traditional methods in estimating the risk of
all-cause mortality at 30 days and 1 year. Results Nine studies were
included (29 608 patients). The summary C-statistic of the top performing
ML models was 0.79 (95% CI 0.71 to 0.86), compared with traditional
methods 0.68 (95% CI 0.61 to 0.76). The difference in C-statistic between
all ML models and traditional methods was 0.11 (p<0.00001). Of the nine
studies, two studies provided externally validated models and three
studies reported calibration. Prediction Model Risk of Bias Assessment
Tool tool demonstrated high risk of bias for all studies. Conclusion ML
models outperformed traditional risk scores in the discrimination of
all-cause mortality following TAVI. While integration of ML algorithms
into electronic healthcare systems may improve periprocedural risk
stratification, immediate implementation in the clinical setting remains
uncertain. Further research is required to overcome methodological and
validation limitations.<br/>Copyright &#xa9; 2025 BMJ Publishing Group.
All rights reserved.

<32>
Accession Number
646305324
Title
Evaluating the 30-day performance of the Myval valve compared to the
Portico selfexpanding valve.
Source
Anatolian Journal of Cardiology. Conference: 40th National Cardiology
Congress. Antalya Turkey. 28(Supplement 1) (pp S21-S23), 2024. Date of
Publication: 2024.
Author
Demirci G.; Aslan S.
Institution
(Demirci, Aslan) Mehmet Akif Ersoy Chest Cardiovascular Surgery Training
and Research Hospital, Istanbul, Turkey
Publisher
Turkish Society of Cardiology
Abstract
Background and Aim: The Myval balloon-expandable (BE) valve has shown
encouraging early clinical data in terms of safety and efficacy.
Comparative data with other well-established contemporary valves are
nonetheless still scarce. This study aims to compare the performance of
the Myval BE valve with the Portico self-expanding (SE) valve. This study
aims to compare the performance of the Myval BE valve with the Portico
self-expanding (SE) valve. <br/>Method(s): In this retrospective
single-center study, 266 patients with symptomatic severe aortic stenosis
(AS) who underwent transcatheter aortic valve replacement were included
and treated with the Myval BE valve (n=122) or with the Portico SE valve
(n=144). The primary endpoint is a composite of device success, technical
success and early safety according to the Valve Academic Research
Consortium-3 criteria at 30-day follow-up. <br/>Result(s): There were no
significant differences between the two groups in terms of demographic
data except diabetes mellitus. STS scores and echocardiographic features
were similar. Hospital length of Stay was significantly longer in the
Portico group. (p=0.020) Especially Valve malposition (p=0.004) and Need
for a second valve (p=0.005) were significantly higher in the Portico
group. Predilatation and postdilatation requirement were significantly
higher in the Portico group (p<0.001). Therefore, it was observed that
Contrast volume was higher in the Portico group (p<0.001). Paravalvular
regurgitation was also significantly higher in the Portico group
(p=0.005). No significant difference was observed in mortality (Myval:
7.4% - Portico: 10.4%, p=0.38), stroke (4.1% - 2.8%, p=0.73) and new
permanent pacemaker (23% - 21%, p=0.66) at 30-day follow-up.
<br/>Conclusion(s): In our study, although there was no difference in
mortality and stroke at 30 days in either valve group, the Myval valve
demonstrated superior device success and paravalvular regurgitation
compared to the Portico valve. A large randomized trial is needed to
confirm these findings. (Figure Presented).

<33>
Accession Number
2032965748
Title
Effect of breathing exercises to prevent pulmonary complications in
patients undergoing coronary artery bypass graft surgery: a prospective
randomized controlled trials study protocol.
Source
Frontiers in Medicine. 11 (no pagination), 2024. Article Number: 1424291.
Date of Publication: 2024.
Author
Li C.; Zhang P.; Zhang Z.; Qi D.; Li H.
Institution
(Li, Zhang, Zhang, Qi, Li) Xuanwu Hospital, Capital Medical University,
Beijing, China
Publisher
Frontiers Media SA
Abstract
Purpose: To study the effects of breathing exercises on preventing
pulmonary complications in patients undergoing coronary artery bypass
graft surgery. <br/>Method(s): Observing whether preoperative breathing
exercises can reduce the incidence of postoperative pulmonary
complications in patients undergoing coronary artery bypass graft surgery;
observing whether these exercises can improve postoperative arterial
oxygen pressure, oxygen saturation, and the distance walked in a
six-minute walk test after surgery; as well as reduce hospital stay
duration, lower treatment costs, and improve the quality of life as
measured by the Short Form-36 Health Survey (SF-36). <br/>Design(s): The
study population includes patients undergoing coronary artery bypass graft
surgery under general anesthesia; the research center is Capital Medical
University Xuanwu Hospital; the sample size is 120. Preoperative
standardized breathing exercises are utilized, and the incidence of
postoperative pulmonary complications, postoperative arterial blood gases,
oxygen saturation, six-minute walk test distances, and comparisons of
hospital stay durations and costs will be observed.<br/>Copyright &#xa9;
2025 Li, Zhang, Zhang, Qi and Li.

<34>
Accession Number
2037092146
Title
The impact of preoperative frailty on perioperative neurocognitive
disorders in elderly patients: A systematic review and meta-analysis.
Source
Journal of Research in Medical Sciences. 29(1) (no pagination), 2024.
Article Number: 47. Date of Publication: 01 Jul 2024.
Author
Zhao S.; Wang B.; Liu M.; Yu D.; Li J.
Institution
(Zhao, Liu, Yu, Li) Department of Anesthesiology, Hebei General Hospital,
Hebei, Shijiazhuang, China
(Zhao) Graduate Faculty, North China University of Science and Technology,
Hebei, Tangshan, China
(Wang) Department of Gynaecology, Hebei General Hospital, Hebei,
Shijiazhuang, China
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background: Perioperative neurocognitive disorders (PNDs) were the most
common complication in elderly patients undergoing surgery. Early
identification of risk factors for PNDs and implementation of preventive
measures were critical to improve prognosis. We performed this systematic
review and meta-analysis to explore the impact of preoperative frailty on
PNDs in elderly surgical patients. <br/>Material(s) and Method(s):
Systematic searches were performed in PubMed, Embase, and Web of Science.
A fixed-effect model in RevMan5.3 software was conducted due to the low
heterogeneity. The potential risk bias was assessed through Funnel plot
and Egger's test. Sensitivity analysis was used to examine the robustness
of the outcomes. <br/>Result(s): Sixteen cohort studies enrolling 4805
elderly patients were qualified for meta-analysis. Pooled results showed
that preoperative frailty was linked to the development of PNDs (pooled
odds ratio [OR]: 2.40, 95% confidence interval [CI]: 2.05-2.80, P < 0.001)
without obvious heterogeneity (P = 0.19, I² = 22%). Subgroup
analyses revealed that the correlation between preoperative frailty and
PNDs was more remarkable in prospective cohort studies (OR: 3.11, 95% CI:
2.47-3.91, P < 0.001) compared to retrospective cohort studies (OR: 1.94,
95% CI: 1.57-2.39, P < 0.001; test for subgroup difference, P = 0.003). In
addition, the correlation in patients with cardiac surgery (OR: 3.38, 95%
CI: 2.44-4.68, P < 0.001) was more noticeable than noncardiac surgery (OR:
2.17, 95% CI: 1.82-2.59, P < 0.001; test for subgroup difference P =
0.02). <br/>Conclusion(s): Our results demonstrated that preoperative
frailty was independently associated with PNDs in geriatric patients
undergoing elective surgery.<br/>Copyright &#xa9; 2024 Journal of Research
in Medical Sciences.

<35>
Accession Number
2035529408
Title
Clonidine (30microg) and Midazolam (2mg) as Intrathecal Adjuvants to
Bupivacaine: Hemodynamic Changes.
Source
Research Journal of Medical Sciences. 18(12) (pp 271-274), 2024. Date of
Publication: 2024.
Author
Thanuja R.; Shalini C.; Harshitha M.G.; Geethashree B.
Institution
(Thanuja, Shalini, Harshitha, Geethashree) Department of Anaesthesiology,
ESIC Medical College and PGIMSR, Karnataka, Bangalore, India
Publisher
MAK Hill Publications
Abstract
Clonidine affects the blood pressure in a complex fashion after neuraxial
or systemic administration because of opposing action at multiple sites.
In the nucleus tractus solitarius and locus coeruleus of the brain stem,
activation of post-synaptic a2 adrenoreceptors reduces sympathetic drive.
It also activates noradrenergic imidazoline preferring binding sites in
the lateral reticular nucleus producing hypotension and anti-arrythmogenic
action. Patients fulfilling the required essential criteria were selected
and 90 patients were randomly allocated to following 2 groups: Group BC
(45 No.)-Spinal Bupivacaine with Clonidine. Group BM (45 No.)-Spinal
Bupivacaine with Midazolam. Patient allocation was made based on computer
generated numbers and sealed envelope method. The study solution for
spinal anaesthesia was prepared separately by a person not involved in the
patient care. Patients and Anaesthesiologists were blinded to both the
study groups. The mean intra-operative fall of heart rate in BC group was
14bpm (range-10-40bpm) with a mean maximum fall of 21.4+/-7.2bpm. On the
other hand, these figures in BM group were 3 bpm (range-2-25 bpm) and
12.5+/-4.4 bpm only.<br/>Copyright &#xa9; MAK HILL Publications.

<36>
Accession Number
2031910494
Title
A Bayesian meta-analysis of double kissing (DK) crush or provisional
stenting for coronary artery bifurcation lesions.
Source
Indian Heart Journal. 76(2) (pp 113-117), 2024. Date of Publication: 01
Mar 2024.
Author
Kumar A.; Shariff M.; Singal A.; Bhat V.; Stulak J.; Reed G.; Kalra A.
Institution
(Kumar) Department of Internal Medicine, Cleveland Clinic Akron General,
Akron, OH, United States
(Kumar, Reed) Department of Cardiovascular Medicine, Heart, Vascular and
Thoracic Institute, Cleveland Clinic, Cleveland, OH, United States
(Shariff, Stulak) Department of General Surgery, Mayo Clinic, Rochester,
MN, United States
(Shariff, Stulak) Department of Cardiovascular Surgery, Mayo Clinic,
Rochester, MN, United States
(Singal) Department of Cardiology, Aakash Healthcare, New Delhi, India
(Bhat) Department of Medicine, St. John's Medical College, Bangalore,
India
(Kalra) Franciscan Health, Lafayette, IN, United States
(Kalra) Krannert Cardiovascular Research Center, Indianapolis, IN, United
States
Publisher
Elsevier B.V.
Abstract
Objective: Despite the development of dedicated, two-stent strategies,
including the double kissing (DK) crush technique, the ideal technique for
coronary artery bifurcation stenting has not been identified. We aimed to
compare and determine the absolute risk difference (ARD) of the DK crush
technique alone versus provisional stenting approaches for coronary
bifurcation lesions, using the Bayesian technique. <br/>Method(s): We
queried PubMed/MEDLINE to identify randomized controlled trials (RCTs)
that compared DK crush technique with provisional stenting for bifurcation
lesions, published till January 2023. We used Bayesian methods to
calculate the ARD and 95% credible interval (CrI). <br/>Result(s): We
included three RCTs, with 916 patients, in the final analysis. The ARD of
cardiac death was centered at -0.01 (95% CrI: -0.04 to 0.02; Tau: 0.02,
85% probability of ARD of DK crush vs. provisional stenting <0). ARD for
myocardial infarction was centered at -0.03 (95%CrI: -0.9 to 0.03; Tau:
0.05, 87% probability of ARD of DK crush vs. provisional stenting <0). ARD
for stent thrombosis was centered at 0.00 (95% CrI: -0.04 to 0.03, Tau:
0.03, 51% probability of ARD for DK crush vs. provisional stenting <0).
Finally, ARD for target lesion revascularization was centered at -0.05
(95% CrI: -0.08 to -0.03, Tau: 0.02, 99.97% probability of ARD for DK
crush vs. provisional stenting <0). <br/>Conclusion(s): Bayesian analysis
demonstrated a lower probability of cardiac death, myocardial infarction
and target lesion revascularization, with DK crush compared with
provisional stenting techniques, and a minimal probability of difference
in stent thrombosis.<br/>Copyright &#xa9; 2024 Cardiological Society of
India

<37>
Accession Number
2032965717
Title
The impact of pulmonary hypertension on prognosis in moderate-to-severe
mitral regurgitation patients treated with transcatheter edge-to-edge
mitral valve repair: a comprehensive meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 11 (no pagination), 2024. Article
Number: 1489674. Date of Publication: 2024.
Author
Wei Z.; Shao X.; An Z.; Chang Y.; Liu S.; Luo Z.; Chen Y.; Song B.
Institution
(Wei, Shao, An, Chang, Liu, Luo, Chen) The First Clinical Medical College
of Lanzhou University, Lanzhou University, Lanzhou, China
(Wei, An, Chang, Liu, Luo, Chen, Song) Department of Cardiovascular
Surgery, First Hospital of Lanzhou University, Lanzhou, China
Publisher
Frontiers Media SA
Abstract
Objective: This meta-analysis aims to assess the impact of pulmonary
hypertension (PH) on the clinical prognosis of patients with moderate to
severe mitral valve regurgitation (MR) undergoing transcatheter
edge-to-edge mitral valve repair (TEER). <br/>Method(s): As of August
2024, relevant studies were identified through searches of the PubMed,
Cochrane Library, Web of Science, and Embase databases. A comprehensive
screening process was conducted, with quality assessment performed
utilizing the Newcastle Ottawa Scale (NOS). Data analysis was carried out
using Stata17.0 software, generating forest plots, funnel plots, Egger's
test, and sensitivity analysis plots to analyze heterogeneity and
publication bias. Odds ratios (OR) and standardized mean differences (SMD)
were calculated for dichotomous and continuous variables, respectively,
each presented with a 95% confidence interval (CI). <br/>Result(s): A
total of 10 studies involving 28,404 patients were included, with all
articles achieving a NOS score of >=7. The outcome indicators were as
follows: 2-year all-cause mortality [OR = 2.06, 95%CI(1.49, 2.84), p <
0.01, I² = 79.9%]; heart failure rehospitalization rate [OR =
1.56, 95%CI(1.29,1.76), p < 0.01, I² = 41.7%]; 30-day all-cause
mortality [OR = 2.10, 95%CI(1.78,2.47), p < 0.01, I² = 0%];
cardiogenic mortality [OR = 2.00, 95%CI (1.61,2.49), p < 0.01,
I² = 0%]; and length of hospital stay [OR = 0.17,
95%CI(0.14,0.20), p < 0.01, I² = 0%]. All outcome indicators
demonstrated that the PH group had significantly worse outcomes compared
to the non-PH group. Subgroup analyses were performed on outcome
indicators with notable heterogeneity, focusing on PH measurement methods,
PH diagnostic criteria, and the severity of PH. The results indicated that
most combined subgroup outcomes were consistent with the overall findings
and showed significantly reduced heterogeneity. The sources of
heterogeneity are likely attributed to the methods of PH measurement,
diagnostic criteria for PH, and the severity of PH. <br/>Conclusion(s):
Within two years after undergoing transcatheter edge-to-edge repair
(TEER), patients with MR and PH experiecne significantly higher rates of
all-cause mortality, 30-day all-cause mortality, heart failure
readmissions, cardiogenic mortality, and longer hospital stays compared to
those without PH. Systematic Review Registration: https://inplasy.com/,
identifier (INPLASY202480068).<br/>Copyright 2025 Wei, Shao, An, Chang,
Liu, Luo, Chen and Song.

<38>
Accession Number
2037125846
Title
Coronary CT angiography-guided management of patients with stable chest
pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in
Scotland.
Source
The Lancet. 405(10475) (pp 329-337), 2025. Date of Publication: 25 Jan
2025.
Author
Williams M.C.; Wereski R.; Tuck C.; Adamson P.D.; Shah A.S.V.; van Beek
E.J.R.; Roditi G.; Berry C.; Boon N.; Flather M.; Lewis S.; Norrie J.;
Timmis A.D.; Mills N.L.; Dweck M.R.; Newby D.E.
Institution
(Williams, Wereski, Tuck, van Beek, Boon, Mills, Dweck, Newby) British
Heart Foundation Centre of Research Excellence, University of Edinburgh,
Edinburgh, United Kingdom
(Williams, van Beek, Newby) Edinburgh Imaging, University of Edinburgh,
Edinburgh, United Kingdom
(Lewis, Mills) Usher Institute, University of Edinburgh, Edinburgh, United
Kingdom
(Lewis) Edinburgh Clinical Trials Unit, University of Edinburgh,
Edinburgh, United Kingdom
(Norrie) Centre for Public Health, Queen's University Belfast, Belfast,
United Kingdom
(Adamson) Christchurch Heart Institute, University of Otago, Christchurch,
New Zealand
(Shah) Department of Non-communicable Disease Epidemiology, London School
of Hygiene & Tropical Medicine, London, United Kingdom
(Roditi, Berry) University of Glasgow, Glasgow, United Kingdom
(Flather) University of East Anglia, Norwich, United Kingdom
(Timmis) Queen Mary University of London, London, United Kingdom
Publisher
Elsevier B.V.
Abstract
Background: The Scottish Computed Tomography of the Heart (SCOT-HEART)
trial demonstrated that management guided by coronary CT angiography
(CCTA) improved the diagnosis, management, and outcome of patients with
stable chest pain. We aimed to assess whether CCTA-guided care results in
sustained long-term improvements in management and outcomes.
<br/>Method(s): SCOT-HEART was an open-label, multicentre, parallel group
trial for which patients were recruited from 12 outpatient cardiology
chest pain clinics across Scotland. Eligible patients were aged 18-75
years with symptoms of suspected stable angina due to coronary heart
disease. Patients were randomly assigned (1:1) to standard of care plus
CCTA or standard of care alone. In this prespecified 10-year analysis,
prescribing data, coronary procedural interventions, and clinical outcomes
were obtained through record linkage from national registries. The primary
outcome was coronary heart disease death or non-fatal myocardial
infarction on an intention-to-treat basis. This trial is registered at
ClinicalTrials.gov (NCT01149590) and is complete. <br/>Finding(s): Between
Nov 18, 2010, and Sept 24, 2014, 4146 patients were recruited (mean age 57
years [SD 10], 2325 [56.1%] male, 1821 [43.9%] female), with 2073 randomly
assigned to standard care and CCTA and 2073 to standard care alone. After
a median of 10.0 years (IQR 9.3-11.0), coronary heart disease death or
non-fatal myocardial infarction was less frequent in the CCTA group
compared with the standard care group (137 [6.6%] vs 171 [8.2%]; hazard
ratio [HR] 0.79 [95% CI 0.63-0.99], p=0.044). Rates of all-cause,
cardiovascular, and coronary heart disease death, and non-fatal stroke,
were similar between the groups (p>0.05 for all), but non-fatal myocardial
infarctions (90 [4.3%] vs 124 [6.0%]; HR 0.72 [0.55-0.94], p=0.017) and
major adverse cardiovascular events (172 [8.3%] vs 214 [10.3%]; HR 0.80
[0.65-0.97], p=0.026) were less frequent in the CCTA group. Rates of
coronary revascularisation procedures were similar (315 [15.2%] vs 318
[15.3%]; HR 1.00 [0.86-1.17], p=0.99) but preventive therapy prescribing
remained more frequent in the CCTA group (831 [55.9%] of 1486 vs 728
[49.0%] of 1485 patients with available data; odds ratio 1.17 [95% CI
1.01-1.36], p=0.034). <br/>Interpretation(s): After 10 years, CCTA-guided
management of patients with stable chest pain was associated with a
sustained reduction in coronary heart disease death or non-fatal
myocardial infarction. Identification of coronary atherosclerosis by CCTA
improves long-term cardiovascular disease prevention in patients with
stable chest pain. <br/>Funding(s): The Chief Scientist Office of the
Scottish Government Health and Social Care Directorates, Edinburgh and
Lothian's Health Foundation Trust, British Heart Foundation, and Heart
Diseases Research Fund.<br/>Copyright &#xa9; 2025 The Author(s). Published
by Elsevier Ltd. This is an Open Access article under the CC BY 4.0
license

<39>
Accession Number
2037130822
Title
Entrapment of Pulmonary Artery Catheters in Cardiac Surgery: A Structured
Literature Review and Analysis of Published Case Reports.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Kumar N.; Toda C.; Couture E.J.; Vlahakes G.J.; Fitzsimons M.G.
Institution
(Kumar, Fitzsimons) Department of Anesthesia, Critical Care, and Pain
Medicine, Massachusetts General Hospital, Harvard Medical School, Boston,
MA, United States
(Toda) Department of Anesthesia, TidalHealth Peninsula Regional,
Salisbury, MD, United States
(Couture) Department of Anesthesiology & Division of Intensive Care
Medicine, Institut Universitaire de Cardiologie et de Pneumologie de
Quebec, Quebec, QC, Canada
(Vlahakes) Cardiac Surgery Division, Department of Surgery, Massachusetts
General Hospital, Harvard Medical School, Boston, MA, United States
Publisher
W.B. Saunders
Abstract
Objectives: This systematic review aims to tabulate and analyze the
published literature regarding pulmonary artery catheter (PAC) entrapment
during cardiac surgery. <br/>Design(s): Systematic review.
<br/>Setting(s): Case reports and series. <br/>Participant(s): Adults
undergoing cardiac surgery. <br/>Intervention(s): None. <br/>Measurements
and Main Results: 223 distinct incidents of PAC entrapment were published
across 77 case reports and 3 retrospective studies. The reported incidence
of an entrapped PAC was 137/200,831 (0.068%, 95% confidence interval:
0.067%, 0.069%). Reported PAC entrapment was most seen in the setting of
mitral valve surgery and was not discovered until the postoperative period
in 77% of cases. Inadvertent fixation to cardiac structures was the most
common mechanism of PAC entrapment. A total of 75% of patients with an
entrapped PAC required an immediate redo sternotomy for PAC retrieval.
After PAC retrieval, these patients still had longer hospital length of
stay compared with the Society of Thoracic Surgeons Adult Cardiac Surgery
Database averages. <br/>Conclusion(s): Although PAC entrapment during
cardiac surgery is rare, an entrapped PAC increases patient morbidity,
delays recovery, and increases hospital length of stay. Surgeons and
anesthesiologists are encouraged to be attentive to PAC entrapment before
chest closure.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<40>
Accession Number
2032978033
Title
Physiology-Versus Angiography-Guided Complete Coronary Revascularization
in STEMI Patients with Multivessel Disease: A Network Meta-Analysis.
Source
Journal of Clinical Medicine. 14(2) (no pagination), 2025. Article Number:
355. Date of Publication: 01 Jan 2025.
Author
Martino G.; Quarta R.; Greco F.; Spaccarotella C.; Indolfi C.; Curcio A.;
Polimeni A.
Institution
(Martino) Department of Medical and Surgical Sciences, Magna Graecia
University, Catanzaro, Italy
(Quarta, Indolfi, Curcio, Polimeni) Department of Pharmacy, Health and
Nutritional Sciences, University of Calabria, Rende, Italy
(Greco, Polimeni) Division of Interventional Cardiology, Annunziata
Hospital, Cosenza, Italy
(Spaccarotella) Division of Cardiology, Department of Advanced Biomedical
Sciences, Federico II University, Naples, Italy
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Abstract
Background: In patients with ST-segment elevation myocardial infarction
(STEMI) and multivessel disease (MVD), complete revascularization (CR) is
recommended over culprit-only PCI to reduce adverse cardiovascular
outcomes. However, the optimal strategy for CR, whether angiography
(Angio)-guided or physiology-guided, remains uncertain. <br/>Method(s):
This network meta-analysis included 14 randomized controlled trials (RCTs)
with 11,568 patients to compare the efficacy of angio-guided CR,
physiology-guided CR, and culprit-only PCI in reducing major adverse
cardiovascular events (MACE), all-cause mortality, recurrent myocardial
infarction (MI), cardiovascular (CV) death, and unplanned
revascularization. The frequentist and Bayesian approaches were applied to
assess the effectiveness of each strategy. <br/>Result(s): The pairwise
meta-analysis showed that angio-guided CR showed superior efficacy,
significantly reducing MACE (OR = 0.44; 95% CI: 0.37-0.52), recurrent
myocardial infarction, and unplanned revascularization compared to
culprit-only PCI. Physiology-guided CR also reduced MACE (OR = 0.64, 95%
CI: 0.45-0.91) and unplanned revascularization. The network metanalysis
showed that CV death was lower in the physiology-guided CR group (OR 0.56;
95% CI 0.25-1.05), suggesting a protective effect, but the difference did
not reach statistical significance. Furthermore, physiology-guided CR was
not significantly better than angio-guided CR in most outcomes.
<br/>Conclusion(s): Angio-guided CR appears to provide the best overall
outcomes for patients with STEMI and MVD, outperforming physiology-guided
CR in most endpoints. Further large-scale trials are needed to clarify the
relative efficacy of angio-guided CR and physiology-guided CR in this
patient population.<br/>Copyright &#xa9; 2025 by the authors.

<41>
Accession Number
2037076568
Title
Assessment of the financial gaps in cardiothoracic surgery in Africa.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 40(1) (no
pagination), 2025. Article Number: ivae228. Date of Publication: 01 Jan
2025.
Author
Nwalibe C.; Effiom V.B.; Anyinkeng A.B.-S.; James M.A.; Genda E.-E.;
Irungu W.; Abaiweh F.-A.; Okonta K.E.
Institution
(Nwalibe) Faculty of Clinical Sciences, Afe Babalola University,
Ado-Ekiti, Nigeria
(Nwalibe, Effiom, Anyinkeng, James, Genda, Irungu, Abaiweh, Okonta)
Research Department, Association of Future African Cardiothoracic and
Vascular Surgeons, Yaounde, Cameroon
(Effiom) Faculty of Clinical Sciences, University of Calabar, Calabar,
Nigeria
(Anyinkeng, Abaiweh) Faculty of Health Sciences, University of Buea, Buea,
Cameroon
(James) Faculty of Clinical Sciences, University of Ibadan, Oyo, Nigeria
(Genda) Faculty of Health Sciences, Official University of Bukavu, Bukavu,
Democratic Republic Congo
(Irungu) Faculty of Health Sciences, University of Nairobi, Nairobi, Kenya
(Okonta) Department of Surgery, University of Port Harcourt, Rivers State,
Port Harcourt, Nigeria
Publisher
Oxford University Press
Abstract
OBJECTIVES: This study identified the challenges to financing
cardiothoracic surgical care in Africa, highlighting the present state of
funding and proffering probable solutions to adequate and effective
funding in the region. <br/>METHOD(S): In a literature review, the authors
elaborated key points, such as areas of financial funding in
cardiothoracic surgery; barriers to appropriate allocation of financial
resources for cardiothoracic surgery in Africa; and the needs and
available resources for cardiothoracic surgery in Africa. Multiple search
engines and databases were used, including but not limited to PubMed,
Medline, Cochrane, Scopus and Google Scholar. Sixty articles were
identified, and 50 of the 60 were used for this review. <br/>RESULT(S):
Operations to treat cardiovascular and thoracic diseases performed on the
African continent are known to be expensive. They also tend to result in
significant morbidity and mortality among the affected individuals because
payment is largely out of pocket and the coverage by health insurance
providers is low. The establishment of cardiothoracic surgical centres and
the delivery of cardiothoracic surgical care are expensive endeavours that
limit access to care of patients without comprehensive health insurance or
philanthropic support. These poor outcomes are attributed mainly to
inadequate funding. <br/>CONCLUSION(S): We therefore have recommended
advocating for increased funding and for support of policies designed to
support the prioritization of cardiothoracic care within national and
regional healthcare agendas in order to include cardiothoracic surgery in
global and national healthcare plans. Non-governmental organizations and
major industries (foreign and local) should be encouraged to invest
substantial funds in building and developing cardiothoracic surgery
centres in Africa.<br/>Copyright &#xa9; 2024 The Author(s).

<42>
Accession Number
2037130891
Title
Advances in Anesthesia Techniques for Postoperative Pain Management in
Minimally Invasive Cardiac Surgery: An Expert Opinion.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Yuan K.; Cui B.; Lin D.; Sun H.; Ma J.
Institution
(Yuan, Cui, Lin, Sun, Ma) Department of Anesthesiology, Beijing Anzhen
Hospital, Capital Medical University, Beijing, China
Publisher
W.B. Saunders
Abstract
Minimally invasive cardiac surgery (MICS) often leads to severe
postoperative pain. At present, multimodal analgesia schemes for MICS have
attracted much attention, and the application of various chest wall
analgesia techniques is becoming increasingly widespread. However,
research on anesthesia techniques for postoperative pain management in
MICS remains relatively limited at present. We searched for relevant
literature and summarized recent related research in eight MICS
techniques, including thoracic epidural anesthesia, spinal anesthesia,
thoracic paravertebral plane block, erector spinae plane block, serratus
anterior plane block, pectoral nerve block, intercostal nerve block, and
parasternal block. This article provides an overview of the anatomy and
procedures involved in these analgesic techniques, their mechanisms of
action, and the latest clinical trial evidence. It also evaluates their
progress in MICS, compares their advantages and disadvantages, and
discusses practical challenges.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<43>
Accession Number
646301247
Title
Incidence and risk factors for skin cancer after heart transplantation: a
systematic review and meta-analysis.
Source
Archives of dermatological research. 317(1) (pp 248), 2025. Date of
Publication: 15 Jan 2025.
Author
Yang Y.; Song Y.; Liu F.; Yao H.
Institution
(Yang, Song) School of Nursing, Zhejiang Chinese Medical University,
Hangzhou, China
(Liu) Department of Emergency affiliationision, Municipal Hospital,
Qingdao, China
(Yao) Department of Intensive Care Unit, Zhejiang Provincial People's
Hospital, Hangzhou, China
Abstract
Studies have shown that patients who undergo heart transplantation (HTx)
are at an increased risk for developing skin cancer. This condition can
add physiological and psychological burden to patients. Therefore,
assessing the incidence and identifying risk factors for skin cancer are
crucial steps in its prevention. The purpose of this skin study is to
systematically evaluate the incidence and risk factors of skin cancer in
HTx. Two researchers independently conducted literature searches across 8
databases. The search covered publications from the establishment of the
database through October 1, 2024. After screening title, abstract, and the
full text, 34 eligible cohort studies were included. The studies were
evaluated using the New castle-Ottawa Scale (NOS) for non-randomized
studies, and papers selection followed PRISMA guidelines. The
meta-analysis was conducted using the Stata 15.0 software. Among 34 cohort
studies on HTx, the pooled incidence of skin cancer was 16% (95% CI:
14-19%). The incidences by type were 10% (95% CI: 8-12%) for squamous cell
carcinoma and 8% (95% CI: 6-9%) for basal cell carcinoma. Regionally, the
highest incidence was observed in the USA 22% (95% CI: 18-27%). Risk
factors significantly associated with skin cancer included age (RR: 1.08,
95% CI: 1.04-1.11), male (RR: 1.53, 95% CI:1.11-2.12), white race (RR:
10.23, 95% CI: 7.32-14.30), smoking history (RR:1.26, 95% CI:1.05-1.51),
prolonged sunlight exposure (>= 2500 h) (RR:3.66, 95% CI: 2.11-6.36),
pre-transplant cancer (RR: 1.61, 95% CI: 1.43-1.82), muromonab-CD3 (OKT3)
(RR: 2.61, 95% CI: 2.11-3.24). The higher incidence of skin cancer
observed in this study highlights the urgent need for follow-up care in
heart transplant recipients. To address this, tailored skin cancer
prevention strategies should be implemented, focusing on modifiable risk
factors. Our findings provide a theoretical foundation to help healthcare
professionals prevent and manage skin cancer in heart transplant
patients.Patient or Public Contribution: YY, and HPY, were responsible for
the conception and design of the study. YYS, FYL, and HPY, were
responsible for the acquisition, analysis and interpretation of the data.
All of the authors drafted the article or revised it critically for
important intellectual content and provided final approval of the version
to be submitted.<br/>Copyright &#xa9; 2024. The Author(s).

<44>
Accession Number
2035518372
Title
A Scoping Review of Factors Associated with Delayed Extubation in Post
Cardiac Surgery Patients.
Source
Vascular Health and Risk Management. 21 (pp 1-15), 2025. Date of
Publication: 2025.
Author
Kumalasari R.I.; Kosasih C.E.; Priambodo A.P.
Institution
(Kumalasari) Master Study Program, Faculty of Nursing, Universitas
Padjadjaran, West Java, Sumedang, Indonesia
(Kosasih, Priambodo) Department of Critical Care and Emergency Nursing,
Faculty of Nursing, Universitas Padjadjaran, West Java, Sumedang,
Indonesia
Publisher
Dove Medical Press Ltd
Abstract
Background: Delayed extubation (DE) after cardiac surgery is associated
with high morbidity, mortality, increased length of stay in the intensive
care unit, and hospital costs. Various studies have identified factors
that influence the occurrence of DE in patients after cardiac surgery, but
no review has systematically synthesized the results. <br/>Purpose(s):
This review aimed to identify the influencing factors and the leading
causes of DE in patients after cardiac surgery. <br/>Method(s): This
scoping review uses the framework developed by Arksey and O'Malley (2005).
Literature was searched through four databases: PubMed, Scopus, Science
Direct, and CINAHL, and two search engines, Sage and Google Scholar,
accessed on October 20, 2024. The articles analyzed met the inclusion
criteria, such as full-text articles in English, published from 2014-2024,
with case-control, cross-sectional, longitudinal, and cohort study designs
and had good quality as assessed using the Joanna Briggs Institute
critical appraisal checklist. Data was synthesized using thematic
analysis. <br/>Result(s): Eight articles with a total of 13801
participants were included in this review. The prevalence of DE after
cardiac surgery ranged from 13.6% to 91.9%. The factors affecting DE were
categorized into preoperative, intraoperative and postoperative. The
factors most commonly reported to influence ED include preoperative
factors (age >= 60 and EF < 50%), intraoperative factors (duration of
surgery >=7 hours, use of IABP and sedatives), and postoperative factors
(BNP>=806 pg/mL). The leading causes of DE after cardiac surgery are
hemodynamic instability requiring increased inotropes (33.51%), reduced
level of consciousness or drowsi-ness (31.91%), and postoperative bleeding
(20.74%). <br/>Conclusion(s): The process of extubation is a crucial phase
in postoperative care. By comprehending the elements that impact DE,
healthcare providers can effectively allocate medical resources to enhance
the success of weaning, extubation, and recovery following cardiac
surgery. Consequently, further research focusing on DE is essential,
particularly in patients who have undergone cardiac surgery.<br/>Copyright
&#xa9; 2025 Kumalasari et al.

<45>
Accession Number
2032965896
Title
Pre-operative subjective functional capacity and postoperative outcomes in
adult non-cardiac surgery: a systematic review and meta-analysis.
Source
Anaesthesia. (no pagination), 2025. Date of Publication: 2025.
Author
Takahashi K.; Chiba K.; Honda A.; Iizuka Y.; Yoshinaga K.; Deo A.S.;
Uchida T.
Institution
(Takahashi, Uchida) Department of Anaesthesiology, Institute of Science
Tokyo Hospital, Tokyo, Bunkyo, Japan
(Chiba, Honda, Iizuka) Department of Anaesthesiology and Critical Care
Medicine, Jichi Medical University Saitama Medical Centre, Saitama, Omiya,
Japan
(Yoshinaga) Department of Anaesthesiology and Critical Care Medicine,
Jichi Medical University, Tochigi, Shimotsuke, Japan
(Deo) Department of Anaesthesiology, NU Hospitals, Karnataka, Bengaluru,
India
Publisher
John Wiley and Sons Inc
Abstract
Introduction: Assessment of functional capacity is an essential part of
peri-operative risk stratification. Subjective functional capacity is
easier to examine than objective tests of patient fitness. However, the
association between subjective functional capacity and postoperative
outcomes has not been established. <br/>Method(s): Four databases were
searched for studies describing the associations between subjective
functional capacity and postoperative outcomes in adults undergoing
non-cardiac surgery. Meta-analysis was conducted among studies where
functional capacity was expressed in metabolic equivalents. The primary
outcome was postoperative major adverse cardiovascular events. Secondary
outcomes were mortality and postoperative overall complications. We
estimated the ORs of the outcomes in patients with poor functional
capacity (< 4 metabolic equivalents) as compared with those with good
functional capacity (>= 4 metabolic equivalents). Random-effects models
were used for the meta-analysis. <br/>Result(s): We identified 7835
abstracts. After screening and a full-text review, 23 studies were
selected. Evaluation methods of functional capacity included:
questionnaires (n = 7); specific questions (n = 6); and subjective
assessment by anaesthetists (n = 5). The probability of major
postoperative adverse cardiovascular events was significantly higher in
patients with poor functional capacity (OR 1.84, 95%CI 1.62-2.08) than in
those with good functional capacity. Patients with poor functional
capacity also had higher odds of mortality (OR 2.48, 95%CI 1.45-4.25) and
postoperative complications (OR 1.85, 95%CI 1.34-2.55).
<br/>Discussion(s): Subjective functional capacity of < 4 metabolic
equivalents was associated with postoperative complications including
cardiovascular events and other serious outcomes. The results need to be
interpreted with caution due to the diverse measures used to assess
functional capacity.<br/>Copyright &#xa9; 2025 Association of
Anaesthetists.

<46>
Accession Number
2037095439
Title
Cost-effectiveness of low-dose colchicine in patients with chronic
coronary disease in The Netherlands.
Source
European Heart Journal - Quality of Care and Clinical Outcomes. 11(1) (pp
89-96), 2025. Date of Publication: 01 Jan 2025.
Author
Fiolet A.T.L.; Keusters W.; Blokzijl J.; Nidorf S.M.; Eikelboom J.W.;
Budgeon C.A.; Tijssen J.G.P.; Romer T.; Westendorp I.; Cornel J.H.;
Thompson P.L.; Frederix G.W.J.; Mosterd A.; de Wit G.A.
Institution
(Fiolet) Department of Cardiology, University Medical Centre Utrecht,
Heidelberglaan 100, Utrecht, Netherlands
(Fiolet, Cornel, Mosterd) Dutch Network for Cardiovascular Research (WCN),
Moreelsepark 1, Utrecht, Netherlands
(Keusters) The Dutch Healthcare Authority, Utrecht, Netherlands
(Blokzijl) Physical Therapy Sciences, University Medical Center Utrecht,
Utrecht University, Utrecht, Netherlands
(Nidorf, Thompson) Heart and Vascular Research Institute of Western
Australia, Perth, WA, Australia
(Nidorf, Thompson) GenesisCare Western Australia, Perth, WA, Australia
(Eikelboom) Department of Medicine, McMaster University, Hamilton, Canada
(Budgeon) School of Population and Global Health, University of Western
Autralia, Perth, WA, Australia
(Tijssen) Department of Cardiology, Amsterdam University Medical Centres,
Amsterdam, Netherlands
(Tijssen) Cardialysis BV, Rotterdam, Netherlands
(Romer) Department of Cardiology, Alrijne Hospital, Leiderdorp,
Netherlands
(Westendorp) Cardiology Center Netherlands, IJmuiden, Netherlands
(Westendorp) Department of Cardiology, Redd Cross Hospital, Beverwijk,
Netherlands
(Cornel) Department of Cardiology, Northwest Clinics, Alkmaar, Netherlands
(Cornel) Department of Cardiology, Radboudumc, Nijmegen, Netherlands
(Thompson) Sir Charles Gairdner Hospital, WA, Perth, Australia
(Frederix, de Wit) Julius Center for Health Sciences and Primary Care,
University Medical Center Utrecht, Utrecht, Netherlands
(Mosterd) Department of Cardiology, Meander Medical Centre, Amersfoort,
Netherlands
(de Wit) National Institute for Public Health and the Environment,
Bilthoven, Netherlands
(de Wit) Department of Health Sciences, Faculty of Science, Vrije
Universiteit, Amsterdam, Netherlands
Publisher
Oxford University Press
Abstract
Aims Recent trials have shown that low-dose colchicine (0.5 mg once daily)
reduces major cardiovascular events in patients with acute and chronic
coronary syndromes. We aimed to estimate the cost-effectiveness of
low-dose colchicine therapy in patients with chronic coronary disease when
added to standard background therapy. Methods and This Markov cohort
cost-effectiveness model used estimates of therapy effectiveness,
transition probabilities, costs, and results quality of life obtained from
the Low-Dose Colchicine 2 trial, as well as meta-analyses and public
sources. In this trial, low-dose colchicine was added to standard of care
and compared with placebo. The main outcomes were cardiovascular events,
including myocardial infarction, stroke, and coronary revascularization,
quality-adjusted life year (QALY), the cost per QALY gained (incremental
cost-effectiveness ratio), and net monetary benefit. In the model,
low-dose colchicine therapy yielded 0.04 additional QALYs compared with
standard of care at an incremental cost of 455 from a societal perspective
and 729 from a healthcare perspective, resulting in a cost per QALY gained
of 12 176/QALY from a societal perspective and 19 499/QALY from a
healthcare perspective. Net monetary benefit was 1414 from a societal
perspective and 1140 from a healthcare perspective. Low-dose colchicine
has a 96 and 94% chance of being cost-effective, from a societal and a
healthcare perspective, respectively, when using a willingness to pay of
50 000/QALY. Net monetary benefit would decrease below zero when annual
low-dose colchicine costs would exceed an annual cost of 221 per patient.
Conclusion Adding low-dose colchicine to standard of care in patients with
chronic coronary disease is cost-effective according to commonly accepted
thresholds in Europe and Australia and compares favourably in
cost-effectiveness to other drugs used in chronic coronary
disease.<br/>Copyright &#xa9; The Author(s) 2024.

<47>
Accession Number
2035516987
Title
Comparison of analgesic effects between erector spinae plane block and
serratus anterior plane block in breast and thoracic surgery: a systemic
review and meta-analysis.
Source
Signa Vitae. 21(1) (pp 10-20), 2025. Date of Publication: 01 Jan 2025.
Author
Zhao P.; Zhao J.; Zhou G.-Z.; Shen Q.-H.; Han Q.-W.
Institution
(Zhao, Zhao, Zhou, Han) Department of Anesthesiology, Hangzhou Xiaoshan
District Orthopedics Hospital of Traditional Chinese Medicine, Zhejiang,
Hangzhou, China
(Shen) Department of Anesthesiology, Affiliated Hospital of Jiaxing
University, Zhejiang, Jiaxing, China
Publisher
Pharmamed Mado Ltd
Abstract
Background: Although erector spinae plane block (ESPB) and serratus
anterior plane block (SAPB) provide effective analgesia following breast
and thoracic surgical procedures, the relative analgesic efficiency of
these blocks remains unclear.This metaanalysis aimed to compare the
analgesic outcomes of ESPB and SAPB in patients undergone breast and
thoracic surgery. <br/>Method(s): Systematic searches were conducted on
Embase, Cochrane Library, Web of Science and PubMed from their inception
until 31 December 2023, to quantify intraoperative and postoperative
opioid consumption with mean differences (MDs) and 95% confidence
intervals (CIs) using randomeffects models. The degree of certainty for
evidence was assessed using the Grade of Recommendations, Assessment,
Development and Evaluation (GRADE) framework. <br/>Result(s): In total,
nine articles were included in the current study. The meta-analysis
revealed that ESPB significantly reduced intraoperative opioid use (MD =
-2.32 mg, 95% CI (-3.92, -0.73); p < 0.01, I² = 65%) and
postoperative opioid consumption (MD = -4.86 mg, 95% CI (-7.85, -1.88); p
< 0.01, I² = 95%) compared to SAPB. Furthermore, the need for
rescue analgesia was lower in the ESPB group, and the differences in the
incidence of nausea and vomiting were not significant between the two
groups. <br/>Conclusion(s): ESPB might offer superior analgesic effects
compared to SAPB in patients after thoracic and breast surgery. However,
further studies are necessary to confirm this conclusion due to the low
quality of evidence. Registration number: This meta-analysis has been
registered to PROSPERO: CRD42022322760.<br/>Copyright &#xa9; 2025 The
Author(s).

<48>
Accession Number
2037082857
Title
Early outcomes of the novel Myval THV series compared to SAPIEN THV series
and Evolut THV series in individuals with severe aortic stenosis.
Source
EuroIntervention. 21(2) (pp e105-e118), 2025. Date of Publication: 20 Jan
2025.
Author
van Royen N.; Amat-Santos I.J.; Hudec M.; Bunc M.; Ijsselmuiden A.;
Laanmets P.; Unic D.; Merkely B.; Hermanides R.S.; Ninios V.; Protasiewicz
M.; Rensing B.J.W.M.; Martin P.L.; Feres F.; De Sousa Almeida M.; van
Belle E.; Linke A.; Ielasi A.; Montorfano M.; Webster M.; Toutouzas K.;
Teiger E.; Bedogni F.; Voskuil M.; Pan M.; Angeras O.; Kim W.-K.; Rothe
J.; Kristic I.; Peral V.; Van den Branden B.J.L.; Westermann D.; Bellini
B.; Garcia-Gomez M.; Tobe A.; Tsai T.-Y.; Garg S.; Thakkar A.; Chandra U.;
Morice M.-C.; Soliman O.; Onuma Y.; Serruys P.W.; Baumbach A.
Institution
(van Royen) Department of Cardiology, Radboud University Hospital,
Nijmegen, Netherlands
(Amat-Santos, Garcia-Gomez) Centro de Investigacion Biomedica en Red -
Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III,
Madrid, Spain
(Amat-Santos, Garcia-Gomez) Department of Cardiology, Hospital Clinico
Universitario de Valladolid, Valladolid, Spain
(Hudec) Department of Acute Cardiology, Middle-Slovak Institute of
Cardiovascular Diseases, Banska Bystrica, Slovakia
(Bunc) Department of Cardiology, University Medical Centre Ljubljana,
Ljubljana, Slovenia
(Ijsselmuiden, Van den Branden) Department of Cardiology, Amphia Hospital,
Breda, Netherlands
(Ijsselmuiden) Department of Interventional Cardiology, Maastricht
University Medical Center, Maastricht, Netherlands
(Ijsselmuiden) Zuyderland Hospital, Limburg, Netherlands
(Laanmets) Department of Invasive Cardiology, North Estonia Medical
Centre, Tallinn, Estonia
(Unic) Department of Cardiac and Transplant Surgery, University Hospital
Dubrava, Zagreb, Croatia
(Merkely) Heart and Vascular Center, Semmelweis University, Budapest,
Hungary
(Hermanides) Department of Cardiology, Isala Hospital, Zwolle, Netherlands
(Ninios) Department of Cardiology, European Interbalkan Medical Center,
Thessaloniki, Greece
(Protasiewicz) Department of Cardiology, Institute of Heart Diseases,
Wroclaw Medical University, Wroclaw, Poland
(Rensing) Department of Cardiology, St Antonius Hospital, Nieuwegein,
Netherlands
(Martin) Department of Interventional Cardiology, University Hospital of
Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain
(Feres) Department of Invasive Cardiology, Instituto Dante Pazzanese, Sao
Paulo, Brazil
(De Sousa Almeida) CHRC, NOVA Medical School, NOVA University Lisbon,
Lisbon, Portugal
(van Belle) Department of Interventional Cardiology, Lille University,
Lille, France
(Linke) Department of Internal Medicine and Cardiology, University Clinic,
Heart Center Dresden, University of Technology Dresden, Dresden, Germany
(Ielasi) Department of Interventional Cardiology, IRCCS Ospedale Galeazzi
Sant'Ambrogio, Milan, Italy
(Montorfano) School of Medicine, Vita-Salute San Raffaele University,
Milan, Italy
(Montorfano, Bellini) Interventional Cardiology Unit, IRCCS San Raffaele
Scientific Institute, Milan, Italy
(Webster) Department of Cardiology, Auckland City Hospital, Auckland, New
Zealand
(Toutouzas) Department of Cardiology, Hippokration Hospital, Athens,
Greece
(Teiger) Department of Interventional Cardiology, Henri Mondor University
Hospital, Creteil, France
(Bedogni) Department of Clinical Cardiology, San Donato Hospital, Milan,
Italy
(Voskuil) Department of Cardiology, University Medical Center Utrecht,
Utrecht, Netherlands
(Pan) Department of Cardiology, University Hospital Reina Sofia,
University of Cordoba, IMIBIC, CIBERCV, Cordoba, Spain
(Angeras) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Angeras) Department of Molecular and Clinical Medicine, Institute of
Medicine, University of Gothenburg, Gothenburg, Sweden
(Kim) Department of Cardiology & Angiology, University of Giessen and
Marburg, Giesen, Germany
(Kim) Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim,
Germany
(Rothe, Westermann) Department of Cardiology and Angiology, Campus Bad
Krozingen, University Heart Center, University of Freiburg, Bad Krozingen,
Germany
(Rothe) Faculty of Medicine, University of Freiburg, Freiburg, Germany
(Kristic) Department of Cardiology, University Hospital of Split, Split,
Croatia
(Peral) Department of Cardiology, University Hospital Son Espases, Health
Research Institute of the Balearic Islands (IdISBa), Balearic Islands,
Palma, Spain
(Tobe, Tsai, Soliman, Onuma, Serruys) Department of Cardiology, School of
Medicine, University of Galway, Galway, Ireland
(Tsai) Cardiovascular Center, Taichung Veterans Hospital, Taiwan (Republic
of China)
(Garg) Department of Cardiology, Royal Blackburn Hospital, Blackburn,
United Kingdom
(Garg) School of Medicine, University of Central Lancashire, Preston,
United Kingdom
(Thakkar, Chandra) Department of Clinical Research, Meril Life Sciences
Pvt. Ltd., Vapi, India
(Morice) Cardiovascular European Research Center (CERC), Massy, France
(Morice) ICPS, Hopital prive Jacques Cartier, Massy, France
(Onuma) Galway University Hospital, Galway, Ireland
(Baumbach) Centre for Cardiovascular Medicine and Devices, William Harvey
Research Institute, Queen Mary University of London, Barts Heart Centre,
London, United Kingdom
(Baumbach) Cleveland Clinic, London, United Kingdom
Publisher
Europa Group
Abstract
BACKGROUND: There are limited head-to-head randomised trials comparing the
performance of different transcatheter heart valves (THVs). AIMS: We aimed
to evaluate the non-inferiority of the balloon-expandable Myval THV series
compared to the balloon-expandable SAPIEN THV series or the self-expanding
Evolut THV series. <br/>METHOD(S): The LANDMARK trial randomised 768
patients in a 1:1 ratio, (Myval THV series [n=384] vs contemporary series
with 50% SAPIEN THV series [n=192] and 50% Evolut THV series [n=192]). The
non-inferiority of Myval over the SAPIEN or Evolut THV series in terms of
the 30-day primary composite safety and effectiveness endpoint as per the
third Valve Academic Research Consortium (VARC-3) was tested in an
intention-to-treat population with a predefined statistical power of 80%
(1-sided alpha of 5%) for a non-inferiority margin of 10.44%.
<br/>RESULT(S): The Myval THV series achieved non-inferiority for the
primary composite endpoint over the SAPIEN THV series (24.7% vs 24.1%,
risk difference [95% confidence interval {CI}]: 0.6% [not applicable {NA}
to 8.0]; p=0.0033) and the Evolut THV series (24.7% vs 30.0%, risk
difference [95% CI]: -5.3% [NA to 2.5]; p<0.0001). The incidences of
pacemaker implantation were comparable (Myval THV series: 15.0%, SAPIEN
THV series: 17.3%, Evolut THV series: 16.8%). At 30 days, the mean
pressure gradient and effective orifice area were significantly better
with the Myval THV series compared to the SAPIEN THV series (p<0.0001) and
better with the Evolut THV series than with the Myval THV series
(p<0.0001). At 30 days, the proportion of moderate to severe prosthetic
valve regurgitation was numerically higher with the Evolut THV series
compared to the Myval THV series (7.4% vs 3.4%; p=0.06), while not
significantly different between the Myval THV series and the SAPIEN THV
series (3.4% vs 1.6%; p=0.32). <br/>CONCLUSION(S): The Myval THV series is
non-inferior to the SAPIEN THV series and the Evolut THV series in terms
of the primary composite endpoint at 30 days.<br/>Copyright &#xa9; 2025,
The Authors.

<49>
Accession Number
2037106758
Title
Therapeutic use of music listening in patients undergoing invasive
coronary procedures: A meta-analysis.
Source
World Journal of Cardiology. 17(1) (no pagination), 2025. Article Number:
97406. Date of Publication: 26 Jan 2025.
Author
Siddiqi A.K.; Shafiq A.; Ahmed M.; Anwer A.; Maniya M.T.; Ahmed A.;
Chachar M.A.; Al Hasibuzzaman M.
Institution
(Siddiqi) Division of Cardiothoracic Imaging, Department of Radiology and
Imaging Sciences, Emory University, Atlanta, GA, United States
(Shafiq, Ahmed) Department of Medicine, Dow University of Health Sciences,
Karachi, Pakistan
(Ahmed) Department of Internal Medicine, Rawalpindi Medical University,
Rawalpindi, Pakistan
(Anwer) Department of Internal Medicine, Dow Medical College, Dow
University of Health Sciences, Karachi, Pakistan
(Maniya, Chachar) Department of Medicine, Ziauddin Medical University,
Karachi, Pakistan
(Al Hasibuzzaman) Department of Medicine, Niramoy Hospital, Panchagarh,
Bangladesh
(Al Hasibuzzaman) Department of Medicine, The First Affiliated Hospital of
Ningbo University, Zhejiang Province, Ningbo, China
Publisher
Baishideng Publishing Group Inc
Abstract
BACKGROUND Listening to music has been shown to reduce pain and anxiety
before, during, and after invasive coronary procedures. AIM To perform a
systematic review and meta-analysis to explore the effect of therapeutic
use of music on both, perioperative and postoperative outcomes of invasive
coronary procedures. METHODS An exhaustive literature search of 3
electronic databases (MEDLINE, Scopus, Cochrane CENTRAL) was conducted
from inception until 10^thDecember 2023. The results of our
analyses are presented as standard mean difference (SMD) or weighted mean
difference, with 95%CI and pooled using a random effects model. A P value
< 0.05 was considered significant in all cases. RESULTS From 21 studies,
2141 participants were included in our analysis. The pooled analysis
demonstrated that music listening significantly improves post-procedural
pain (SMD = -0.78, 95%CI: -1.34 to -0.23; P = 0.006), anxiety (SMD =
-0.86, 95%CI: -1.43 to -0.29; P = 0.003), heart rate [mean difference (MD)
= -3.38, 95%CI: -5.51 to -1.25; P = 0.002], and systolic blood pressure
(MD = -5.89, 95%CI: -9.75 to -2.02; P = 0.003). There was no significant
improvement in diastolic blood pressure (MD = -3.22, 95%CI: -6.58 to 0.14;
P = 0.06) or respiratory rate (MD = -0.97, 95%CI: -1.98 to 0.03; P =
0.06). CONCLUSION Music listening can be used in healthcare settings for
patients undergoing invasive coronary procedures to reduce anxiety levels
and improve their physiological parameters.<br/>Copyright &#xa9; 2025
Baishideng Publishing Group Inc. All rights reserved.

<50>
Accession Number
2037128077
Title
Surgical timing and mortality in nonsevere paediatric congenital heart
disease: A EUROlinkCAT cohort analysis across Europe.
Source
Progress in Pediatric Cardiology. 77 (no pagination), 2025. Article
Number: 101808. Date of Publication: 01 Jun 2025.
Author
Damkjaer M.; Garne E.; Loane M.; Urhoj S.K.; Ballardini E.;
Cavero-Carbonell C.; Coi A.; Garcia-Villodre L.; Given J.; Gissler M.;
Heino A.; Jordan S.; Limb E.; Neville A.J.; Pierini A.; Rissmann A.; Tan
J.; Scanlon I.; Morris J.K.
Institution
(Damkjaer, Garne) Department of Paediatrics and Adolescent Medicine,
Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding,
Denmark
(Damkjaer, Garne) Department of Regional Health Research, University of
Southern Denmark, Denmark
(Loane, Given) Faculty of Life & Health Sciences, Ulster University,
Northern Ireland, United Kingdom
(Urhoj) Section of Epidemiology, Department of Public Health, University
of Copenhagen, Copenhagen, Denmark
(Ballardini) Neonatal Intensive Care Unit, Paediatric Section, IMER
Registry, Dep. of Medical Sciences, University of Ferrara, Italy
(Cavero-Carbonell, Garcia-Villodre) Rare Diseases Research Unit,
Foundation for the Promotion of Health and Biomedical Research in the
Valencian Region, Valencia, Spain
(Coi, Pierini) Unit of Epidemiology of Rare Diseases and Congenital
Anomalies, Institute of Clinical Physiology, National Research Council,
Pisa, Italy
(Gissler, Heino) THL Finnish Institute for Health and Welfare, Department
of Knowledge Brokers, Helsinki, Finland
(Jordan, Scanlon) Faculty of Medicine, Health and Life Science, Swansea
University, Wales, Swansea, United Kingdom
(Limb, Tan, Morris) Population Health Research Institute, St George's,
University of London, London, United Kingdom
(Neville) Registro IMER - IMER Registry (Emila Romagna Registry of Birth
Defects), Center for Clinical and Epidemiological Research, University of
Ferrara, Azienda Ospedaliero-Universitaria di Ferrara, Via Aldo Moro 8,
Cona Ferrara, Italy
(Rissmann) Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty
Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
Publisher
Elsevier Ireland Ltd
Abstract
Background: Management and outcomes amongst children with congenital heart
defects (CHD) are relatively heterogeneous. Traditionally, the
highest-risk conditions and procedures have received the most attention,
with less focus on outcome for less severe CHDs. <br/>Objective(s):
Evaluate the management of children born with certain less severe CHDs
across Europe. <br/>Method(s): This population-based linkage cohort study
included children diagnosed with ventricular septal defect (VSD), atrial
septal defect (ASD), pulmonary valve stenosis (PS), and patent arterial
duct (PDA) from nine European regions. Data on surgery/intervention and
survival from 1995 to the age of 10 years or until the end of 2014 were
collected through electronic linkage to mortality and hospital databases.
Kaplan-Meier survival estimates and meta-analyses were used to analyze the
proportion of children undergoing surgery/intervention and survival rates.
<br/>Result(s): The study included 20,608 children with the less severe
CHDs. Surgical correction rates for the anomaly within the first year of
life varied significantly, particularly for VSD. The median age for
initial surgery/intervention was consistent for VSD but varied for other
conditions. Most conditions were corrected in a single procedure, except
for PS, which required a median of 1.7 (95 % CI; 1.4-2.0) interventions.
Postoperative mortality was highest for neonates undergoing VSD
surgery/intervention, 8.7 (95 % CI; 4.0-15.8) deaths per 100 surgeries.
The overall 5-year survival rate for all conditions was approximately 98
%. <br/>Conclusion(s): There was considerable variation in the management
of less severe CHDs across Europe, particularly in the timing of surgical
interventions. Despite these differences, the overall 5-year survival rate
is comparable and high.<br/>Copyright &#xa9; 2024

<51>
Accession Number
646300840
Title
Safety and Efficacy of Tranexamic Acid in General Surgery.
Source
JAMA surgery. (no pagination), 2025. Date of Publication: 15 Jan 2025.
Author
Park L.J.; Marcucci M.; Ofori S.N.; Borges F.K.; Nenshi R.; Kanstrup
C.T.B.; Rosen M.; Landoni G.; Lomivorotov V.; Painter T.W.; Xavier D.;
Martinez-Zapata M.J.; Szczeklik W.; Meyhoff C.S.; Chan M.T.V.; Simunovic
M.; Bogach J.; Serrano P.E.; Balasubramanian K.; Cadeddu M.; Yang I.; Kim
W.H.; Devereaux P.J.
Institution
(Park, Marcucci, Ofori, Borges, Nenshi, Balasubramanian, Devereaux)
Population Health Research Institute, Hamilton, Ontario, Canada
(Park, Nenshi, Simunovic, Bogach, Serrano, Cadeddu, Yang) Department of
Surgery, Division of General Surgery, McMaster University, Hamilton,
Ontario, Canada
(Park, Marcucci, Ofori, Borges, Serrano, Balasubramanian, Devereaux)
Department of Health Research Methods, Evidence & Impact, McMaster
University, Hamilton, Ontario, Canada
(Marcucci) Clinical Epidemiology and Research Centre (CERC), Humanitas
University and IRCCS Humanitas Research Hospital, Milan, Italy
(Ofori, Borges) Department of Medicine, McMaster University, Hamilton,
Ontario, Canada
(Kanstrup) Department of Surgery, Copenhagen University Hospital, North
Zealand, Denmark
(Rosen) Digestive Disease Institute, Cleveland Clinic Foundation,
Cleveland, OH, United States
(Landoni) Department of Anesthesia and Intensive Care, IRCCS San Raffaele
Scientific Institute, Milan, Italy
(Lomivorotov) Department of Anesthesiology and Intensive Care, E.
Meshalkin National Medical Research Center, Novosibirsk, Russian
Federation
(Painter) Royal Adelaide Hospital, Adelaide, SA, Australia
(Xavier) Division of Clinical Research & Training, St John's Research
Institute, Bengaluru, India
(Martinez-Zapata) Iberoamerican Cochrane Center, Institut de Recerca Sant
Pau, CIBER Epidemiologia y Salud Publica, Barcelona, Spain
(Szczeklik) Centre for Intensive Care and Perioperative Medicine,
Jagiellonian University Medical College, Krakow, Poland
(Meyhoff) Department of Anaesthesia and Intensive Care, Copenhagen
University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark
(Chan) Chinese University of Hong Kong, Hong Kong SAR, China
(Kim) Department of Anesthesiology and Pain Medicine, Seoul National
University College of Medicine, Seoul, South Korea
(Devereaux) Department of Medicine, Division of Cardiology, McMaster
University, Hamilton, Ontario, Canada
(Devereaux) World Health Research Trust, Hamilton, Ontario, Canada
Abstract
Importance: Perioperative bleeding is common in general surgery. The
POISE-3 (Perioperative Ischemic Evaluation-3) trial demonstrated efficacy
of prophylactic tranexamic acid (TXA) compared with placebo in preventing
major bleeding without increasing vascular outcomes in noncardiac surgery.
<br/>Objective(s): To determine the safety and efficacy of prophylactic
TXA, specifically in general surgery. <br/>Design, Setting, and
Participant(s): Subgroup analyses were conducted that compared randomized
treatment with TXA vs placebo according to whether patients underwent
general surgery or nongeneral surgery in the POISE-3 blinded,
international, multicenter randomized clinical trial. Participants were 45
years or older, were undergoing noncardiac surgery, had increased
cardiovascular risk, and were expected to require at least an overnight
hospital admission after surgery. Among 26 581 eligible patients
identified, 17 046 were excluded, resulting in 9535 patients randomized to
the POISE-3 trial. Participants were enrolled from June 2018 through July
2021. The data were analyzed during December 2023. <br/>Intervention(s):
Prophylactic, 1-g bolus of intravenous TXA or placebo at the start and end
of surgery. <br/>Main Outcomes and Measures: The primary efficacy outcome
was a composite of life-threatening bleeding, major bleeding, or bleeding
into a critical organ. The primary safety outcome was a composite of
myocardial injury after noncardiac surgery, nonhemorrhagic stroke,
peripheral arterial thrombosis, or symptomatic proximal venous
thromboembolism at 30 days. Cox proportional hazards models were
conducted, incorporating tests of interaction. <br/>Result(s): Among 9535
POISE-3 participants, 3260 underwent a general surgery procedure. Mean age
was 68.6 (SD, 9.6) years, 1740 were male (53.4%), and 1520 were female
(46.6%). Among general surgery patients, 8.0% and 10.5% in the TXA and
placebo groups, respectively, had the primary efficacy outcome (hazard
ratio [HR], 0.74; 95% CI, 0.59-0.93; P = .01) and 11.9% and 12.5% in the
TXA and placebo groups, respectively, had the primary safety outcome (HR,
0.95; 95% CI, 0.78-1.16; P = .63). There was no significant interaction by
type of surgery (general surgery vs nongeneral surgery) on the primary
efficacy (P for interaction = .81) and safety (P for interaction = .37)
outcomes. Across subtypes of general surgery, TXA decreased the composite
bleeding outcome in hepatopancreaticobiliary surgery (HR, 0.55; 95% CI,
0.34-0.91 [n = 332]) and colorectal surgery (HR, 0.67; 95% CI, 0.45-0.98
[n = 940]). There was no significant interaction across subtypes of
general surgery (P for interaction = .68). <br/>Conclusions and Relevance:
In this study, TXA significantly reduced the risk of perioperative
bleeding without increasing cardiovascular risk in patients undergoing
general surgery procedures. Trial Registration: ClinicalTrials.gov
Identifier: NCT03505723.

<52>
Accession Number
2037154159
Title
CABG triumphs over PCI: A meta-analysis reveals superior long-term
outcomes for LMCAD.
Source
Current Problems in Surgery. 63 (no pagination), 2025. Article Number:
101699. Date of Publication: 01 Feb 2025.
Author
Akemu J.; Aimaiti G.; Xia D.
Institution
(Akemu) Cardiovascular Center, The First Affiliated Hospital of Xinjiang
Medical University, Xinjiang, Urumqi City, China
(Aimaiti) Department of Critical Care Medicine, The First Affiliated
Hospital of Xinjiang Medical University, Xinjiang, Urumqi City, China
(Xia) Cardiovascular Intensive Care Unit, The First Affiliated Hospital of
Xinjiang Medical University, Xinjiang, Urumqi City, China
Publisher
Elsevier Inc.

<53>
Accession Number
2037072075
Title
Individualised acute normovolaemic haemodilution for non-cardiac surgery
with anticipated high-dose red cell transfusion: study protocol for a
randomised controlled trial in West China Hospital of Sichuan University.
Source
BMJ Open. 15(1) (no pagination), 2025. Article Number: e088326. Date of
Publication: 02 Jan 2025.
Author
Liao C.; Tan J.; An J.; Zhong J.; Lai X.; Tian L.; Liao R.
Institution
(Liao, An, Zhong, Lai, Tian, Liao) Department of Anesthesia and Operation
Center, West China Hospital of Sichuan University, Sichuan, Chengdu, China
(Liao, Zhong, Lai, Liao) Chinese Academy of Medical Sciences (2018RU012),
Sichuan, Chengdu, China
(Tan) Department of Blood Transfusion, West China Hospital of Sichuan
University, Sichuan, Chengdu, China
Publisher
BMJ Publishing Group
Abstract
Introduction Acute normovolaemic haemodilution (ANH) is a perioperative
blood management technique involving the removal of whole blood and
simultaneous infusion of colloids or crystalloids to achieve haemodilution
while maintaining normovolaemia. However, its efficacy in reducing the
requirement for perioperative allogeneic blood transfusion remains
controversial due to inconsistent findings in the literature. An
individualised red cell transfusion strategy, guided by the West China
Liu's Score, has demonstrated effectiveness in reducing the need for
allogeneic red cell transfusion. Building on this evidence, we propose an
individualised ANH approach and hypothesise that individualised ANH,
guided by the West China Liu's Score, can reduce the requirement for
allogeneic red cells during the perioperative period. Methods and analysis
This is a single centre, prospective, randomised controlled trial designed
to evaluate the superiority of the individualised ANH, based on the West
China Liu's Score, in reducing perioperative red cell requirements
compared with current clinical practice. Adult patients undergoing
elective non-cardiac surgery with an anticipated red cell transfusion
volume exceeding eight units (or 1600 mL) will be enrolled and randomly
allocated to either the ANH group' or the Control group' in a 1:1 ratio.
The primary outcome is the perioperative consumption of the allogeneic red
blood cells. Data analysis will adhere to the intent-to-treat principle.
Ethics and dissemination The study protocol (V.1.0) has been approved by
the Biological Medical Ethical Committee of the West China Hospital of
Sichuan University, with approval No. 2024(595) on 17 April 2024. The
results of this trial will be disseminated by publication in peer-reviewed
journals and academic conference presentations.<br/>Copyright &#xa9;
Author(s) (or their employer(s)) 2025.

<54>
Accession Number
2037096361
Title
Comparison of Landmark Guided Posterior and Anterior Approach for Internal
Jugular Vein Cannulation.
Source
International Journal of Life Sciences Biotechnology and Pharma Research.
12(3) (pp 1481-1484), 2023. Date of Publication: 01 Jul 2023.
Author
Gandhi T.J.; Trivedi P.; Shah V.D.; Shukla H.; Dave P.
Institution
(Gandhi, Trivedi, Shukla, Dave) Department of Anaesthesia, NHL Municipal
Medical College, Gujarat, Ahmedabad, India
(Shah) Department of Anaesthesia, Narendra Modi Medical College, Gujarat,
Ahmedabad, India
Publisher
International Journal of Life Sciences Biotechnology and Pharma Research
Abstract
Background and Aim: Central venous catheterization is commonly performed
in elective and emergency major surgeries and in intensive care units.
Cannulation of the IJV is usually preferred because of its anatomical
position and large diameter in the trendelenburg position. The purpose of
our study was to compare the two commonly practiced anterior and posterior
approaches for cannulation of internal jugular vein. <br/>Material(s) and
Method(s): This was a randomized observational study in which fifty adult
patients of ASA physical status II and III undergoing elective major
gastrointestinal, and cardiothoracic and vascular surgeries requiring
central venous pressure monitoring or central venous access were included
in the study. Patients were randomly assigned to two groups on a one is to
one ratio randomly: Landmark Guided Anterior Approach (A Group) and
Landmark Guided Posterior Approach (P Group). The analyzed criteria were
number of attempts, time taken to identify the vein (Access time), total
duration of cannulation, carotid puncture, hematoma, pneumothorax,
hemothorax, catheter kinking, catheter displacement, thrombophlebitis,
nerve injuries and overall total complications. <br/>Result(s): The number
of attempts to identify the vein was lesser with the posterior approach
than the anterior approach. The access time and duration of cannulation
were lesser with the posterior approach. Cannulation by posterior approach
reduced the rate of carotid puncture and haematoma. <br/>Conclusion(s):
Landmark guided posterior approach is better than landmark guided anterior
approach for internal jugular vein cannulation as it improves the success
rate, reduces the access time and overall total duration of
cannulation.<br/>Copyright &#xa9;2023Int.

<55>
Accession Number
2037118155
Title
The Renal Effect of 20% Human Albumin Solution Fluid Bolus Therapy in
Patients After Cardiac Surgery. A Secondary Analysis of the HAS FLAIR II
Randomized Clinical Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Wigmore G.J.; Deane A.M.; Presneill J.J.; Serpa Neto A.; Eastwood G.;
Maiden M.J.; Bihari S.; Baker R.A.; Bennetts J.S.; Ghanpur R.; Anstey
J.R.; Raman J.; Bellomo R.
Institution
(Wigmore, Deane, Presneill, Serpa Neto, Maiden, Bellomo) Department of
Critical Care, Melbourne Medical School, University of Melbourne,
Parkville, VIC, Australia
(Wigmore) Department of Anaesthesia and Pain Medicine, Western Health,
Melbourne, VIC, Australia
(Deane, Presneill, Maiden, Anstey, Bellomo) Department of Intensive Care,
Royal Melbourne Hospital, Melbourne, VIC, Australia
(Presneill, Serpa Neto, Bellomo) Australian and New Zealand Intensive Care
Research Centre (ANZIC-RC), School of Public Health and Preventive
Medicine, Monash University, Melbourne, VIC, Australia
(Serpa Neto, Eastwood, Raman, Bellomo) Department of Intensive Care,
Austin Hospital, Melbourne, VIC, Australia
(Serpa Neto) Department of Critical Care Medicine, Hospital Israelita
Albert Einstein, Sao Paulo, Brazil
(Maiden) Intensive Care Unit, Barwon Health, Geelong, VIC, Australia
(Bihari) College of Medicine and Public Health, Flinders University,
Bedford Park, SA, Australia
(Bihari) Department of ICCU, Flinders Medical Centre, Bedford Park, SA,
Australia
(Baker, Bennetts) Cardiothoracic Quality and Outcomes, Flinders Medical
Centre and College of Medicine and Public Health Flinders University, SA,
Australia
(Ghanpur) Department of Intensive Care, Warringal Private Hospital,
Melbourne, Australia
(Raman) University of Melbourne, Parkville, VIC, Australia
(Raman) St Vincent's Hospital, Melbourne, VIC, Australia
(Raman) Department of Cardiothoracic Surgery, Townsville University
Hospital, Townsville, QLD, Australia
(Bellomo) Data Analytics Research and Evaluation Centre, Austin Hospital,
Melbourne, VIC, Australia
Publisher
W.B. Saunders
Abstract
Objective: To compare the effects of fluid bolus therapy (FBT) with 20%
albumin to crystalloid FBT on the incidence of cardiac surgery-associated
acute kidney injury (CSA-AKI) and its severity and duration.
<br/>Design(s): Secondary analysis of the multicenter, parallel-group,
open-label, randomized HAS FLAIR-II trial. <br/>Setting(s): Six intensive
care units. <br/>Participant(s): Patients who required
clinician-determined FBT after cardiac surgery requiring cardiopulmonary
bypass. <br/>Intervention(s): Patients were randomized to receive FBT with
20% albumin (up to 400 mL/day) or crystalloid fluid for all FBTs in the
intensive care unit. <br/>Measurements and Main Results: A total of 452
patients were included in the modified intention-to-treat population (224
in the 20% albumin group and 228 in the crystalloid group). AKI occurred
in 54 (24%) patients in the 20% albumin group and 50 (22%) in the
crystalloid group (odds ratio: 1.13, 95% confidence interval [CI]: 0.73 to
1.76). However, in patients who developed stages 2 and 3 AKI, those
allocated to 20% albumin had a significantly lower median time-weighted
average (TWA) creatinine: 144 micromol/L (interquartile range [IQR]: 109
to 162) versus 254 micromol/L (IQR: 182 to 294) than the crystalloid group
(difference -105 micromol/L, [95% CI -170 to -41], p = 0.003) and a lower
peak serum creatinine (-110 micromol/L [-189 to -32], p = 0.01). The
reduced TWA creatinine in the 20% albumin group was seen in patients with
both a low (p = 0.04) and normal preoperative serum albumin concentration
(p < 0.001). <br/>Conclusion(s): FBT with 20% albumin compared with
crystalloid-based regimen did not reduce the occurrence of AKI in patients
after cardiac surgery. However, it reduced the severity and duration of
stages 2 and 3 AKI.<br/>Copyright &#xa9; 2025 The Authors

<56>
Accession Number
2037119512
Title
Percutaneous coronary intervention (PCI) in patients of rheumatoid
arthritis(RA): A systematic review and meta-analysis.
Source
Indian Heart Journal. (no pagination), 2025. Date of Publication: 2025.
Author
Piplani S.; Kostojchin A.; Kong S.; Brown D.; Jelic V.; Chaturvedi S.;
Reddy V.; Chang Pieri K.; Akpan E.; Simpson T.; Xiao W.; Sakellakis M.;
Sharma A.; Jain P.; Radulovic M.
Institution
(Piplani, Kong, Brown, Jelic, Chaturvedi, Reddy, Chang Pieri, Akpan,
Simpson, Xiao, Sakellakis, Sharma, Radulovic) Jacobi Medical Center/North
Central Bronx, Albert Einstein College of Medicine, NYC Health and
Hospitals, 3424 Kossuth Avenue, NY, Bronx, United States
(Kostojchin) Department of Cardiology North Central Bronx Hospital/VA
Medical Center, Icahn School of Mount Sinai, 3424 Kossuth Avenue, NY,
Bronx, United States
(Sharma) Department of Cardiology, Yale School of Medicine, New Haven, CT,
333 Cedar Street, New Haven, CT, United States
(Jain) Department of Internal Medicine, Jawaharlal Nehru Medical College,
Karnataka, Belagavi, India
Publisher
Elsevier B.V.
Abstract
Aim: The present study aims to investigate the outcomes of Percutaneous
coronary intervention (PCI) in patients with Rheumatoid arthritis (RA).
<br/>Method(s): A systemic search was conducted from electronic databases
(PubMed/Medline, Cochrane Library, and Google Scholar) from inception to
15th September 2023. All statistical analyses were conducted using Review
Manager 5.4.1. Studies meeting inclusion criteria were selected. A
random-effect model was used when heterogeneity was seen to pool the
studies, and the result was reported in the odds ratio (OR) and the
corresponding 95 % confidence interval (CI). <br/>Result(s): Eight
observational studies were selected to conduct the analysis. A
statistically significant increase in major adverse cardiovascular event
(MACE) was seen in RA patients after undergoing PCI as compared to the
control group (OR = 1.18 (1.16, 1.21); p < 0.00001; I2 = 0 %). There was
no significant difference found in the long-term revascularization outcome
between the RA and non-RA patients (OR = 1.18 (0.81, 1.71); p = 0.39; I2 =
93 %). Survival rates of all-cause mortality in the long-term outcome were
statistically insignificant among the two groups (OR = 1.21 (0.84, 1.74);
p = 0.31; I2 = 99 %). <br/>Conclusion(s): Percutaneous coronary
intervention is an important intervention to reduce morbidity and
mortality but special precautions and attention should be made when it
comes to patients with RA. Different precautions such as close monitoring
for medication interaction, and tailored post-procedural care are
essential in reducing morbidity and mortality.<br/>Copyright &#xa9; 2024

<57>
Accession Number
2037099947
Title
The Angiotensin Receptor-Neprilysin Inhibitor is Related to Lower
Post-transplant Use of Extracorporeal Membrane Oxygenation.
Source
Heart Surgery Forum. 28(1) (pp E010-E018), 2025. Date of Publication:
2025.
Author
Yuan L.; Yang Z.; Ma W.; Cui J.; Liu J.; Yang S.; Zhang H.; Wang F.; Liu
H.; Wang C.; Sun X.
Institution
(Yuan, Yang, Ma, Liu, Yang, Zhang, Wang, Liu, Wang, Sun) Department of
Cardiac Surgery, Zhongshan Hospital Fudan University, Shanghai, China
(Cui) Department of Cardiology, Zhongshan Hospital Fudan University,
Shanghai, China
Publisher
Forum Multimedia Publishing LLC
Abstract
Background: Extracorporeal membrane oxygenation (ECMO) support after heart
transplant is a risk factor for mortality in patients with severe graft
dysfunction. Extensive studies have shown that angiotensin
receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan has a
significant effect on unloading and vascular remodeling in patients with
heart failure; however, the impact of ARNIs on heart transplant recipients
remains unknown. <br/>Method(s): This observational, retrospective cohort
study included 152 patients who underwent heart transplantation between
January 2015 and April 2021. We excluded patients <18 years old and those
who underwent re-transplantation or multiple organ transplantation.
Patients were divided into two groups based on whether they received an
ARNI for at least one month before transplant. The clinical data of
recipients and donors from our institutional medical records and the China
Organ Transplant Response System were interrogated. <br/>Result(s): In
total, 67 patients (mean age, 49.6 years; 81% male) were treated with
sacubitril/valsartan before transplant and included in the cohort. The
total rate of post-transplant ECMO use was 21.1% (n = 32). Kaplan-Meier
survival analysis showed a considerable increase in 6-month mortality in
heart transplant recipients supported by ECMO (log-rank p < 0.001). The
rate of ECMO use was significantly lower in patients treated with ARNIs
than for those who were not (13% vs. 27%; p = 0.041). The multivariate
analyses that included three models with different preset covariates
demonstrated a lower risk of post-transplant ECMO support in patients
receiving the ARNI (all p < 0.05). After propensity score matching, the
results also suggested that ARNIs can be a protective factor against
post-transplant ECMO support (p = 0.042). <br/>Conclusion(s):
Pretransplant use of ARNI agents was associated with a lower risk of ECMO
support after HT. Randomized controlled trials are warranted to confirm
the effectiveness of ARNIs in improving post-transplant hemodynamics and
reducing ECMO use in HT recipients.<br/>Copyright: &#xa9; 2025 The
Author(s).

<58>
Accession Number
2037074011
Title
A review of nomenclature in minimally invasive coronary artery bypass
grafting - The anarchy of terminology.
Source
Interdisciplinary Cardiovascular and Thoracic Surgery. 40(1) (no
pagination), 2025. Article Number: ivae204. Date of Publication: 01 Jan
2025.
Author
Gortzen D.Q.; Akca F.
Institution
(Gortzen) Department of Cardiothoracic Surgery, Catharina Hospital,
Eindhoven, Netherlands
Publisher
Oxford University Press
Abstract
OBJECTIVES: Since the development of minimally invasive coronary surgery,
nomenclature has rapidly grown to distinguish each unique method. The goal
of this review was to provide a comprehensive overview of the different
terms used for minimally invasive coronary bypass grafting through the
years. <br/>METHOD(S): A literature search was performed in August 2024
using the PubMed electronic database. To extract the best search results:
"minimally invasive"and "coronary artery bypass grafting"were used as
either keywords or MeSH terms. The term robotic was specifically included
for a second search. Eligible articles for this review were articles using
an abbreviation to describe minimally invasive coronary artery bypass
grafting. <br/>RESULT(S): A total of 2118 publications on non-robotic
minimally invasive coronary procedures and 392 on robotic-assisted
techniques were reviewed, describing 40 unique terms for the procedure.
Procedures were grouped based on left internal mammary artery harvest and
anastomosis methods: mini-thoracotomy for both harvesting and coronary
anastomosis (n = 586), endoscopic harvest with mini-thoracotomy (n = 37),
robotic harvest with mini-thoracotomy (n = 144) and closed-chest
revascularization (n = 140). Minimally invasive direct coronary artery
bypass grafting was the most studied technique (486 publications,
non-robotic and robotic), followed by closed-chest totally endoscopic
coronary artery bypass (n = 124). <br/>CONCLUSION(S): In conclusion, a
wide variety of terms are used within the field of minimally invasive
coronary surgery. A total of 40 different terms have been published, each
describing certain specifics of the procedure. For anyone involved in the
field of minimally invasive surgery, it is important to understand the
differences and similarities of these procedures.<br/>Copyright &#xa9;
2024 The Author(s).

<59>
Accession Number
2037120472
Title
Perioperative Use of GLP-1 Receptor Agonists in Patients Undergoing
Cardiac Procedures: A Scoping Review.
Source
Heart Lung and Circulation. (no pagination), 2025. Date of Publication:
2025.
Author
Wookey O.; Galligan A.; Wilkie B.; MacIsaac A.; Paratz E.
Institution
(Wookey) St Vincent's Hospital Melbourne, Melbourne, VIC, Australia
(Galligan) Department of Endocrinology and Diabetes, St Vincent's Hospital
Melbourne, Melbourne, VIC, Australia
(Wilkie) Department of Surgery, Eastern Health, Melbourne, VIC, Australia
(MacIsaac, Paratz) Department of Cardiology, St Vincent's Hospital
Melbourne, Melbourne, VIC, Australia
(Paratz) Heart, Exercise and Research Trials (HEART) Laboratory, St
Vincent's Institute of Medical Research, Melbourne, VIC, Australia
(Paratz) Faculty of Medicine, Dentistry and Health Sciences, University of
Melbourne, Melbourne, VIC, Australia
Publisher
Elsevier Ltd
Abstract
Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapies
are increasingly used for the treatment of type 2 diabetes mellitus and
obesity. Despite growing awareness of potentially increased risk of
pulmonary aspiration due to delayed gastric emptying, the risks and
benefits of their perioperative use in patients undergoing cardiac
procedures remains unexplored. A scoping review was performed to
investigate the perioperative GLP-1RA use in patients undergoing cardiac
procedures and recommendations. <br/>Method(s): PubMed and Ovid MEDLINE
were searched up to April 2024 to identify English-language studies on the
perioperative use of weekly and daily dosed GLP-1RAs in adult patients
undergoing cardiac procedures (including cardiac surgery,
trans-oesophageal echocardiograms, and cardiac catheterisation
procedures). <br/>Result(s): Three studies were identified, which
investigated daily dosed GLP-1RAs in patients undergoing cardiac surgery.
No studies were found investigating GLP-1RA use in cardiac catheterisation
or trans-oesophageal echocardiograms procedures, and none which
specifically examined risk of pulmonary aspiration in patients using
GLP-1RAs undergoing cardiac procedures. <br/>Conclusion(s): GLP-1RAs are
beneficial for perioperative weight loss, glycaemic control, and
cardiovascular health. Existing guidelines and consensus recommendations
are highly contradictory on perioperative GLP-1RA management. Although no
known published case reports exist to date of pulmonary aspiration in
patients using GLP-1RAs undergoing cardiac procedures, non-cardiac
surgical literature strongly suggests that patients are at theoretical
risk and a cautious approach is advised in the absence of robust evidence
informing recommendations for optimal withholding periods.<br/>Copyright
&#xa9; 2024 Australian and New Zealand Society of Cardiac and Thoracic
Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand
(CSANZ)

<60>
Accession Number
646283266
Title
Effectiveness and safety of negative pressure wound therapy in patients
with deep sternal wound infection: a systematic review and meta-analysis.
Source
International journal of surgery (London, England). 110(12) (pp
8107-8125), 2024. Date of Publication: 01 Dec 2024.
Author
Liu Y.-T.; Lin S.-H.; Peng C.; Huang R.-W.; Lin C.-H.; Hsu C.-C.; Chen
S.-H.; Lin Y.-T.; Lee C.-H.
Institution
(Liu, Peng, Huang, Lin, Hsu, Chen, Lin, Lee) Department of Plastic and
Reconstructive Surgery, Chang Gung Memorial Hospital, Taiwan and College
of Medical, Chang Gung University, Taoyuan, Taiwan (Republic of China)
(Lin) School of Medicine, Chang Gung University, Taoyuan, Taiwan (Republic
of China)
(Lin) Center for Vascularized Composite Allotransplantation, Chang Gung
Memorial Hospital, Taoyuan, Taiwan (Republic of China)
Abstract
BACKGROUND: Deep sternal wound infection (DSWI) is a severe and
life-threatening complication following cardiovascular surgery. Negative
pressure wound therapy (NPWT) has emerged as a promising therapeutic
bridging option for DSWI. In this systematic review and meta-analysis, the
authors aimed to evaluate the impact of NPWT on clinical outcomes in
patients with DSWI. MATERIAL AND METHODS: A comprehensive literature
search was conducted according to the PRISMA guideline in electronic
databases, including PubMed, Embase, and Cochrane Library. Data extraction
was performed independently by two reviewers, and risk of bias was
assessed by ROBINS-I tool. The primary outcomes assessed were mortality
rate and reinfection rate. The secondary outcomes assessed were length of
hospital stay and ICU stay. <br/>RESULT(S): In this systematic review
identified a total of 36 studies, comprising 3681 patients with DSWI who
received treatment. The meta-analysis revealed that NPWT was associated
with a significant reduction in mortality rate (RR 0.46, 95% CI:
0.35-0.61, P<0.000001) and reinfection rate (RR 0.43, 95% CI: 0.25-0.74,
P=0.002) compared to conventional wound management. Furthermore, pooling
of these studies showed significant difference between the NPWT and
conventional treatment groups in length of hospital stay (mean difference:
-4.49, 95% CI: -8.14 to -0.83; P=0.02) and length of ICU stay (mean
difference: -1.11, 95% CI: -2.18 to -0.04; P=0.04). <br/>CONCLUSION(S):
This systematic review and meta-analysis provide evidence that NPWT is
superior to conventional treatment for patients with DSWI following
cardiovascular surgery.<br/>Copyright &#xa9; 2024 The Author(s). Published
by Wolters Kluwer Health, Inc.

<61>
Accession Number
646282540
Title
Meta-analysis of longitudinal comparison of transcatheter versus surgical
aortic valve replacement in patients at low to intermediate surgical risk.
Source
International journal of surgery (London, England). 110(12) (pp
8097-8106), 2024. Date of Publication: 01 Dec 2024.
Author
Ahmed M.; Ahsan A.; Shafiq A.; Nadeem Z.A.; Arif F.; Zulfiqar E.; Kazmi
M.H.; Yadav R.; Jain H.; Ahmed R.; Alam M.; Shahid F.
Institution
(Ahmed) Rawalpindi Medical University, Rawalpindi, Pakistan
(Ahsan) Foundation University School of Health Sciences, Islamabad,
Pakistan
(Shafiq, Arif, Zulfiqar) Dow University of Health Sciences, Karachi,
Pakistan
(Nadeem) Allama Iqbal Medical College, Lahore, Pakistan
(Kazmi) Sunderland Royal Hospital, Sunderland, United Kingdom
(Yadav) Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan
University, Kathmandu, Nepal
(Jain) All India Institute of Medical Sciences, Jodhpur, India
(Ahmed) Royal Brompton Hospital, London, United Kingdom
(Ahmed) National Heart and Lung Institute, Imperial College London,
London, United Kingdom
(Alam) Baylor College of Medicine, Houston, TX, United States
(Shahid) Queen Elizabeth Hospital, London, United Kingdom
Abstract
BACKGROUND: Surgical aortic valve replacement (SAVR) is the commonly used
approach for aortic valve replacement (AVR) in patients with aortic
stenosis at low or intermediate surgical risk. However, transcatheter
aortic valve replacement (TAVR) has emerged as an alternative to SAVR for
AVR. This meta-analysis aims to assess the comparative efficacy and safety
of TAVR versus SAVR in low-to-intermediate surgical risk patients by
analyzing temporal trends in the outcomes of TAVR and SAVR at various
follow-up intervals, providing a more detailed understanding.
<br/>METHOD(S): A thorough literature search was performed across
PubMed/MEDLINE, Embase, and the Cochrane Library from their inception up
to May 2024 to identify eligible randomized controlled trials (RCTs).
Clinical outcomes were evaluated using a random-effects model to pool risk
ratios (RRs) with 95% CIs. <br/>RESULT(S): A total of 17 studies reporting
data at different follow-ups for nine trials were included (n=9092). No
statistically significant difference was observed between TAVR and SAVR
for reducing all-cause death at 30 days, 1 year, and 2 years but
significantly increased risk with TAVR at 5 years or longer follow-up
(RR=1.13, 95% CI: 1.03-1.23). However, TAVR was associated with a
significantly decreased risk for cardiac death at 1-year follow-up
(RR=0.79, 95% CI: 0.64-0.96) and comparable risk for cardiac death at 30
days, 2 years, and 5 years or longer follow-up when compared with SAVR. No
statistically significant difference was observed between TAVR and SAVR
for reducing the risk of myocardial infarction (MI) at 30 days, 1 year, 2
years, and 5 years or longer follow-up.TAVR was associated with a
significantly lower risk of major bleeding events at 30 days (RR=0.38, 95%
CI: 0.21-0.67); lower risk of acute kidney injury (AKI) at 30 days
(RR=0.38, 95% CI: 0.26-0.54) and 1 year (RR=0.58, 95% CI: 0.41-0.82) and
lower risk of new onset or worsening atrial fibrillation (AF) at 30 days
(RR=0.25, 95% CI: 0.18-0.34), 1 year (RR=0.26, 95% CI: 0.16-0.41) and 2
years (RR=0.32, 95% CI: 0.20-0.49) when compared with SAVR. However, TAVR
was associated with a significantly increased risk of permanent pacemaker
implantation (PPI) at 30 days (RR: 2.62, 95% CI: 1.40-4.91), at 1 year
(RR: 2.19, 95% CI: 1.24-3.87), at 2 years (RR: 2.74, 95% CI: 1.31-5.71),
and beyond 5 years (RR: 1.95, 95% CI: 1.20-3.15). TAVR was also associated
with a significantly increased risk of prosthetic valve thrombosis at 2
years (RR=2.70, 95% CI: 1.08-6.71), though no significant association was
observed at 30 days, 1 year, or 5 years. Similarly, no significant
differences were observed in aortic-valve reintervention rates at 30 days,
2 years, or 5 years, but TAVR showed a significantly increased risk at 1
year (RR=1.98, 95% CI: 1.21-3.24). TAVR was associated with a
significantly increased risk of major vascular complications at 30 days
(RR=2.37, 95% CI: 1.38-4.04) and a significantly increased risk of TIA at
2 years (RR: 1.43, 95% CI: 1.02-2.00, I2=0%). The risk of hospitalizations
was comparable between the groups. <br/>CONCLUSION(S): TAVR and SAVR
demonstrated comparable rates of all-cause death up to 2 years of
follow-up. However, at 5 years or longer follow-up, TAVR was associated
with a higher risk of all-cause death. While TAVR showed certain
procedural advantages, such as a lower risk of major bleeding, AKI, and
new-onset or worsening AF, the choice between TAVR and SAVR in patients
with low or intermediate surgical risk should consider long-term outcomes,
with SAVR potentially being more favorable due to better survival observed
on longer follow-up durations.<br/>Copyright &#xa9; 2024 The Author(s).
Published by Wolters Kluwer Health, Inc.

<62>
Accession Number
2037061578
Title
Rationale and design for the thoracic Paravertebral Adjunctive
Dexamethasone Palmitate Reducing chronic pain After cardiac surgery
(PANDORA) trial: a parallel-group, double-blinded, randomised controlled,
single-centre study.
Source
BMJ Open. 15(1) (no pagination), 2025. Article Number: e086392. Date of
Publication: 15 Jan 2025.
Author
Zhang H.; Zhang T.; Zheng Z.; Gao J.; Gao B.; Hou L.; Zhao J.; Wang L.;
Dong H.; Lei C.
Institution
(Zhang, Zhang, Zheng, Gao, Gao, Hou, Zhao, Wang, Dong, Lei) Department of
Anesthesiology and Perioperative Medicine, Xijing Hospital of Air Force
Military Medical University, Shaanxi, Xian, China
(Zheng, Gao, Wang, Lei) Anesthesia Clinical Research Center, Xijing
Hospital of Air Force Military Medical University, Shaanxi, Xian, China
Publisher
BMJ Publishing Group
Abstract
Introduction Minimally invasive cardiac surgery (MICS) is important for
enhanced recovery in cardiac surgery. However, the incidence of chronic
postsurgical pain (CPSP) is high and is associated with worsened quality
of recovery and life, as well as raised short-term or long-term mortality.
The mechanism is not clear, and there is still a lack of safe and
effective preventive measures. Methods and analysis The Paravertebral
Adjunctive Dexamethasone Palmitate Reducing chronic pain After cardiac
surgery (PANDORA) trial is a parallel-group, double-blinded, randomised
controlled, single-centre study recruiting 902 participants undergoing
MICS. Participants will be randomised in a 1:1 ratio to dexamethasone
palmitate (D-PAL) emulsion group and dexamethasone (DSP) group. To
investigate the effect of a single bolus perineural administration of
D-PAL as an adjuvant treatment to a standard thoracic paravertebral block
(TPVB) with ropivacaine decreases the incidence of CPSP in adult patients
as compared with single bolus perineural administration of DSP combined
with ropivacaine in TPVB. The primary endpoint is the incidence of chronic
postoperative pain at 3 months following surgery defined as per the
updated International Classification of Diseases. CPSP is defined as a new
development of pain or increase in the intensity of pain at the surgical
area or projected onto the innervation area of a nerve in this area after
a surgical procedure that persists for at least 3 months. The nature and
intensity of pain will be evaluated with a Brief Pain Inventory Short Form
(BPI-SF) questionnaire. Ethics and dissemination The trial was approved by
the Ethics Committee of Xijing Hospital, the First Affiliated Hospital of
Air Force Military Medical University (KY20232194-C-1). Results will be
submitted for publication in peer-reviewed journals and presented at
academic meetings. Trial registration number ClinicalTrials.gov,
NCT05920967.<br/>Copyright &#xa9; Author(s) (or their employer(s)) 2025.
Re-use permitted under CC BY-NC. No commercial re-use. See rights and
permissions. Published by BMJ Group.

<63>
Accession Number
2037081251
Title
The relationship between dynamic cerebral autoregulation and postoperative
cognitive dysfunction during cardiac and noncardiac surgery: A systematic
review and meta-analysis.
Source
Clinical Nutrition ESPEN. Conference: 10th World Congress of the ERAS
Society. Malaga Spain. 65 (pp 529-530), 2025. Date of Publication: 01 Feb
2025.
Author
Su X.; Gao C.; Ji C.; Gao B.; Liu Y.; Liu Q.; Fu Q.
Institution
(Su, Liu, Gao, Ji, Gao, Liu, Liu, Fu) Department of
Anesthesiology&Operation Room, The First Hospital of Lanzhou University,
LanZhou, China
Publisher
Elsevier Ltd
Abstract
Background: Cerebral autoregulation is one of the key mechanisms in the
regulation of cerebral blood flow, in which dynamic cerebral
autoregulation (dCA) refers to the cerebral pressure-flow relationship
during transient changes in MAP, which means that the autoregulation is
responsive to rapid changes in blood pressure over a period of seconds or
minutes. During rapid changes in blood pressure, dynamic cerebral
autoregulation produces a relatively time-dependent buffering effect,
thereby maintaining cerebral blood flow as stable as possible.
<br/>Objective(s): The goal of this study was to synthesize the findings
of existing literature on impaired dynamic cerebral autoregulation during
surgery and postoperative cognitive dysfunction by means of meta-analysis,
to assess the necessity of applying dynamic cerebral autoregulation
monitoring to reduce postoperative cognitive dysfunction, and to provide
theoretical support and research direction for future studies.
<br/>Method(s): We summarized available data on dCA and postoperative
cognitive function in cardiac and noncardiac surgery by searching PubMed,
Embase, and Web of Science databases (inception-April 2024). Twelve
Studies were included in the qualitative synthesis, of which six were
eligible for meta-analysis Results: All studies assessed dCA during
surgery using an index of correlation between mean arterial pressure and
cerebral blood flow. Meta-analysis showed a significant association
between impaired intraoperative dynamic cerebral autoregulation and
postoperative cognitive dysfunction (OR: 1.08, 95% CI: 1.02-1.15, p <
0.05). Heterogeneity analysis showed I² = 69.9%, indicating
moderate inter-study heterogeneity. We further performed sensitivity
analyses, which showed that the combined effect sizes were robust.
<br/>Conclusion(s): In conclusion, current evidence suggests a significant
association between impaired intraoperative dynamic cerebral
autoregulation and postoperative cognitive dysfunction. However, high
quality interventional studies based on the implementation of standardized
dCA monitoring and postoperative assessment of cognitive function are
still needed for validation. Conflicts of interest: None<br/>Copyright
&#xa9; 2024

<64>
Accession Number
646271841
Title
Transcatheter versus Surgical Aortic Valve Replacement in Patients Younger
than 65 Years in the US.
Source
The Journal of thoracic and cardiovascular surgery. (no pagination),
2025. Date of Publication: 09 Jan 2025.
Author
Alabbadi S.; Bowdish M.E.; Sallam A.; Tam D.Y.; Hassan I.; Kumaresan A.;
Alzahrani A.H.; Iribarne A.; Egorova N.; Chikwe J.
Institution
(Alabbadi, Alzahrani, Egorova) Department of Population Health Science and
Policy, Icahn School of Medicine at Mount Sinai, NY, United States
(Bowdish, Tam, Hassan, Kumaresan, Chikwe) Department of Cardiac Surgery,
Cedars-Sinai Medical Center, Los Angeles, CA, United States
(Sallam) Department of Cardiac Surgery, Smidt Heart Institute,
Cedars-Sinai Medical Center, Los Angeles, California, USA; National
Clinician Scholars Program, University of California, Los Angeles, Los
Angeles, California, USA
(Iribarne) Department of Cardiothoracic Surgery, Staten Island University
Hospital, Staten Island, Northwell Health, NY, United States
Abstract
OBJECTIVE: To characterize trends and outcomes of aortic valve replacement
in patients <65 with aortic stenosis between 2013 and 2021.
<br/>METHOD(S): This retrospective analysis included 9,557 patients who
underwent biological aortic valve replacement in California, New York, and
New Jersey from 2013 through 2021. Patients were stratified by approach:
transcatheter aortic valve replacement (TAVR) versus surgical aortic valve
replacement (SAVR). Our primary outcomes were 30-day and 6-year mortality
and morbidity (stroke, heart failure rehospitalization, reintervention,
and new pacemaker implantation). After propensity score matching,
Cox-proportional hazard and Fine-Gray models were used to compare outcomes
following TAVR and SAVR. <br/>RESULT(S): The proportion of patients <65
years with aortic stenosis undergoing TAVR versus SAVR increased from 7.1%
in 2013 to 54.7% in 2021. After propensity score matching, 30-day
mortality was similar between both groups (1.0% vs. 1.5%, p=0.33). TAVR
had a higher 6-year mortality (23.3% vs. 10.5%, HR: 2.27; CI: 1.82-2.83;
p<0.001). The 30-day rate of new pacemaker implantation was higher after
TAVR (10.7 vs. 6.2%, p<0.001). There was no difference in the 6-year
cumulative incidence of stroke, heart failure hospitalizations, or
reoperations. Multiple sensitivity analyses confirmed these findings.
<br/>CONCLUSION(S): Despite clinical guidelines, the utilization of TAVR
has increased in patients <65. TAVR in this population is associated with
a higher 6-year mortality and a higher rate of new permanent pacemaker
implantation when compared to a matched cohort treated with biologic SAVR.
These findings support the need for a randomized controlled trial
comparing long-term outcomes of TAVR versus SAVR in patients
<65.<br/>Copyright &#xa9; 2025. Published by Elsevier Inc.

<65>
Accession Number
2032958920
Title
Predicting Factors Affecting Survival Rate in Patients Undergoing On-Pump
Coronary Artery Bypass Graft Surgery Using Machine Learning Methods: A
Systematic Review.
Source
Health Science Reports. 8(1) (no pagination), 2025. Article Number:
e70336. Date of Publication: 01 Jan 2025.
Author
Jafarkhani A.; Imani B.; Saeedi S.; Shams A.
Institution
(Jafarkhani, Imani) Department of Operating Room, School of Paramedicine,
Hamadan University of Medical Sciences, Hamadan, Iran, Islamic Republic of
(Saeedi) Department of Health Information Technology, School of Allied
Medical Sciences, Hamadan University of Medical Sciences, Hamadan, Iran,
Islamic Republic of
(Shams) Department of Cardiac Surgery, School of Medicine, Hamadan
University of Medical Sciences, Hamadan, Iran, Islamic Republic of
Publisher
John Wiley and Sons Inc
Abstract
Background and Aim: Coronary artery bypass grafting (CABG) is a key
treatment for coronary artery disease, but accurately predicting patient
survival after the procedure presents significant challenges. This study
aimed to systematically review articles using machine learning techniques
to predict patient survival rates and identify factors affecting these
rates after CABG surgery. <br/>Method(s): From January 1, 2015, to January
20, 2024, a comprehensive literature search was conducted across PubMed,
Scopus, IEEE Xplore, and Web of Science. The review adhered to the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. Inclusion criteria included studies that evaluated
survival rates and predictors associated with CABG patients during the
specified period. <br/>Result(s): After eliminating duplicates, a total of
1330 articles were identified. Following a systematic screening, 24
studies met the inclusion criteria. Our findings revealed 43 distinct
factors influencing survival rates in patients undergoing CABG. Notably,
five factors-age, ejection fraction, diabetes mellitus, a history of
cerebrovascular disease or accidents, and renal function-were consistently
identified across multiple studies as significant predictors of
postsurgical survival. <br/>Conclusion(s): This systematic review
identifies key factors influencing survival rates after CABG surgery and
highlights the role of machine learning in improving predictive accuracy.
By identifying high-risk patients through these key factors, our findings
offer practical insights for healthcare providers, enhancing patient
management and customizing therapeutic strategies after CABG. This study
significantly enhances existing literature by combining machine learning
techniques with clinical factors, thereby improving the understanding of
patient outcomes in CABG surgery.<br/>Copyright &#xa9; 2025 The Author(s).
Health Science Reports published by Wiley Periodicals LLC.

<66>
Accession Number
2037081306
Title
Probiotic ameliorates acute gastrointestinal injury with gut hypoperfusion
in heart valve replacement patients.
Source
Clinical Nutrition ESPEN. Conference: 10th World Congress of the ERAS
Society. Malaga Spain. 65 (pp 493), 2025. Date of Publication: 01 Feb
2025.
Author
Yang X.; Waydhas C.; Meng W.
Institution
(Yang, Meng) The First Hospital of Lanzhou University, Lanzhou, China
(Waydhas) Department of Trauma Surgery, University Hospital Essen, Essen,
Germany
Publisher
Elsevier Ltd
Abstract
Background: Acute gastrointestinal injury (AGI) after cardiopulmonary
bypass (CPB) is one of the signs of poor prognosis. This study aimed to
investigate the effect of preoperative probiotics supplementation on AGI.
<br/>Method(s): In this double-blind randomized controlled trial, patients
undergoing heart valve replacement with CPB were randomly assigned to
receive either a probiotic (Lac group) or placebo (Placebo group). The
probiotic was given daily, for seven days before surgery. Patients were
followed up for at least 30 days after surgery. This study was registered
with clinicaltrials.gov (NCT05498948). <br/>Result(s): During the
follow-up period, 15 of the 52 patients had AGI (28.8%). The occurrence of
AGI was 42.3% in the Placebo group and 15.4% in the Lac group with a
difference of 26.9% between the two groups (P = 0.038). Multivariate
analyses showed that the cardiac surgery score (odds ratio [OR] 2.248; 5%
confidence interval [CI], 1.205-4.194, P = 0.011), and the duration of CPB
>= 132 min (OR 18.288; 95% CI, 1.31-255.352, P = 0.031) were independent
risk factors for the occurrence of AGI. Probiotic supplementation was the
only preventive factor for the occurrence of AGI (OR 0.079; 95% CI,
0.007-0.861, P = 0.037). The 30-day mortality was 1 (1.92%) of 52
patients, no deaths occurred in the Lac group; The intensive care unit
(ICU) stay time and Nosocomial infection following CPB were significantly
different (P < 0.05) between the two groups. We also found that intestinal
fatty acid binding protein 2 (I-FABP 2), procalcitonin (PCT), N-Terminal
pro-brain natriuretic peptide (NT-pro BNP), and high sensitive cardiac
troponin I (hs-Tn I) levels of the Lac group lower than Probiotic group.
<br/>Conclusion(s): Preoperative probiotics supplementation may be an
effective preventive strategy to reduce the rate of AGI and AGI-related
complications and can promote rapid postoperative recovery in patients
undergoing heart valve replacement with CPB.<br/>Copyright &#xa9; 2024

<67>
Accession Number
2037118457
Title
Combined Short-Long Axis Versus Medial Oblique Axis for Internal Jugular
Vein Cannulation: A Prospective Single-Blinded Randomized Clinical Trial.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2025.
Date of Publication: 2025.
Author
Afifi S.; Soltan S.A.; Farag A.M.G.
Institution
(Afifi) Department of Anesthesia, Faculty of Medicine, Ain Shams
University, Cairo, Egypt
(Afifi, Soltan) Specialized Anesthesia Department, King Abdullah Medical
City in Holy Capital KAMC-HC, Makkah, Saudi Arabia
(Soltan) Department of Anesthesia, Faculty of Medicine, Al Azhar
University, Cairo, Egypt
(Farag) Department of Cardiac Anesthesia, King Abdullah Medical City in
Holy Capital KAMC-HC, Makkah, Saudi Arabia
Publisher
W.B. Saunders
Abstract
Objective(s): Previous literature suggested the advantage of combined
short-long axis (CSLA) technique to avoid posterior wall puncture during
internal jugular vein (IJV) cannulation. The purpose of this study is to
define the best ultrasound-guided IJV cannulation technique regarding the
success rate in the first trial of insertion, time to successful central
line placement, number of attempts, procedural complications, and operator
satisfaction. <br/>Design(s): Single-blinded, prospective randomized
clinical trial. <br/>Setting(s): Elective cardiac surgeries in a tertiary
care center. <br/>Participant(s): One hundred seventy-eight elective
cardiac surgery patients older than 18 years accepted to participate in
the study and signed the informed consent. <br/>Intervention(s): Patients
were randomized into two equal groups: medial oblique axis and CSLA.
During the technique, vein dimensions, patient characteristics, technique
duration, posterior wall puncture, number of attempts, complications, and
operator satisfaction were documented. <br/>Measurements and Main Results:
Apart from body weight, there were no significant differences in baseline
characteristics between both groups. Compared to the CSLA, the medial
oblique approach showed significantly higher first-trial success rate
(92.1% v 75.0%, p = 0.002), less time for successful insertion (mean +/-
SD, 60.9 +/- 54.9 seconds v 110.7 +/- 101.6 seconds, p < 0.001),
accomplishment with fewer attempts (mean +/- SD, 1.09 +/- 0.28 v 1.44 +/-
0.81, p < 0.001), and higher operator satisfaction (mean +/- SD, 4.45 +/-
0.92 v 3.46 +/- 1.32, p < 0.001). No significant difference in
complications, including posterior wall puncture (p = 0.469), was noted
between both groups. <br/>Conclusion(s): This study demonstrated the
medial oblique axis approach was superior to the CSLA approach regarding
first-trial success rate, time to successful line placement, number of
attempts, and operator satisfaction when used during elective cannulation
of the IJV. However, regarding the incidence of complications, there was
no advantage of one approach over the other. Further research is needed to
confirm these results among specific groups of operators, with awake
patients and in emergent situations.<br/>Copyright &#xa9; 2025 Elsevier
Inc.

<68>
Accession Number
2032956166
Title
Early and Late Outcomes of Transcatheter Aortic Valve Replacement in
Patients With Prior Chest Radiation: A Systematic Review and
Meta-Analysis.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2025.
Date of Publication: 2025.
Author
Tzoumas A.; Kyriakoulis I.; Ntoumaziou A.; Sagris M.; Kampaktsis P.N.
Institution
(Tzoumas) Division of Cardiovascular Health and Disease, University of
Cincinnati Medical Center, Cincinnati, OH, United States
(Kyriakoulis) Faculty of Medicine, School of Health Sciences, University
of Thessaly, Larissa, Greece
(Ntoumaziou) Cincinnati Children's Hospital, Cincinnati, OH, United States
(Sagris) School of Medicine, "Hippokration" General Hospital, National and
Kapodistrian University of Athens, Athens, Greece
(Kampaktsis) Hackensack University Medical Center, Hackensack, NJ, United
States
(Kampaktsis) Aristotle University of Thessaloniki, Thessaloniki, Greece
Publisher
John Wiley and Sons Inc
Abstract
Background: Patients with prior history of chest or mediastinal radiation
are deemed high risk for surgical AVR. Transcatheter aortic valve
replacement (TAVR) has emerged as a promising alternative for these
patients, however, this patient population was underrepresented in prior
TAVR trials. <br/>Aim(s): To compare the outcomes of TAVR in patients with
versus without a history of prior chest or mediastinal radiation.
<br/>Method(s): This study was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Systematic search of electronic databases was conducted up to September
2023. We compared early and late mortality as well as complications. A
meta-analysis was conducted with the use of a random effects model. The
I-square statistic was used to assess heterogeneity. <br/>Result(s): Seven
studies comprising 6358 patients were included in this meta-analysis.
Patients undergoing TAVR in the radiation group had a higher risk for
heart failure exacerbation (OR: 2.06; 95% CI: 1.18-3.59) and aortic valve
reintervention (OR: 5.68; 95% CI: 1.83-17.67) in the early postoperative
period compared to the nonradiation group. Analysis revealed similar
short-term (in-hospital or 30-day) all-cause-mortality (OR: 1.63; 95% CI:
0.89-2.98) between the two groups. Other perioperative complications
including myocardial infarction (MI), stroke, pacemaker insertion
requirement, major bleeding as well as access-related complications were
not significantly different between the two groups. TAVR in the radiation
group was not associated with increased all-cause mortality compared to
the nonradiation group (OR: 1.40; 95% CI: 0.93-2.11) after a mean
follow-up of 17.6 months. Other endpoints including MI, stroke, need for
pacemaker insertion, heart failure readmission rate, and need for aortic
valve reintervention were similar in the mid-term follow-up between the
two groups. <br/>Conclusion(s): TAVR in patients with a history of prior
chest or mediastinal radiation was associated with similar short-term and
mid-term mortality compared to patients without radiation. The history of
chest or mediastinal radiation was associated with more frequent heart
failure hospitalizations and aortic valve reintervention in the
postoperative period. No difference was found in mid-term complications.
Future studies are warranted to validate our findings.<br/>Copyright
&#xa9; 2025 Wiley Periodicals LLC.

<69>
[Use Link to view the full text]
Accession Number
2037029769
Title
Transcatheter Valve Replacement in Severe Tricuspid Regurgitation.
Source
New England Journal of Medicine. 392(2) (pp 115-126), 2025. Date of
Publication: 09 Jan 2025.
Author
Hahn R.T.; Makkar R.; Thourani V.H.; Makar M.; Sharma R.P.; Haeffele C.;
Davidson C.J.; Narang A.; O'neill B.; Lee J.; Yadav P.; Zahr F.;
Chadderdon S.; Eleid M.; Pislaru S.; Smith R.; Szerlip M.; Whisenant B.;
Sekaran N.K.; Garcia S.; Stewart-Dehner T.; Thiele H.; Kipperman R.;
Koulogiannis K.; Lim D.S.; Fowler D.; Kapadia S.; Harb S.C.; Grayburn
P.A.; Sannino A.; Mack M.J.; Leon M.B.; Lurz P.; Kodali S.K.
Institution
(Hahn, Leon, Kodali) Columbia University Irving Medical Center, New York,
NY, United States
(Makkar, Makar) Cedars-Sinai Medical Center, Los Angeles, CA, United
States
(Thourani, Yadav) Piedmont Heart Institute, Marcus Heart Valve Center,
Atlanta, United States
(Davidson, Narang) Northwestern University Feinberg School of Medicine,
Chicago, United States
(O'neill, Lee) Henry Ford Hospital, Detroit, United States
(Zahr, Chadderdon) Oregon Health and Science University, Portland, United
States
(Eleid, Pislaru) Mayo Clinic, Rochester, MN, United States
(Smith, Szerlip, Grayburn, Mack) Baylor Scott and White Heart Hospital
Plano, Plano, TX, United States
(Grayburn, Sannino) Baylor Scott and White Research Institute, Cardiac
Imaging Core Laboratory, Plano, TX, United States
(Whisenant, Sekaran) Intermountain Medical Center, Murray, UT, United
States
(Garcia, Stewart-Dehner) Christ Hospital, Cincinnati, United States
(Kapadia, Harb) The Cleveland Clinic Foundation, Cleveland, United States
(Thiele) Heart Center Leipzig at Leipzig University, Leipzig, Germany
(Lurz) University Medical Center Mainz, Mainz, Germany
(Kipperman, Koulogiannis) Morristown Medical Center, Morristown, NJ,
United States
(Lim, Fowler) The University of Virginia, Charlottesville, United States
(Sharma, Haeffele) Stanford University, Stanford, CA, United States
Publisher
Massachussetts Medical Society
Abstract
Background Severe tricuspid regurgitation is associated with disabling
symptoms and an increased risk of death. Data regarding outcomes after
percutaneous transcatheter tricuspid-valve replacement are needed. Methods
In this international, multicenter trial, we randomly assigned 400
patients with severe symptomatic tricuspid regurgitation in a 2:1 ratio to
undergo either transcatheter tricuspid-valve replacement and medical
therapy (valve-replacement group) or medical therapy alone (control
group). The hierarchical composite primary outcome was death from any
cause, implantation of a right ventricular assist device or heart
transplantation, postindex tricuspid-valve intervention, hospitalization
for heart failure, an improvement of at least 10 points in the score on
the Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS), an
improvement of at least one New York Heart Association (NYHA) functional
class, and an improvement of at least 30 m on the 6-minute walk distance.
A win ratio was calculated for the primary outcome by comparing all
possible patient pairs, starting with the first event in the hierarchy.
Results A total of 267 patients were assigned to the valve-replacement
group and 133 to the control group. At 1 year, the win ratio favoring
valve replacement was 2.02 (95% confidence interval [CI], 1.56 to 2.62;
P<0.001). In comparisons of patient pairs, those in the valve-replacement
group had more wins than the control group with respect to death from any
cause (14.8% vs. 12.5%), postindex tricuspid-valve intervention (3.2% vs.
0.6%), and improvement in the KCCQ-OS score (23.1% vs. 6.0%), NYHA class
(10.2% vs. 0.8%), and 6-minute walk distance (1.1% vs. 0.9%). The
valve-replacement group had fewer wins than the control group with respect
to the annualized rate of hospitalization for heart failure (9.7% vs.
10.0%). Severe bleeding occurred in 15.4% of the valve-replacement group
and in 5.3% of the control group (P=0.003); new permanent pacemakers were
implanted in 17.4% and 2.3%, respectively (P<0.001). Conclusions For
patients with severe tricuspid regurgitation, transcatheter
tricuspid-valve replacement was superior to medical therapy alone for the
primary composite outcome, driven primarily by improvements in symptoms
and quality of life.<br/>Copyright &#xa9; 2024 Massachusetts Medical
Society.

<70>
Accession Number
2037101519
Title
Cardiac surgery outcomes: The efficacy of dexmedetomidine in reducing
postoperative delirium - A bibliometric study.
Source
Current Problems in Cardiology. 50(3) (no pagination), 2025. Article
Number: 102984. Date of Publication: 01 Mar 2025.
Author
Yabo W.; Dongxu L.; Xiao L.; Qi A.
Institution
(Yabo, Dongxu, Xiao, Qi) Department of Cardiovascular Surgery, West China
Hospital, Sichuan University, No.37 GuoXue Xiang, Sichuan, Chengdu, China
Publisher
Elsevier Inc.
Abstract
Postoperative delirium (POD) is a prevalent complication following cardiac
surgery, characterized by acute brain dysfunction observed in critically
ill patients. Despite the significant impact of POD, there is currently no
established treatment. Recent research has suggested that modulation of
cholinergic neurotransmission and alpha2-adrenergic receptors may offer a
therapeutic strategy for managing delirium during critical illness. This
study employs bibliometric analysis to examine the emerging evidence on
the role of dexmedetomidine, an alpha2-receptor agonist drug, in the
prevention and treatment of POD. A systematic bibliometric analysis was
conducted to identify and evaluate the literature on the use of
dexmedetomidine in relation to POD. The study period spanned from 2006 to
2022, and the search was conducted in the Web of Science (WOS) database,
focusing on relevant references. The analysis included the examination of
the most frequent keywords, research trends, and frontiers to provide a
comprehensive overview of the field. The bibliometric analysis revealed
160 research papers on the topic, indicating a significant increase in
research output over the past decades. The field distribution, knowledge
structure, and research topic evolution were identified as key areas of
exploration. The analysis also highlighted the emergence of new topics and
trends in the study of POD and its management. This bibliometric analysis
provides a robust framework for understanding the current state of
research on dexmedetomidine's efficacy in managing POD. It highlights the
need for continued investigation and underscores the potential of this
pharmacological approach to improve patient outcomes following cardiac
surgery.<br/>Copyright &#xa9; 2025 Elsevier Inc.

<71>
Accession Number
2037117753
Title
Single vs dual antiplatelet therapy after left atrial appendage closure: A
propensity score matching analysis.
Source
Heart Rhythm. (no pagination), 2025. Date of Publication: 2025.
Author
Galea R.; Krsnik J.P.; Bini T.; Chalkou K.; Gasys A.; Brugger N.; Madhkour
R.; Seiffge D.J.; Roten L.; Siontis G.C.M.; Raber L.
Institution
(Galea, Krsnik, Bini, Gasys, Brugger, Madhkour, Roten, Siontis, Raber)
Department of Cardiology, Bern University Hospital, University of Bern,
Bern, Switzerland
(Galea) Department of Cardiology, Hospital Centre of Biel, Biel,
Switzerland
(Chalkou) Department of Clinical Research, University of Bern, Bern,
Switzerland
(Seiffge) Department of Neurology, Bern University Hospital, University of
Bern, Bern, Switzerland
Publisher
Elsevier B.V.
Abstract
Background: Dual antiplatelet therapy and oral anticoagulation in
combination with aspirin represent recommended treatment regimens after
left atrial appendage closure (LAAC). As most patients receiving LAAC have
high bleeding risk, less aggressive antithrombotic treatments are needed,
such as single antiplatelet therapy. <br/>Objective(s): We sought to
compare both ischemic and bleeding outcomes in patients receiving single
antiplatelet therapy (SAPT) or dual antiplatelet therapy (DAPT) after
successful LAAC. <br/>Method(s): Data on consecutive patients undergoing
percutaneous LAAC between 2009 and 2023 were prospectively collected
including 1-year follow-up. Propensity score matching was performed for
patients discharged under SAPT and DAPT. The primary end point was the
1-year composite of cardiovascular death, stroke, systemic embolism, or
device-related thrombosis (DRT). The secondary end points included major
bleeding and DRT. <br/>Result(s): Of 1033 patients discharged with
antiplatelet therapy, 154 patients receiving SAPT were compared with 230
matched patients receiving DAPT. The primary end point was similar between
the study groups (SAPT 11.0% vs DAPT 8.3%; rate ratio, 1.14; 95%
confidence interval [CI], 0.83-1.55; P = .420). Consistently, we found no
difference in terms of both major bleeding (SAPT 9.7% vs DAPT 12.6%;
hazard ratio, 0.77; 95% CI, 0.43-1.39; P = .387) and DRT (2.6% vs 1.1%;
rate ratio, 1.47; 95% CI, 0.89-2.43; P = .130) between the SAPT and DAPT
groups. <br/>Conclusion(s): In this propensity score matching analysis of
a single-center LAAC cohort, ischemic and bleeding outcomes did not differ
at 1 year for patients discharged with SAPT or DAPT. These results have to
be confirmed in an adequately powered randomized clinical
trial.<br/>Copyright &#xa9; 2024 Heart Rhythm Society

<72>
Accession Number
646266788
Title
Single Nucleotide Polymorphism Marker Analysis In Donor-Derived Cell-Free
DNA For Solid Organ Transplantation (Next-Generation Sequencing):
Systematic Review.
Source
International Journal of Technology Assessment in Health Care. Conference:
HTAi 2024 Meeting. Seville Spain. 40(Supplement 1) (pp S47), 2024. Date of
Publication: 01 Dec 2024.
Author
Kim Y.; Im J.; Lee W.; Choi J.
Publisher
Cambridge University Press
Abstract
Introduction: Single nucleotide polymorphism marker analysis in
donor-derived cell-free (dd-cf) DNA for solid organ transplantation is a
technique for post-transplantation monitoring, including early detection
of injury to the transplanted organ, signs of infection, and treatment
decision-making, by measuring dd-cf-DNAs as a percentage of the total
cf-DNAs in the patient's body in donors and recipients of kidney, heart,
lung, or liver transplants. <br/>Method(s): The assessments were performed
via a systematic review. Searching five databases (KoreaMed, Ovid MEDLINE,
Ovid Embase, and Cochrane) yielded 1,619 related studies. Two reviewers
independently assessed the quality of these studies using a Scottish
Intercollegiate Guidelines Network checklist, and the assessment results
were described based on the results of the quality appraisal and level of
evidence. <br/>Result(s): The population of the included studies was
patients who underwent kidney, heart, lung, or liver transplantation.
Medical outcomes in kidney transplantation patients were reported in 15
studies. The index test was reported to have an area under curve (AUC) of
0.68 to 0.99 and a sensitivity of 0.24 to 1.00. Four studies reported
effectiveness data for the index test for lung transplantation patients.
The diagnostic accuracy of the index test for acute cellmediated rejection
was reported have an AUC of 0.72. Sensitivity was reported as 0.44 and
specificity as 0.80 for heart transplant patients, and sensitivity as 0.73
to 1.00 and specificity as 0.60 to 0.95 for liver transplant patients.
<br/>Conclusion(s): This is a safe and effective technique for
posttransplantation monitoring, including the early detection of injury to
the transplanted organ and signs of infection, and for treatment
decision-making, by measuring dd-cf-DNA as a percentage of total cf-DNA in
the patient's body in recipients and donors of kidney, heart, lung, or
liver transplantation (level of evidence: C).

<73>
Accession Number
646266732
Title
Evaluating The Efficacy Of Cytokine Filtration In Cardiac Surgery For
Endocarditis: A Comprehensive Study.
Source
International Journal of Technology Assessment in Health Care. Conference:
HTAi 2024 Meeting. Seville Spain. 40(Supplement 1) (pp S140-S141), 2024.
Date of Publication: 01 Dec 2024.
Author
Borin M.C.; Martins C.R.; Dos Reis D.P.; Ribeiro G.J.C.; Tupinambas J.T.;
De Castro Zocrato K.; De Almeida Carvalho L.M.; De Freitas M.P.; Da Gloria
Cruvinel Horta M.; Barbosa M.M.; Talim M.C.T.; Bersan S.A.L.; Kelles
S.M.B.
Publisher
Cambridge University Press
Abstract
Introduction: Despite medical advancements, endocarditis still results in
high mortality rates. Surgery, while often essential, elevates the risk of
hyperinflammation, sepsis, and cytokine release. The use of a cytokine
filter to prevent this remains controversial. This study reviewed existing
literature to assess the efficacy of cytokine filters and to support its
integration into supplementary health services Methods: An exhaustive
search of the MEDLINE, Cochrane Library, Embase, LILACS, and CytoSorbents
Corporation databases was conducted to identify relevant meta-analyses and
systematic reviews. The study focused on randomized controlled trials and
case series studies assessing the efficacy of cytokine filtration. Key
variables considered were the duration of antibiotic treatment, severity
of endocarditis, and surgical treatment rationale. These factors were
crucial for evaluating clinical outcomes and patient survival after
surgery. <br/>Result(s): The systematic reviews yielded mixed outcomes.
Two found no benefits for hemoadsorption, while one found that it reduced
mortality rates and intensive care unit stays based on observational
studies. Randomized controlled trials, however, showed no significant
impact for cytokine filters on mortality rates or postoperative
hemodynamic parameters. In contrast, case series studies reported
potential benefits, but these results were confounded by biases in patient
allocation and failure to account for critical variables like antibiotic
treatment duration, case severity, and surgical rationale. These
discrepancies highlight the complexity of evaluating the effectiveness of
cytokine filtration in surgical settings. <br/>Conclusion(s): Randomized
and non-randomized controlled trials on the role of cytokine filters in
cardiac surgery for endocarditis reported contradictory findings. Only
case series studies suggested benefits from cytokine filters,
necessitating further high quality research before recommending their
widespread use. Understanding the implications of these results is
essential, underscoring the need for more rigorous studies to resolve
these inconsistencies.